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This thesis has studied intracellular mechanisms involved in prostaglandin (PG) synthesis by and release from the guinea-
pig uterus and placenta. Adenosine, ATP and its analogues stimulated prostaglandin output (particularly PGF2u) from the
superfused guinea-pig uterus, and from the endometrium and myometrium cultured for 24 h Adenosine and ATP-induced
PGF2a output from the superfiised guinea-pig uterus was inhibited by the adenosine (A) receptor antagonist, 8-
sulphophenyltheophylline and the P2 purinoceptor antagonist, suramin, respectively Adenosine and ATP-induced 6-keto-
PGF)a output from the superfiised guinea-pig uterus was unaffected by 8-sulphophenyltheophylline and suramin
respectively Therefore, adenosine and ATP-induced increases in PGF2a output from the superfused guinea-pig uterus
appear to be receptor mediated responses, while the mechanisms involved in 6-keto-PGF,a production remain unclear
PG output, particularly PGF2a, from the guinea-pig placenta and sub-placenta cultured for 24 h increased significantly
between days 22 and 29 of pregnancy. Metabolism of PGF2a by the placenta also increased between these two days
suggesting that increased PG output was not due to decreased metabolism. Indomethacin, a non-selective inhibitor of
PGHS, and NS-398 a PGHS-2 selective inhibitor, reduced PG output from day 22 and day 29 guinea-pig placenta and sub-
placenta after 24 h of culture. PGHS-2 appears to be the predominant enzyme responsible for PGF2a synthesis by day 22
and day 29 guinea-pig placenta and sub-placenta, while both isoforms of the PGHS enzyme are involved in PGE2 and 6-
keto-PGF)a synthesis by day 22 and day 29 guinea-pig placenta and sub-placenta.
The outputs of PGF2a, and PGE2 from the placenta and sub-placenta and 6-keto-PGF1(I output from day 29 guinea-pig
placenta in culture were reduced by the inclusion of cycloheximide, puromycin and actinomycin D (protein synthesis
inhibitors) in the culture medium This suggests that the production of PGF2a, PGE2 and 6-keto-PGFUl is dependent on
protein synthesis.
The presence of calcium-depleted medium inhibited 6-keto-PGFla output from day 29 guinea-pig placenta after 24 h of
culture, but had no effect on PGF2a and PGE2 outputs This suggests that 6-keto-PGF!a production is dependent on
extracellular calcium, while PGF2„ and PGE2 production by day 29 placenta is not PGF2a, PGE2 and 6-keto-PGFl(I outputs
from day 29 guinea-pig sub-placenta were inhibited in the presence of calcium-depleted medium, which suggests that
extracellular calcium is a requirement for their synthesis The inclusion of EGTA (a calcium chelator), TMB-8 (a calcium
antagonist), TFP and W-7 (calmodulin antagonists) in tissue culture medium, inhibited 6-keto-PGFla output from the
placenta after 24 h of culture Therefore, 6-keto-PGFla output from day 29 guinea-pig placenta is dependent on intracellular
calcium and calmodulin for its synthesis. PGF2u and PGE2 production by day 29 guinea-pig placenta was also inhibited by
TMB-8 and are dependent on intracellular calcium for their synthesis TFP and W-7 had no inhibitory effect on PGF2cl and
PGE2 outputs from the guinea-pig placenta after 24 h of culture Therefore, calmodulin does not appear to be necessary for
PGF2a and PGE2 production by the placenta. PG production by the guinea-pig sub-placenta was inhibited by the calcium
antagonist TMB-8 but was not inhibited by the calmodulin antagonists TFP and W-7 Therefore, PGF2u, PGE2 and 6-keto-
PGF|a production by day 29 guinea-pig sub-placenta is dependent on intracellular calcium but not on calmodulin PG
output from day 29 placenta and sub-placenta was inhibited by nifedipine and verapamil (calcium channel blockers) which
suggests that PGF2a, PGE2 and 6-keto-PGF!a production requires calcium entry via voltage-dependent calcium channels
Inclusion of TPA (a PKC activator) in the culture medium demonstrated that PKC is not a requirement for PGF2u, PGE2 or
6-keto-PGFla synthesis by day 29 guinea-pig placenta or sub-placenta since TPA had no effect on PG output
1 uteinising hormone releasing hormone (LHRH) appeared to have opposing actions on PGF2a and PGE2 outputs after 24 h
of culture, inhibiting PGF2u and PGE2 outputs from day 29 guinea-pig placenta and stimulating PGF2(I and PGE2 output
from the sub-placenta. LHRH had little effect on 6-keto-PGF]a output from the guinea-pig sub-placenta and had opposing
actions on 6-keto-PGF|a output from the placenta, inhibiting 6-keto-PGF|(1 output after 2 h and increasing it after 24 h of
culture
This work has shown that the mechanisms involved in PG production by the guinea-pig uterus and placenta are complex
These include the synthesis and availability ofPLA2, PGHS and calcium (extracellular and intracellular)
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1.1.1 The History of Prostaglandins
The discovery of prostaglandins (PGs) is attributed to American gynaecologists
Kurzrok & Lieb (1930). Kurzrok & Lieb (1930) demonstrated that fresh human
semen contained a substance which contracted and relaxed human uterine smooth
muscle in vitro. In 1935, von Euler and Goldblatt independently observed that
extracts from the prostatic and related glands of human, monkey, sheep and goat, and
extracts from sheep seminal vesicles caused contraction of smooth muscle.
Discovery of this substance in the human and sheep prostate gland prompted von
Euler to suggest the name prostaglandin (von Euler, 1939). Despite their name
prostaglandins were later discovered to be synthesized by the seminal vesicles and
not by the prostate gland (Eliasson, 1959).
Limited techniques restricted analysis but von Euler (see Moore, 1985) was the first
to attempt extraction of prostaglandin. He demonstrated that prostaglandin was
soluble in both water and organic solvents, was destroyed at extremes of pH, lacked
nitrogen and was an unsaturated fatty acid. The chemical nature of prostaglandin
was later confirmed by Bergstrom (see Moore, 1985). Bergstrom also reported that
seminal fluid extract contained more than one prostaglandin (see Moore, 1985).
It was a decade later before prostaglandins were isolated and recognised as a family
of compounds. In 1957, Bergstrdm & Sjovall published the structure of
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prostaglandin 'factor' (later shortened to PGF) extracted from sheep seminal vesicles.
Prostaglandin E was also isolated from sheep vesicular glands (Bergstrom & Sjovall,
1957). The structures of PGF!a and PGE| were later confirmed by Bergstrom et al.
(1963). Subsequently more prostaglandins were discovered and named alphabetically
i.e. PGA, B, C and D (see Fig. 1.1.2.1).
In the 1970s, cyclic endoperoxide prostaglandins (i.e. PGG2 and PGH2) were found
to be intermediates in prostaglandin synthesis (flamberg & Samuelsson, 1973) (see
Fig. 1.1.2.1). In addition two other compounds were discovered i.e. thromboxane A2
(Hamberg et al., 1975) and prostacyclin (PGI2) (Moncada & Vane, 1979). Also,
Vane (1971) demonstrated that aspirin-like drugs inhibited prostaglandin synthesis.
Also in the 1970s key roles of prostaglandins in reproduction became evident (see
Poyser, 1981), but there is still much to be learned about their synthesis, catabolism
and mechanism of action in reproductive tissues.
1.1.2 Structure, Chemistry, Biosynthesis & Metabolism
Prostaglandins (PGs), thromboxanes and leukotrienes are collectively known as
eicosanoids. They influence and are produced by all nucleated cells in the body
(Christ & van Dorp, 1972). PGs are not stored in the tissues but are synthesised and
released from the cell as required (Piper & Vane, 1971). They have a short half-life
and are rapidly metabolised especially in the lungs, liver, kidneys and the placenta.
Prostaglandins are 20 carbon-containing, unsaturated fatty acids consisting of a
cyclopentane ring and two side chains of 7 and 8 carbons. They are classified
according to which group is attached to the cyclopentane ring and to the side chain.









Figure 1.1.2.1 Structure of prostanoic acid and structural differences
between prostaglandin A to H. The structure for prostaglandin (PGI2) is




present. The majority of PGs in mammalian tissues have 2 double bonds between
carbons 5 and 6 and carbons 13 and 14, signified by the 2 subscript as in PGF2ct. The
subscript a signifies the stereochemical configuration of the hydroxyl group at C9.
It was reasoned from the structure of prostaglandins that they were derived from an
unsaturated fatty acid. Bergstrom el al. (1964) and van Dorp el al. (1964)
demonstrated the conversion of radioactive arachidonic acid (cis-5, 8, 11, 14-
eicosatetraenoic acid; arachidonic acid)) to PGE2 in sheep seminal vesicle
homogenates. Arachidonic acid was also observed to be converted into PGF2a by
guinea-pig lung homogenates (Anggard & Samuelsson, 1965).
Prostaglandins are synthesised from fatty acids that make up the structural part of the
plasma membrane. The specific PG or leukotriene produced depends on which fatty
acid is in the membrane and which enzymes are present in the cell. The main
precursor of eicosanoids, and particularly prostaglandins of the 2-series, is
arachidonic acid, which is taken in via the diet or is enzymatically converted from
linoleic acid, which is also taken in through the diet. PG precursors (e.g. arachidonic
acid) are found bound to phospholipids and require phospholipases to free them.
Phospholipids have a backbone of 3 carbon atoms on which saturated fatty acids,
unsaturated fatty acids and bases are attached. For example, phosphatidylinositol
exists in cell membranes as a glycerol backbone with a saturated fatty acid attached
at position 1, an unsaturated fatty acid (e.g. arachidonic acid) at position 2, and
inositol through a phosphate group at position 3. Arachidonic acid is generally the
most abundant of unsaturated fatty acids in biological tissues.
The mobilisation of arachidonic acid from phospholipids is attributed to the action of
phospholipase A2(PLA2). PLA2 attacks position 2 and releases unsaturated fatty acid.
13
The free arachidonic acid is then converted to PGH2 by the action of prostaglandin H
synthase (PGHS or COX). PGHS has two different enzymatic activities. This first
step is the cyclooxygenase component of the reaction, which involves the conversion
of arachidonic acid to the cyclic endoperoxide PGG2. The cyclooxygenase reaction is
followed by the peroxidase reaction and the rapid conversion of PGG2 to PGH2 (see
Fig. 1.1.2.2). The final form of prostaglandin produced is dependent upon the cell
type and the enzymes contained therein (Samuelsson et al., 1978). Recently it has
been discovered that there are two forms of PGHS, named PGHS-1 (or COX-1) (a
constitutive enzyme) and PGHS-2 (or COX-2) (an inducible enzyme) (Hedin et al.,
1987; Wong & Richards, 1991).
The major site of PG inactivation (particularly of PGE2 and PGF2a) is in the lungs,
although PGs are rapidly metabolised in most tissues including the placenta. The
initial step of PG catabolism is their uptake from the extracellular space across the
plasma membrane; they then pass into the cytoplasm which contains degradative
enzymes. The first enzyme responsible for the biological inactivation of PGs is 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) of which there are 2 types, namely
Type 1 and Type II (see Hansen, 1976). This enzyme converts, for example, PGF2a
into 15-keto-PGF2a. This compound is then metabolised by 13, 14-prostaglandin
dehydrogenase into 13, 14-dihydro-15-keto-PGF2cx. This is the main circulatory
metabolite. This compound is further metabolised by enzymes in the liver into dinor-
and tetranor compounds. Dienoic acids may also be produced. The metabolites are
excreted in the urine.
Prostaglandins regulate physiological and pathological processes in all body systems,
14
ARACHIDONIC ACID
Figure 1.1.2.2. Major pathways of biosynthesis of prostaglandins (PG) and
thromboxanes of the '2' series. PGHS-CO: cyclooxygenase component of
prostaglandin H synthase enzyme complex. PGHS-PO: peroxidase component of
prostaglandin H synthase enzyme complex. 12-L-hydroxy-5,8,10-heptadecatrienoic
(HHT) and malondialdehyde (MDA) may also be formed from PGH2-
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including the reproductive processes. Therefore, the mechanisms controlling PG
production by and action on reproductive tissues have been extensively studied.
1.1.3 Prostaglandins and Reproduction
In reproduction the stable prostaglandins, PGF2a and PGE2, appear to be the most
important prostaglandins and seem to be necessary for several reproductive
processes. Gonadotrophin releasing hormone (GnRH) is released in a pulsatile
manner from peptidergic neurons originating in the hypothalamus and stimulates
release of follicle stimulating hormone (FSH) and luteinising hormone (LPI) from the
anterior pituitary gland. These hormones promote growth of follicles within the
ovaries and ovulation, respectively. There is much evidence that PGs are involved in
the post-ovulatory surge of LH. Administration of PGs increases plasma
concentrations of LH in sheep (Carlson et al., 1973), and in pro-oestrous rats and
ovarectomized rats (Tsafriri et al., 1973; Kimball et al., 1979). Similar stimulatory
effects of PGs have been observed in other mammalian species including cattle
(Louis et al., 1974), rabbit (Carlson et al., 1977a), hamster (Saksena et al., 1974) and
monkey (Carlson et al., 1977b). PG synthesis inhibitors delay the LH surge at the
start of the cycle in pro-oestrous rats (Brown & Poyser, 1984), which provides
further evidence that PGs are involved in LH release. The stimulatory action appears
to be directly on the gonadotrophin releasing hormone (GnRH) neurons, as there is
no effect when PGE2 is injected into the anterior pituitary gland while injection into
the third ventricle stimulates LH release (Harms et al., 1974).
PGs also appear to be involved in ovulation. The ovarian concentrations of PGs
increase prior to ovulation in many species including sheep, pig, rat, rabbit and horse
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(see Poyser, 1992). This is particularly true regarding the concentrations of PGF2a,
PGE2 and 6-keto-PGF1(X in follicles destined to ovulate. Indomethacin has been
observed to prevent ovulation in sheep, cattle, pigs, rats, mice, monkeys and women
(see Poyser, 1992). Ovulation is suggested to occur due to thinning of the follicular
wall through activation of collagenase by PG stimulation (see Poyser, 1995).
Luteolysis is the regression of the corpus luteum, the structure in the ovary that
secretes progesterone. It was first suggested by Loeb (1923) that the uterus may
secrete a luteolytic hormone, but it is only in the last thirty years that this hormone
has been identified as PGF2(X in many non-primate mammalian species (see Poyser,
1992). PGF2a may reach the ovaries through a counter-current mechanism between
the ovarian artery and the utero-ovarian vein and/or the uterine lymph vessels (see
Poyser, 1995). In the ovary, PGF2cx combines with specific receptors (FP) leading to
functional and structural luteolysis. If a successful fertilisation occurs, then this
process has to be prevented. In several species (e.g. sheep and cow) an interferon-
a (now called interferon-x) is responsible for inhibiting PGF2tl production by the
uterus during early pregnancy (see Poyser, 1995).
Measurement of the PGF2(I metabolite, 5a, 7a-dihydroxy-l 1-ketotetranor-prostanoic
acid, in guinea-pig urine showed that PGF2a production by the early pregnant guinea-
pig uterus is suppressed (Granstrom & Kindahl, 1976). This is due to reduced PGF2(X
output from the uterus (see Poyser, 1995). The factor responsible for suppressing
PGF2a synthesis by the early pregnant guinea-pig uterus is not known, but it is not an
interferon (Leckie & Poyser, 1990). The concentration of the PGF2a metabolite in the
guinea-pig urine rapidly increases again at approximately day 25 of gestation and
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remains high as pregnancy proceeds. Therefore, from day 25 there must be increased
PGF2(X production by the pregnant guinea-pig uterus or its contents. Norman &
Poyser (1998b) observed that PGF2tx output from the guinea-pig placenta increases
15-fold between days 22 and 36 of pregnancy and speculated that this increase in
PGF2(x output may account for the increase in concentration of the PGF2ct metabolite
observed in guinea-pig urine from day 25 of pregnancy.
1.1.4 The Placenta and Prostaglandins
The placenta is a specialised organ that develops in the pregnant female. It is very
important to the growing fetus and contains fetal and maternal components. The
placenta functions by exchanging nutrients and secreting hormones that help to
maintain pregnancy.
The guinea-pig placenta resembles the human placenta in that it is discoid and
haemochorial in structure and is therefore a potential model for studies of human
placental function. (Egund & Carter, 1974). In addition implantation is interstitial as
in man. Figures 1.1.4.1-3 show photographs taken from a day 29 guinea-pig,
illustrating the uterine horns, conceptuses, and dissection of the placentae. The
guinea-pig placenta consists of two parts, the main placenta (chorio-allantoic
placenta), within which fetal-maternal exchanges occur and, the sub-placenta that
interfaces with the maternal tissues. The sub-placenta appeared as a gelatinous ovoid
structure, greyish in colour, while the chorio-allantoic placenta appeared dark red in
colour (Fig. 1.1.4.3). The main placenta is separated from the sub-placenta by a




Figure 1.1.4.1 Photograph of ventral dissection of day 29 pregnant guinea-pig











Chorion surrounding amnionitic membrane containing conceptus in amniotic fluid
Figure 1.1.4.2 Photograph demonstrating dissection of day 29 pregnant guinea-pig with
single uterine horn opened, revealing two conceptuses attached to endometrium by sub-
placenta.
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Subplacenta - note central mesenchyme





Figure 1.1.4.3 Photograph of dissection of day 29 pregnant guinea-pig. The two
placentae, namely the sub-placenta and the chorio-allantoic placenta, are shown.
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epithelial and mesenchymal cell types of the guinea-pig placenta (Carter et al.,
1998).
All intrauterine tissues, including the placenta, have the potential for PG production
but it is not clear which tissue makes the most important contribution or how the
synthetic pathways in different tissues are co-ordinated to obtain the required level of
PG in the appropriate place and amount (Mitchell, 1986). Proposed functions for
increased PG synthesis by the uterus and/or its contents during pregnancy include
regulation of uterine contractions, ripening of the cervix, regulation of the patency of
the ductus arteriosus, luteolysis and regulation of utero-placental haemodynamics
(Hoedemaker et al., 1991). They may also play a role in the regulation of blood flow
in the utero-fetal unit (Moussard et al., 1986).
It has been observed that the placenta is a major site of PG biosynthesis during
pregnancy (Keirse, 1979). The fetal portion of the placenta (chorio-allantoic
placenta) appears to have a higher capacity for prostanoid synthesis compared to the
sub-placenta (maternal placenta) (Lytton & Poyser, 1982) or to other intrauterine
tissues (Mitchell & Flint, 1977; Wimsatt et al., 1993). PG levels in the rabbit fetal
placenta are seven times higher than in the maternal placenta (Lytton & Poyser,
1982).
The guinea-pig placenta is an important source of endogenous PGs and may
contribute to the augmented intra-uterine availability of prostanoids near parturition
(Moussard et al., 1986). Csapo et al. (1981) reported a sustained increase in PGF2a
output from the guinea-pig placenta from day 30 of pregnancy, and it has also been
observed that the guinea-pig placenta has a decreased capacity for PG metabolism in
late gestation (Moussard et al., 1986). Schellenberg & Kirby (1997) also
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demonstrated that PG output from the guinea-pig placenta tends to increase as
pregnancy proceeds. Also mentioned earlier, recent studies have shown that PGF2a
output from the guinea-pig placenta increases 15-fold between days 22 and 36 of
gestation (Norman & Poyser, 1998b).
Rice et al. (1995) have proposed that increased PG synthesis by the placenta during
pregnancy, particularly the second half of pregnancy, may have a role in fetal
maturation and may enhance the transport of essential substances such as glucose,
oxygen and amino acids, to the fetus.
1.1.5 Parturition
Prostaglandins have been used in human pregnancy since 1967. They were first
employed for the induction of labour (Karim et al., 1968), and then later used for
pregnancy termination (Karim & Filshie, 1970), for preparing the cervix for
induction (Calder & Embrey, 1973) and for the treatment of post-partum
haemorrhage (Tagaki et al., 1976; Keirse et al., 1989).
It has been hypothesised from studies on the sheep that, when the fetus enters its
rapid growth period (two thirds of the way through gestation), it puts an increased
metabolic demand on the placenta which, in turn, stimulates the production of PGE2.
Increased PGE2 output then stimulates the fetal pituitary-adrenal axis leading to
parturition (Thorburn, 1991). Removal of the ovine fetal pituitary reduces PGE2
output from the placenta (Thorburn, 1991), which is consistent with the view that, in
the pregnant sheep, the fetal pituitary gland exerts direct control on placental steroid
and PG synthesis. PGE2 output from the placenta and from fetal membranes has been
observed to increase in the final stages of gestation in the sheep (Risbridger el al.,
23
1985; Rice et al., 1988), rabbit (Elliot et al., 1984), pig (Rice et al., 1989) and the
guinea-pig (Schellenberg & Kirby, 1997). Addition of arachidonic acid does not
increase PGE2 output any further from the sheep placenta (Risbridger et al., 1985) or
the guinea-pig placenta (Schellenberg & Kirby, 1997), and it has been suggested that
the cyclooxygenase activity of PGHS may be the rate-limiting step in PG production
by the placenta.
It is not clear what regulates PG synthesis during the last trimester of gestation but
the fetal pituitary hormones have been suggested, including the gonadotrophins
(Thorburn, 1991). Fetal pituitary hormones, particularly gonadotrophins regulate
steroid and PG synthesis by the placenta (Thorburn et al., 1989). It has been
proposed that luteinising hormone (LH) may induce the cyclooxygenase activity of
the PGHS enzymes in the placenta as it does in the ovary (Thorburn, 1991). In sheep
an increase in PGE2 by the fetal trophoblast activates the fetal hypothalamic-
pituitary-adrenal (HPA) axis leading to an increase in fetal Cortisol. High Cortisol
leads to an increase in placental 17a-hydroxylase activity, which decreases maternal
progesterone while increasing maternal oestrogen. An increase in the
oestogen:progesterone ratio results in increased PGE2 release from the placenta thus
increasing uterine activity and parturition (Thorburn, 1991). Gonadotrophin releasing
hormone (GnRH) may also have a role in PG synthesis by the placenta. Hanig et al.
(1982) demonstrated that GnRH stimulated PGF2a production by human placental
homogenates. GnRH has also been observed to stimulate PG production by the
human placenta (Kang et al., 1991). It has been postulated that GnRH may be
stimulating the production of a gonadotrophin within the guinea-pig placenta, and
this gonadotrophin may be related to human chorionic gonadotrophin (Humphreys et
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al., 1982). However, GnRH has also been observed to inhibit PG output from human
placenta (Siler-Khodr et al., 1986a, 1986b; Kang et al., 1991). Further investigation
is required to determine the role ofGnRH in PG production by the placenta.
The type of placenta produced depend on the species and the guinea-pig placenta is
the same as the human placenta in this respect i.e. it is discoidal and haemochorial in
structure. Ovarian progesterone is necessary for maintenance of pregnancy and this is
the role of the corpus luteum in early pregnancy in both human and guinea-pigs.
Gestation in the guinea-pig last between 62-70 days. The corpora lutea of the guinea-
pig are maintained until day 58-67, but are not essential for maintenance of
pregnancy beyond day 25 (Bland & Donovan, 1969). Luteal-placental shift occurs on
day 25 of pregnancy when the placenta takes over progesterone production.
However, luteal progesterone production is functional until day 40 of pregnancy after
which progesterone secretion gradually declines (Heap & Deansesly, 1966). The
guinea-pig and the human are the only species where progesterone levels remain
high as parturition approaches (see Horton & Poyser, 1976). It is believed that the
guinea-pig placenta is a useful model to use for the studies carried out in this thesis.
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1.2 PUR1NOCEPTORS
1.2.1 The History of Purinoceptors
The potent cardiovascular effects of adenosine led to an interest in the synthesis of
new adenosine analogues (Fredholm et al., 1994). Biochemical evidence for multiple
receptor types for adenosine was provided by the demonstration that adenosine
analogues increased cAMP production in some preparations, while decreasing it in
others. Thus adenosine receptors were classified as A! and A2 (van Calker et al.,
1979) or Ri and Ra (Londos et al., 1980). More recently the A2 receptor has been
sub-divided into an A2A and an A2b receptor. Adenosine (A) receptors are G protein-
linked receptors. A2 receptors have been defined on their ability to stimulate
adenylate cyclase, by being coupled to the G protein Gs. Response to A] receptor
activation is blocked by pertussis toxin and this is compatible with Gi/Go
involvement. A third adenosine receptor has been classified as A3. The existence of
four separate adenosine receptors is now well established, Ax, A2A, A2B and A3
(Girdlestone & Watson, 1996).
ATP was also observed to have important cardiovascular effects (Green & Stoner,
1950), and Burnstock (1972) postulated the existence of specific ATP receptors.
Receptors for adenosine, ATP and ADP are collectively known as purinoceptors. In
1978, Burnstock classified these as PI (now known as A receptors) and P2
purinoceptors for adenosine and ATP, respectively.
The P2 receptors until recently were divided into the sub-types P2X, P2y, P2u, P2t, P2z
and P2d based mainly on different agonist potencies. Initial work was carried out by
Burnstock & Kennedy (1985) who discriminated between the two major types of
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receptor, P2x and P2y, by their response to ATP and different ATP analogues. P2
classification was thought to be unsatisfactory for the long term (Fredholm et al.,
1994), as it had been shown that the P2Y receptor has different agonist pharmacology
in different tissues (Burnstock 1991, Fischer et al., 1993). Thus the 'classic' P2Y
purinoceptor required further sub-classification.
In 1991, Dubyak proposed that there were two different signal transduction
mechanisms for P2 purinoceptors. This observation and the cloning of these
receptors, which began with cloning of the P2Y receptor from chick brain (Webb et
al., 1993), led to a more logical classification of receptor types and sub-types (see
Fredholm et al., 1997). Abbrachio & Burnstock (1994) reclassified the purinoceptors
into 2 main families, P2Y and P2X. The international union of pharmacology
committee on receptor nomenclature and drug classification (NC-IUPHAR) also
classified purinoceptors into these 2 families. The P2Y family of receptors, which
are G protein-linked, often couple to stimulate phospholipase C and inositol
triphosphate (IP3) formation (O'Conner et al., 1991). This receptor family contains
several sub-types (P2Yj, P2Y2, P2Y4 and P2Y6), most of which have been cloned in
humans.
There is evidence that receptors exist that are structurally similar to receptors for
ATP but strongly prefer UTP or UDP (Communi & Boeyneams, 1997; Harden et al.,
1997). These receptors have previously been classified as the P2U or 'nucleotide' or
'pyramidine' receptors (O'Conner et al., 1991; Dubyak, 1991). Recently it has been
suggested that distinct pyrimidinoceptors do exist although they do not appear to
constitute a separate receptor family of their own (Communi & Boeynaems, 1997). It
has now been proposed that this family of receptors be named P2 receptors rather
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than P2 purinoceptors. A P2 receptor is now described as a receptor for a purine or
pyrimidine nucleotide (or dinucleotide). The P2Y2, P2Y4 and P2Y6 receptors are all
stimulated by UTP.
The P2X family of receptors are ion channels permeable to Na+, K+ and Ca2+ (Bean,
1992), and has been sub-divided into 7 different receptor types. P2z is now
considered to be a member of the P2X family (P2X7) (see Fredholm, 1997). P2X7
mediates the response to ATP in mast cells (Dahlqvist & Diamant, 1974) and
macrophages (Steinberg & Silverstein, 1987).
Kennedy & Leff (1995) suggested that the classification of receptors based on
agonist potencies could be wrong due to the breakdown of ATP and 2-methyIthio-
ATP by ecto-nucleotidases. Recent studies have shown that the potencies of ATP
and 2 methylthio-ATP decrease between 100- to 1000-fold by breakdown and, when
breakdown of these compounds is prevented, that both are more potent than
ap methylene-ATP at the P2X receptor. ATP and 2 methylthio-ATP are broken
down by nucleotidases but ap methylene-ATP is relatively resistant (Welford et al.,
1986; Welford et al., 1987) and ap methylene-ATPis generally considered to be less
potent than ATP or 2 methylthio-ATP. At the moment there are limited, highly
selective, metabolically stable agonists and antagonists available to classify
purinoceptors.
In summary, in addition to their role in energy metabolism, purines, especially
adenosine and adenine nucleotides, produce a wide range of pharmacological effects
mediated by activation of cell surface receptors. Studying these receptors is
complicated by the rapid metabolism and uptake of the agonists, thus making it
difficult to determine which compound specifically is producing the effect.
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1.2.2 G Proteins and Second Messengers
G proteins are guanine nucleotide binding proteins, which provide a link between the
receptor site and intracellular activity. They are membrane-associated compounds
and are heterotrimers consisting of a, P and y sub-units. They respond to ligand-
activated receptors by dissociating into their component a- and Py-sub-units
(Axelrod et al., 1988). Therefore, G proteins exist in 2 states, namely 'active' with
GTP bound to the a-sub-unit or 'inactive' with GDP bound to the p-sub-unit. The
GTP bound a-sub-unit then activates a second messenger system which can
stimulate a number of processes in the cell (Axelrod et al., 1988). These second
messenger systems include activation of regulatory proteins such as adenylate
cyclase, cGMP phosphodiesterase and some voltage-sensitive ion channels. In some
situations, the Py-sub-umt has also been observed to activate enzymes (see Axelrod
et al., 1988).
There are a number of different G proteins, Gs, Gi, Gt and Go. G proteins can be
identified by their reactions to specific toxins. Cholera toxin induces ADP
ribosylation of Gs which under normal conditions stimulates adenylate cyclase. The
toxin stabilises the dissociated form of the G protein i.e. the GTP bound a-sub-unit
which leads to persistent activation of adenylate cyclase. Another toxin, pertussis
toxin, causes ADP ribosylation of Gi proteins, which normally inhibit adenylate
cyclase. Pertussis toxin prevents the coupling of the G protein with the activated
receptor and stabilises the G protein in its associated state, thus preventing inhibition
of adenylate cyclase.
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There is evidence that PLA2 and PLC are activated through G proteins (Axelrod el
al., 1988). Toxin effects on a particular effector system may be an indication of
regulation by a GTP-binding protein (Axelrod et al., 1988). It has been reported that
PLA2 is activated by a G protein that is inhibited by pertussis toxin. Pertussis toxin
inhibits PG synthesis in a number of tissues, suggesting the involvement of G
proteins in their synthesis (Burch et al., 1986; Burgoyne et al., 1987; Axelrod et al.,
1988; Wang et al., 1988; Nakashima et al., 1988). Receptor-mediated release of
arachidonate has been demonstrated in fibroblasts, platelets and neutrophils
(Samuelsson et al., 1978; Hirata et al., 1979; Ohta et al., 1985; Bokoch et al., 1984).
However, in some of these experiments arachidonate release may not have been by
direct action of PLA2 but by a prior action of PLC (Bokoch et al., 1984).
Experiments with noradrenaline-stimulated thyroid cells and light activated rod outer
segments (ROS) of bovine retina have provided evidence for the direct, G protein-
dependent regulation ofPLA2 which does not involve PLC (see Axelrod et al., 1988).
It is probable that arachidonic acid release by PLC and PLA2 involves the activation
of different G proteins. Pregnancy suppresses G protein coupling to phosphoinositol
hydrolysis in the guinea-pig myometrium, which may contribute to a decrease in
contractile sensitivity during pregnancy (Arkinstall & Jones, 1990).
1.2.3 ATP, Prostaglandins and the Uterus
Adenosine and adenine nucleotides are potent stimulators of PG release in a number
of critical organs (Needleman et al., 1974) and have been shown to stimulate
contraction and relaxation in various tissues. These agonists mediate their effects via
A (adenosine) receptors and P2 purinoceptors. Both A and P2 receptors have been
30
identified in the guinea-pig uterus and their activation causes contraction of uterine
smooth muscle (Smith et al., 1988). Previously, it has been shown that the smooth
muscle of the guinea-pig uterus responds by contracting to both ATP and adenosine
(Moritoki et al., 1979) and appears to be one of the few smooth muscle tissues that
responds this way. ATP-induced contractions of the guinea-pig uterus are blocked by
indomethacin (an inhibitor of PGHS), PG antagonists and ATP antagonists (Moritoki
et al., 1979).
Scheimann et al. (1991) reported that A\ receptor activation stimulates PG synthesis
in guinea-pig myometrium and observed increased 6-keto-PGF1(x, PGE2 and PGF2„
production when this receptor type was stimulated. ATP has also been observed to
stimulate PGF2a, PGE2, 6-keto-PGFla and TxB2 production by the rabbit
myometrium (Suzuki, 1991). Pregnant rabbit myometrium appears to be more
sensitive to adenosine and adenine nucleotides than non-pregnant myometrium,
which could be due to an increase in the number of receptors or an increase in the
affinity of the receptors (Suzuki, 1991).
There are conflicting views as to whether the contractile actions of adenosine and
ATP on the uterus involve PGHS, the enzyme responsible for the conversion of
arachidonic acid to PGH2. Bradley et al. (1993) suggests that PGHS is not necessary
to produce the contractile response of the guinea-pig uterus to adenosine, as
indomethacin had no effect on adenosine-induced contractions of the guinea-pig
myometrium. Moritoki et al. (1979) and Suzuki (1991) concluded otherwise and
demonstrated that indomethacin inhibited adenosine- and ATP-induced contractions
of the guinea-pig uterus, respectively. This difference in opinion may be due to
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different experimental techniques, and whether PGHS is involved remains to be
resolved.
ATP and adenosine could be linked to stimulation of phosphoinositide hydrolysis
(PI), leading to inositol triphosphate (IP3) and diacylglycerol (DAG) production and
the subsequent release of PGs. Activation of adenosine receptors in uterine tissue
results in increased phosphoinositide metabolism (Scheimann et al., 1991) and
increased intracellular calcium concentrations (Bradley & Buxton, 1991). Suzuki
(1991) demonstrated that ATP stimulates diacylglycerol formation in myometrial
strips, which is indicative of PLC activation. Inositol 1,4,5-triphosphate (IP3) is a
breakdown product of PLC-mediated phosphatidylinositol 4,5-biphosphate (PIP2)
hydrolysis. IP3 releases calcium from the sarcoplasmic reticulum of muscle cells
(Schrey et al., 1988), and is involved in smooth muscle contraction. IP3 has been
shown to facilitate uterine contractions in a dose-dependent manner by releasing
calcium from pregnant rat (Kanmuru et al., 1988) and pregnant bovine (Carsten &
Miller, 1985) sarcoplasmic reticulum microsomes. Formation of prostanoids could
result from the liberation of arachidonic acid from DAG, another product of
phosphoinositide hydrolysis, if the receptor is coupled directly to PLC activation
(Scheimann et al., 1991). Addition of PLC has been shown to increase PGE2
production by the guinea-pig uterus (Poyser, 1987a). P2Y receptors are linked to G
proteins and PLC in a number of tissues including erythrocytes, aortic endothelial
cells and the lungs (Berrie et al., 1988; Parr et al., 1994; Lazarowski & Harden,
1994; Wilkinson et al., 1994).
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In the experiments of Scheimann et al. (1991), increased production of inositol
phosphates was not blocked by pertussis toxin (PTx), indicating adenosine (A)
receptor coupling to a PTx-insensitive G protein. This is consistent with previous
work implicating the role of a PTx-insensitive G proteins in regulating receptor
activated increases in inositol phosphates in muscle tissue (Masters et al., 1985;
Marc et al., 1988) and suggesting a role for calcium release in the contractile action
of adenosine (Scheimann et al., 1991). Overall, the ability ofATP to exert its effects
via G protein indicates the presence of A receptors and/or P2Y purinoceptors, which
are coupled to G proteins (O'Conner et al., 1991). P2X receptors cannot be involved
since these are ligand-gated ion channels (Bean, 1992). One of the main aims of this
thesis has been to study the effects of ATP, ATP analogues and adenosine on
prostaglandin production by the non-pregnant guinea-pig uterus, particularly by the
endometrium. This is because it has been reported that ATP-induced contractions of
the guinea-pig uterus are inhibited by indomethacin and by removal of the
endometrium (Piper & Hollingsworth, 1996)
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1.3 PROSTAGLANDIN H SYNTHASE (PGHS)
1.3.1 Isoforms of Prostaglandin H Synthase (PGHS)
Prostaglandin endoperoxide synthase (PGHS) is a membrane-bound, glycoprotein
complex and is the enzyme required to produce PGs. PGs of the 2-series are
produced from arachidonic acid, and the first step is the conversion of arachidonic
acid to PGH2 by PGHS (see Fig. 1.1.2.2). This enzyme has two actions. Initially,
arachidonic acid is converted to the unstable PGG2 by the cyclooxygenase activity of
PGHS, and then the peroxidase activity converts PGG2 to PGH2. PGH2 is the key
intermediate in the biosynthesis of the prostaglandins and the final form of
prostaglandin produced is dependent on the cell type and the enzymes they contain
(Samuelsson et a/., 1978).
Recently two isoforms of this enzyme have been identified, cloned and sequenced
(DeWitt & Smith, 1988; Merlie et al., 1988; Kujubu et al., 1991; Wong & Richards,
1991; O'Banion et al., 1992). They have been named PGHS-1 and PGHS-2. The two
enzymes catalyse identical reactions, and have similar amino acid sequences,
catalytic properties and structures. PGHS-1 is expressed constitutively in prostanoid
producing cells. PGHS-1 mRNA and protein are found in most tissues under normal
conditions. PGHS-2 is the inducible form of this enzyme, and its mRNA and protein
levels are very low or even undetectable in most tissues under normal circumstances
(Feng et al., 1993; Kargman et al., 1994). PGHS-2 is expressed when cells are
exposed to mitogens such as growth factors or cytokines. These differences suggest
different physiological roles for these isozymes in the body. It has been proposed that
PGHS-1 is responsible for cellular housekeeping such as vascular homeostasis, water
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resorption in the collecting tubule of the kidney and control of gastric acid secretion
in the stomach (see Otto & Smith, 1995). PGHS-1 is continually available to these
tissues for rapid synthesis of PGH2. PGHS-2 is thought to be involved in
differentiative responses including inflammatory processes, ovulation and
mitogenesis. PGHS-1 and PGHS-2 are found on the endoplasmic reticulum and on
the nuclear envelope (Regier et al., 1993) but it has been proposed that PGHS-1 is
predominantly located on the endoplasmic reticulum, while PGHS-2 is localised
predominantly on the nuclear envelope (see Otto & Smith, 1995).
The question is raised as to why there are two forms of the same enzyme that both
carry out the same reaction? A possible explanation comes from experiments in
fibroblasts and macrophages (Reddy & Herschman, 1994). Reddy & Herschman,
(1994) observed that these cells can constitutively produce PGHS-1 and be induced
by TPA (a protein kinase G activator) to produce PGHS-2. When expression of
>
PGHS-2 protein in response to TPA was blocked, no PGs were produced even
though arachidonic acid mobilisation was observed. It was hypothesised that PGHS-
1 can utilise exogenous arachidonic acid but not that released due to TPA. Therefore,
the arachidonic acid released by TPA must be specifically channelled to PGHS-2
(Reddy & Herschman, 1994). Therefore, different pools of arachidonic acid may
exist in tissues and these pools are specifically channelled to different PGHS
enzymes (Reddy & Herschman, 1994). It has also been proposed that PGHS-1 and
PGHS-2 could be linked to distinct prostaglandin synthases (Naraba et al., 1998).
Several lines of evidence have reported that the two isoforms of PGHS regulate
different phases of prostanoid biosynthesis rather than exert overlapping functions in
activated cells (Langenbach et al., 1995; Murakami et al., 1994; Reddy &
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Herschman, 1994). PGHS-1, but not PGHS-2, functions in thromboxane generation
by activated platelets (Langenbach et al., 1995), and in immediate PGD2 generation
by IgE/Ag-activated mast cells (Murakami et al., 1994; Reddy & Herschman, 1994),
while PGHS-2 is an absolute requirement for delayed prostanoid generation,
extending over several hours, elicited by pro-inflammatory stimuli, even though
PGHS-1 co-exists in the same cell (Murakami et al., 1994; Reddy & Herschman,
1994).
Expression of PGHS has been proposed as the rate-limiting step in PG synthesis
(Poyser, 1973). However, others disagree because an immediate rise in PG synthesis
is seen when exogenous arachidonic acid is added, for example, to intrauterine
tissues (Risbridger et al., 1985; Bennett et al., 1992; Schellenberg & Kirby, 1997).
However, this was not the case in all intrauterine tissues studied. PG output from the
placenta does not increase in the presence of exogenous arachidonic acid (Risbridger
etal., 1985; Schellenberg & Kirby, 1997).
PGHS exhibits self-catalysed breakdown. As PGs are formed, the enzyme catalysing
the reaction is inactivated (Lands, 1979). Therefore, this suggests that fresh PGHS
enzyme must be synthesised in order to produce PGs. It appears that protein
synthesis may be necessary for prostaglandin production. The message and the
protein for PGHS-1 are found in most cells at stable levels, while the message and
the protein for PGHS-2 are low or undetectable but are strongly and rapidly induced
in response to cytokines and mitogens (see Kulmacz, 1998). Important regulation of
PGs occur at the level of catalytic activity with different control of PGHS-1 and
PGHS-2. PGHS-2 is not required to overcome insufficient catalytic capacity but
supplements the latent enzyme, PGHS-1, with a catalytically active enzyme, PGHS-2
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(see Kulmacz, 1998). Once synthesised by the action of PGHS enzymes,
prostaglandins act at specific 7 transmembrane domain prostaglandin receptors.
Pharmacologically, the prostanoid receptors were initially categorised according to
their endogenous ligands. DP receptors are activated by PGD2, EP receptors by
PGE2, FP receptors by PGF2a, IP receptors by PGI2 and TP receptors by TXA2. The
EP receptors were further subdivided into four distinct receptor subtypes, EPM (see
Pierce & Regan, 1998). All prostanoid receptors are G protein coupled receptors.
EP3 receptors are coupled to inhibition of adenylyl cyclase, while DP, IP EP2 and
EP4 recpetors are coupled to the activation of adenylyl cyclase. The EPb FP and TP
receptors are coupled to phosphatidylinositol hydrolysis. Recently different isoforms
of the EP1? EP3, FP and TP receptors (see Pierce & Regan, 1998). Therefore, there
are several possible signal transduction mechanisms that may be involved in the
actions ofPGs.
1.3.2 PGHS and the Placenta
Prostaglandin synthesis is regulated in vivo by the availability of substrate i.e.
arachidonic acid, and by the level of catalytically active PGFIS (Smith el al., 1991;
Challis & Olson, 1988; Shimokawa & Smith, 1991). The change in expression of
PGHS is a rate-limiting step in PG production (Van den Ouderaa et al., 1979). As
mentioned previously, two isoforms of the PGHS enzyme (PGHS-1 and PGHS-2)
have been identified, cloned and sequenced (DeWitt & Smith, 1988; Merlie et al.,
1988; Kujubu el al., 1991; O'Banion et al., 1992). It has previously been
hypothesised that increased PG synthesis by intra-uterine tissues is a result of
increased tissue content of PGHS (Rice et al., 1990). This could involve an increase
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in PGHS synthesis, increased half-life of PGHS or increased affinity of PGHS for its
substrate (Rice et al., (1992).
Previous workers have attributed increased PG production by placenta to increased
PGHS activity which, in turn, is dependent on the gestational age (Rice et al., 1988;
Risbridger et al., 1985). Poyser (1993) showed that guinea-pig placental
homogenates have a high capacity for synthesising PGs. This reflects a high
concentration of PGHS. However, more recent work has concentrated on which
isoform of the PGHS enzyme is responsible for increased prostanoid synthesis from
the placenta throughout gestation. Gibb et al. (1996) observed an increase in PGHS-2
mRNA throughout gestation in ovine placenta, particularly by the trophoblast, while
no change was seen in PGHS-1 mRNA. This is consistent with the results of other
workers (Freed et al., 1995; Rice et al., 1995). It appears likely that the increase in
PGHS-2 mRNA observed was responsible for the increased PGHS-2
immunoreactivity reported by Wimsatt el al. (1993) and the increased PGHS activity
seen during pregnancy (Rice et al., 1988). It has been proposed that increased PGHS
activity during pregnancy may be associated with an increase in phospholipase
activity (Bennett et al., 1992; Rice et al., 1994). One of the aims of this thesis is to
establish which isoform of PGHS is responsible for increased PG output from the
guinea-pig placenta after day 25 of pregnancy.
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1.4 THE INVOLVEMENT OF PHOSPHOLIPASE ENZYMES, CALCIUM,
CALMODULIN AND PROTEIN KINASE C IN PROSTAGLANDIN
PRODUCTION BY THE PLACENTA.
1.4.1 Phospholipase Enzymes and Calcium
It is generally considered that the release of bound arachidonic acid from membrane
phospholipids is the rate-limiting step in the synthesis of prostaglandins (Vogt,
1978), although changes in the concentration of PGHS are able to regulate the
amount of PG synthesised from free arachidonic acid (Herschman, 1996). Release of
arachidonic acid from phospholipids is brought about by the action of phospholipase
(PL) enzymes. At present there are four major groups of phospholipases, PLA]3
PLA2, PLC and PLD (Dennis, 1983). Arachidonic acid can be released from
phospholipids indirectly from inositol phospholipids by the sequential actions of
phospholipase C (PLC), diglyceride lipase and monoglyceride lipase.
PLC is a phosphodiesterase which can hydrolyse phosphatidylinositol-4,5-
biphosphate (PIP2), producing diacylglycerol (DAG) and inositol-1,4,5-triphosphate
(IP3). IP3 causes mobilisation of intracellular calcium from the endoplasmic
reticulum. DAG has a number of actions. It activates protein kinase C (PKC), which
has been observed to stimulate the release of arachidonic acid from phospholipids
and PG synthesis (Wijkander & Sundler, 1989; Zaker & Olson, 1989). DAG may
also regulate arachidonic acid mobilisation through inhibition of one of the enzymes
responsible for arachidonic acid uptake e.g. acyl transferase, thus increasing free
available arachidonate (Fuse et al., 1989). DAG can also be converted to
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phosphatidic acid (PA) (Takuwa et al., 1986). PLA2 can release arachidonic acid
from PA.
Arachidonic acid is predominantly found esterified to the sn-2 position of membrane
phospholipids and PLA2 is most likely responsible for its release and subsequent
eicosanoid biosynthesis (Flower & Blackwell, 1976). PLA2 mobilises arachidonic
acid from phospholipids in a one-step reaction (Mayer & Marshall, 1993; Kramer et
al., 1993; Dennis, 1994; Mukherjee et al., 1994). 'PLA2' is rapidly becoming a large
superfamily of distinct enzymes, and their products are important for signal
transduction processes, eicosanoid and platelet activating factor (PAF) formation,
membrane remodelling and general lipid metabolism. Two major groups of PLA2
enzymes have been identified, extracellular or secretory PLA2 (14-18 kDa) and
intracellular or cytosolic PLA2 (31-110 kDa) (Loeb & Gross, 1986; Davidson &
Dennis, 1990). Secretory PLA2 was discovered by Loeb & Gross (1986) and a second
type of PLA2 (cPLA2) was discovered and observed to have a high molecular mass,
which was greater than the molecular masses of the recognised sPLA2 (Davidson &
Dennis, 1990).
Secreted PLA2 (sPLA2) enzymes were originally sub-divided into three groups, I, II
and III but only types I and II have been identified in mammalian tissues (see Dennis,
1997). A large number of new distinct PLA2 enzymes have been recently discovered,
and from those that have been sequenced, it is clear that they do not fit into the
traditional groups. Two more mammalian forms of sPLA2 have been identified. Type
IIC PLA2 has been identified in the rat and mouse testes (Chen et al., 1994a) and
type V PLA2 has been identified in human, rat and murine macrophages (Chen et al.,
1994b; Chen et al., 1994c; Balboa et al., 1996). The major groups of PLA2 have been
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extended up to group IX, and include secreted and cytosolic PLA2 enzymes that are
both dependent and independent of calcium. Recently identified, but only partially
characterised, was a 42 kDa PLA2 from the human placenta (Buhl et al., 1995).
Initially there was some controversy as to whether PLA2 enzymes were calcium
requiring enzymes (Withnall & Brown, 1982; Downing & Poyser, 1983; Moskowitz
et al., 1985). However, recent studies have observed that sPLA2 enzymes can be
activated by millimolar concentrations of calcium and do not demonstrate any
selectivity for the fatty acids present in the sn-2 position of phospholipid substrate
(Glaser et al., 1993). cPLA2 preferentially hydrolyses arachidonoyl phospholipids
and can be activated by sub-micromolar concentrations of calcium ions and by
phosphorylation by mitogen-activated protein kinase (MAPK) (Leslie, 1997; Clark et
al., 1991; Sharp et al., 1991; Lin et al., 1993; Kramer et al., 1996). In mammalian
cells both sPLA2 and cPLA2 have been reported to mediate liberation of arachidonic
acid from tissue lipids in response to chemical signals (Lin et al., 1992; Fonteh et al.,
1994).
cPLA2 has no homology with known forms of sPLA2 (Clark et al., 1991; Sharp et al.,
1991) and is subject to diverse mechanisms of regulation. cPLA2 can be quickly
activated by post-translational mechanisms to rapidly mobilise arachidonic acid for
PG production, but is also subject to increased synthesis and long term activation,
leading to prolonged PG production (Leslie, 1997). Calcium and mitogen-activated
protein kinase (MAPK) are capable of stimulating cPLA2 activity but it has been
demonstrated that full activation of cPLA2 is only achieved when MAPK-induced
phosphorylation is followed by increased calcium ion concentrations and
translocation of the enzyme to the membrane (Leslie, 1997). cPLA2 contains a
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specific calcium-dependent phospholipid binding domain (CaLB) which shares
homology with the C2 domain of PKC (Clark et al., 1991; Sharp et al., 1991).
Srinivasa et al. (1997) and Balsinde et al. (1996) suggested recently that functional
cPLA2 may be essential for sPLA2 to function. cPLA2 may modify the structure of
the plasma membrane rendering it susceptible to sPLA2. Type V sPLA2 has been
shown to stimulate PG production but prior activation with cPLA2 is necessary
(Balboa et al., 1996; Balsinde et al., 1996). Inflammatory stimuli often induce
expression of type IIA sPLA2 (Pfeilschifter et al., 1993; Nakano et al., 1990;
Nakazato et al., 1991) and cPLA2 (Lin et al., 1992) while anti-inflammatory agents
down-regulate their expression and function (Nakano et al., 1990; Lin et al., 1992;
Muhl etal., 1992).
1.4.2 Phospholipases and the Placenta
As just described, multiple forms of PLA2 have been identified and two functionally
distinct groups characterised i.e. sPLA2 and cPLA2. To date only four types of PLA2
have been identified in human intra-uterine tissues and the human placenta. These
are cPLA2, type II sPLA2, type IV sPLA2 and type V sPLA2 (Seilhamer et al., 1989;
Bennett et al., 1993; Freed et al., 1997; Rice et al., 1998). Recently Buhl et al.
(1995) discovered a novel PLA2 in the human placenta at term. It has a molecular
mass of 42 kDa, which distinguishes it from sPLA2 and cPLA2 although it shares
some properties with both enzymes. This PLA2 enzyme prefers phosphatidylcholine
(PC) as its substrate (Buhl et al., 1991). This 42 kDa enzyme has been named type V
sPLA2 and contains a calcium-dependent lipid-binding domain. While cPLA2
requires p.M concentrations of calcium for activation, it can be further stimulated by
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mM concentrations of calcium (Clark et al., 1990; Leslie et al., 1988; Kim et al.,
1991). Placental PLA2 identified by Buhl et al. (1995) can be stimulated by 10 juM
calcium but cannot be further stimulated by increased calcium concentrations. The
cellular origin of this 42 kDa PLA2 is not clear; it may be exclusively expressed in
placental cells or may originate in some other maternal organ e.g. the uterus.
Expression of type II PLA2 in the placenta has been studied in great detail. Type II
PLA2 mRNA, immunoreactive content and enzymatic activity have been identified
and localised in several gestational tissues including the amnion, choriodecidua and
placenta (Aitken et al., 1990, 1992, 1996; Farrugia et al., 1993; Andersen et al.,
1994). Type II PLA2 is a major component of the net PLA2 in the human placenta
(Rice, 1995). It has been proposed that increased expression of type II PLA2 may
contribute to a labour-associated increase in eicosanoid formation by gestational
tissues (Keirse et al., 1977; Sellers et al., 1981) and to increased type II sPLA2
concentrations in maternal plasma (Rice et al., 1992). Rice (1995) proposed that type
II PLA2 is released by human gestational tissues and acts extracellularly to promote
phospholipid metabolism. A 2-fold increase in immunoreactive type II PLA2 has
been demonstrated in explants of the human term placenta (Farrugia et al., 1997).
Type II PLA2 released from the placenta may enhance placental and/or vascular
glycerophospholipid metabolism and eicosanoid formation (Farrugia et al., 1997).
Although other forms of PLA2 enzymes have been observed in the placenta,
particularly the human placenta, type II PLA2 appears to be the dominant isoform
(Freed et al., 1997). Rice et al. (1994) reported that type II PLA2 accounted for 60-
80% of the total PLA2 enzymatic activity in the human term placenta. A recent study
by Rice et al. (1998) observed that extraction of type II PLA2 from the human
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placenta using antibodies was associated with an 82% decrease in PLA2 enzymatic
activity.
Expression of cPLA2 mRNA has also been demonstrated in the human placenta but
cPLA2 mRNA expression was very low compared to the expression of type II PLA2
mRNA. cPLA2 mRNA expression was much higher in the human amnion (Freed et
al., 1997). However, the activity of cPLA2 in the placenta may have an important
role to play in the development of the fetus, as it has been demonstrated that cPLA2
deficient mice have impaired female reproductive functions (Uozumi et al., 1997).
Recent reports have described the molecular cloning and characterisation of a
receptor for sPLA2 in various mammalian species (Higashino et al., 1994; Ishizaki et
al., 1994; Lambeau et al., 1994; Ancian et al., 1995). PLA2 receptor mRNA has been
identified in human gestational tissues and may contribute to the regulatory effects of
sPLA2 isozymes in these tissues (Moses et al., 1998).
In cases of pre-eclampsia, there are reports of elevated PLA2 enzymatic activity in
homogenates of the placenta (see Aitken et al., 1996) and elevated maternal plasma
concentrations of immunoreactive type II PLA2 (Lin et al., 1995). Immunoreactive
type II PLA2 is also elevated in the maternal plasma of women delivering preterm
(Rice et al., 1992). This may be associated with bacterial infection.
Differential expression of PLA2 enzymes may relate to different functional
characteristics and different roles. For example, sPLA2 enzymes act extracellularly
and may affect phospholipid metabolism in the cell of origin, in adjacent cells or in
distal cells. However, cPLA2 functions only within the cell of origin (Freed et al.,
1997).
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Norman & Poyser (1998a) demonstrated the presence of PLA2 in the guinea-pig
placenta and sub-placenta. However, the PLA2 inhibitor, aristolochic acid, had very
little inhibitory effect on PG production by the guinea-pig placenta and sub-placenta,
while consistently inhibiting PG production by the guinea-pig endometrium. Several
possible explanations for this include the fact that arachidonic acid may not be the
rate-limiting step for PG synthesis by the guinea-pig placenta and sub-placenta. This
has previously been suggested by Schellenberg & Kirby (1997) who observed no
increase in PG output from the guinea-pig placenta in the presence of exogenous
arachidonic acid. Alternatively, the release of arachidonic acid from the guinea-pig
placenta may be dependent on a PLA2 which is unaffected by aristolochic acid, or
the release of arachidonic acid may be via a pathway that does not involve PLA2
(Norman & Poyser, 1998b). Therefore, PLA2 enzymes may contribute to cell
membrane phospholipid metabolism and the formation of second messengers during
pregnancy and at the time of labour and delivery (Rice, 1996). However, it remains
to be seen which PLA2 isozymes are active in the guinea-pig placenta.
1.4.3 Calmodulin and Protein Kinase C
Calmodulin is a 17 kDa cytosolic acidic protein which binds calcium at a ratio of
1:4. It functions in a variety of cells (Cheung, 1980) and, in some tissues, PLA2 is a
calmodulin-dependent enzyme (Wong & Cheung, 1979; Maskowitz et a/., 1983).
Calmodulin may have a critical role in controlling PG production in many tissues. It
has been suggested that calcium binds with calmodulin which in turn combines with
PLA2 and activates the enzyme to release arachidonic acid for PG synthesis from
phospholipids (Poyser, 1985a). Calmodulin has previously been observed to play a
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role in PG synthesis by the guinea-pig uterus (Poyser, 1985a, b; Riley & Poyser,
1987). The use of calmodulin antagonists, trifluoperazine (TFP) and N-(6-
aminohexyl)-5-chloro-l-naphthalenesulphonamide (W-7) significantly reduced PG
output from the superfused guinea-pig uterus and the guinea-pig endometrium in
culture (Poyser, 1985a, b; Riley & Poyser, 1987). It is considered that calcium
binding to calmodulin creates a 'hydrophobic domain' on the surface of calmodulin,
which is essential for the binding of the complex to its acceptor protein. This domain
is assumed to be the binding site of TFP (Andersson et al., 1983). Calmodulin is
difficult to antagonise if it is already tightly bound to its acceptor protein i.e. PLA2
(Spedding, 1983).
The transmission of extracellular signals into their intracellular targets is mediated
by a network of interacting proteins that regulate a large number of cellular
processes. It is well documented that phorbol esters stimulate the activation of
protein kinase C (PKC) in a number of tissues. PKC has long been implicated in
activation of arachidonic acid release, and hence PLA2 activation. The PKC
activator, phorbol 12-myristate 13-acetate (TPA), has no effect on the outputs of PGs
from cultured day 7 and 15 guinea-pig endometrium (Riley & Poyser, 1987b) or
from guinea-pig uterine horns superfused in vitro (Poyser, 1987a). flowever, PKC
has been observed to increase arachidonic acid release in, and PGF2tx and PGE2
production by human decidual cells (Schrey & Read, 1986). Phorbol esters also
stimulate PGHS-2 mRNA expression in cultured human amnion cells (Zakar et al.,
1996). These differences could be due to species variation. PKC has been identified
in human fetal membranes (Okazaki et al., 1984) and in the rat uterus (Baraban et
al., 1985).
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Mitogen-activated protein kinase (MAPK) is a protein involved in signalling
mechanisms. During stimulus-initiated arachidonic acid release accompanied by an
increase in the free intracellular calcium concentration, cPLA2 is phosphorylated and
activated by MAPK (Lin et al., 1993). The cPLA2 is then translocated from the
cytosol to the perinuclear and endoplasmic reticulum membranes (Schievella et al.,
1995). Phosphorylation of cPLA2 increases its activity but does not cause its
translocation to the nuclear envelope. Ca2+ is required for this process. PKC
increases calcium channel activity (Shearman et al., 1989) and thereby activates
PLA2 in some cell types (Xing & Insel, 1996; Felder, 1995). Translocation of cPLA2
to phospholipid membranes is crucial for its function because of the localisation of
its substrate. Phospholipid membranes are also the location of several enzymes
which are important for PG production e.g. PGHS (Morita et al., 1995). An increased
intracellular calcium concentration seems to be the crucial step for cPLA2
translocation because many of the agents stimulate its activity by increasing the
influx of extracellular calcium (Kramer et al., 1995). Kan et al. (1996) observed an
influx of calcium was necessary for translocation of cPLA2 but not for
phosphorylation of cPLA2. Therefore, the second main aim of this thesis is to
investigate some of the intracellular processes controlling placental PG production,
using the guinea-pig placenta as a model.
It is evident that PGs are produced by the non-pregnant uterus and by the placenta
during gestation. PG production by the uterus has been implicated in a number of
physiological processes including luteolysis and ovulation. However, little is known
about the mechanisms involved in their production. Piper & Hollingsworth (1996)
have suggested that ATP and ATP analogues stimulate PG synthesis from the guinea-
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pig uterus. ATP may be stimulating PG production via P2 purinoceptors. This has
been investigated using the non-pregnant guinea-pig uterus as a model.
PGs may also have a role in placental function, the control of placental and uterine
blood flow, and in parturition (Hoedemaker et al., 1991). Pre-eclampsia of
pregnancy is associated with reduced PGI2 production by the placenta (Walsh et al.,
1985). Therefore, a number of factors that may be involved in regulating PG
production by the guinea-pig placenta have been investigated in this thesis. These
include a study to determine whether PGHS-1 and/or PGHS-2 are important for PG
production by the guinea-pig placenta and whether protein synthesis is necessary for
this PG Production. The involvement of intracellular and extracellular calcium has
been investigated. Calcium may be necessary for the activation of phospholipase A2
(PLA2). Calmodulin may also be a requirement for PLA2 activation and PG
synthesis. Therefore, the effects of two calmodulin antagonists on PG production by
the guinea-pig placenta were studied. Protein kinase C (PKC) has long been
implicated in arachidonic acid release, and hence PLA2 activation. The effect of a
PKC activator on PG output from the guinea-pig placenta was investigated. The role
of gonadotrophin releasing hormone (GnRH) in PG production by the guinea-pig
placenta was studied also.
These studies may help to clarify the mechanisms involved in PG synthesis from the
guinea-pig uterus and placenta.
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1.5 SPECIFIC AIMS
In summary, the specific aims of the studies performed in this thesis are:
1. To investigate the effects of adenosine, ATP and ATP analogues on PG production
by the guinea-pig uterus, particularly the endometrium.
2. To investigate whether prostaglandin H synthase-1 or -2 is the predominant form
of the en2yme responsible for PG output from the day 22 and 29 guinea-pig placenta
and sub-placenta.
3. To determine whether protein synthesis is necessary for PG synthesis by the day
29 guinea-pig placenta and sub-placenta.
4. To investigate the calcium requirement for PG production by the day 29 guinea-
pig placenta and sub-placenta.
5.To investigate the roles of calmodulin and protein kinase C in PG production by
the day 29 guinea-pig placenta and sub-placenta.
6. To investigate a possible role for Gonadotrophin releasing hormone (GnRH) in PG
production by the day 29 guinea-pig placenta and sub-placenta.
These studies should provide further information concerning the control of
prostaglandin production by the uterus and placenta.
49
SECTION TWO
2. METHODS & MATERIALS
INTRODUCTION
Many of the general methods used in this project are common to a number of
experiments including uterine superfusion, prostaglandin extraction, tissue culture
and homogenisation of guinea-pig uterus and placenta. These methods are described
here in detail.
2.1 GENERAL METHODS
2.1.1 GUINEA-PIG UTERINE SUPERFUSION
Female Dunkin-Hartley guinea-pigs (600-900 g) were examined daily and a vaginal
smear was taken when the vagina was open. The first day of the oestrous cycle was
taken as the day before the post-ovulatory influx of leucocytes when cornification is
at a maximum. All animals exhibited at least three normal cycles (about 16-18 days
long) before being used. Guinea-pigs were killed by stunning and incising the neck.
Experiments were carried out on day 7 of the oestrous cycle. The uterus was
removed and separated into its two uterine horns. Each uterine horn was blotted dry,
weighed and then cut longitudinally along the mesometrial side. These were then
suspended in separate organ baths with one end attached to an isotonic lever under 2
g tension. Each horn was superfused independently with Krebs' solution (see Section
2.2.7f for composition) at 5 ml/min at 37°C, as described by Poyser & Brydon
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(1983). After equilibrating for 60 min, superfusate samples were collected every 10
min over the next 80 min (8 samples per uterine horn) or 100 min (10 samples per
uterine horn). The test uterine horn was superfused with the agonist between 90-110
min (experiments consisting of 8 samples), or with the antagonist between 90-110
min followed by the agonist plus antagonist between 110-130 min (experiments
consisting of 10 samples). The control uterine horn was superfused with Krebs'
solution only throughout the 140 or 160 min superfusion period. After collection, the
pH of each sample was lowered to 4.0 using 1 M HC1 and the prostaglandins were
extracted by shaking twice with 50 ml ethyl acetate, according to the method
described by Poyser (1972). The two extracts were combined (total volume 100 ml)
and the samples were evaporated to dryness at 50°C in a rotary evaporator and re-
dissolved in 10 ml of ethyl acetate. The recoveries of PGF2a and PGE2 by this
method are >90%, and the recovery of 6-keto-PGFIa is >80% (Poyser & Scott, 1980;
Swan & Poyser, 1983). Samples were stored at -20°C until their PG content was
measured.
2.1.2 GUINEA-PIG ENDOMETRIAL AND MYOMETRIAL CULTURE
Culture experiments using guinea-pig uterus were carried out according to the
method of Baker & Neal (1969) and modified for the culture of endometrial tissue
by Abel & Baird (1980) and Ning et al. (1983). Guinea-pigs were killed on day 7 of
the oestrous cycle by stunning followed by exanguination. The uterine horns were
removed under aseptic conditions and placed in sterile culture dishes containing
tissue culture medium (TCM). TCM was made prior to use and consisted of 500 ml
modified Medium Ml99 plus Earles salts (Table 2.1.2.1 for composition), L-
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Table 2.1.2.1 Composition of Medium 199 modified with Earle's salts and 2.20 g/1
sodium bicarbonate without glutamine. Storage Temperature 2-8 °C
Ingredient mg/litre Ingredient nig/litre
L-Alanine 25.(X) 1-Inositol 0.05
L-Arginine.HCl 70.00 Menadione, NaHSO,.3H20 0.019
L-Aspartic acid 30.00 Nicotinamide 0.025
L-Cysteine.HCl.H20 0.11 p-Aminobenzoic acid 0.05
L-Cystine.2HCl 26.00 Pyridoxine.HCl 0.05
L-Glutamic acid 75.00 Riboflavin 0.01
L-Glutamine 1(X).(M) Thiamine.HC1 0.01
Glutathione 0.05 DL-aTocopherolphosphate
disodium salt 0.01
Glycine 50.00 CaCl2 (anhydrous) 200.00
L-Histidine.HCl.H20 21.88 Fe(N03)3.9H20 0.72
L-Hydroxyproline 10.00 KC1 400.00
L-Isoleucine 20.00 MgS04 (anhydrous) 97.7
L-Leucine 60.00 Vitamin A acetate 0.14
L-Lysine.HCl 70.00 NaHCOi
2200.00
L-Methionine 15.00 NaH2P04.H20 140.00
L-Phenylalanine 25.00 Adenine sulphate 10.00
L-Proline 40.00 Adenylic acid 0.20
L-Serine 25.00 ATP, disodium salt 1.00
L-Threonine 30.00 Cholesterol 0.20
L-Tryptophan 10.00 2-Deoxyribose 0.50
L-Tyrosine disodium 57.66 D-Glucose
salt.2H20
1000.00
L-Valine 25.00 Guanine.HCl 0.30
Ascorbic acid 0.05 Hypoxanthine, Na 0.354
Biotin 0.01 D-Ribose 0.50
Calciferol 0.10 Sodium acetate (anhydrous) 50.00
D-Calcium pantothenate 0.01 Phenol red sodium salt 10.00
Chlorine chloride 0.50 Thymine 0.30
Folic acid 0.01 Tween 80 5.00
NaCl 6800.00 Uracil 0.30
Xanthine, Na 0.34
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glutamine (4 ml; 200 mM solution), amphotericin B (3 ml; 250 pg/ml solution) and
kanamycin (3 ml; 10 mg/ml solution). Each horn was cut longitudinally and 'opened'.
The endometrium was carefully cut away from the myometrium with a pair of fine
■y
dissecting scissors into small pieces approximately 1 mm . The myometrium was
also cut into pieces approximately the same size. The endometrium and myometrium
were placed on sterile lens tissue on top of sterile stainless steel gauze platforms in
Petri dishes containing 4 ml TCM plus the appropriate agonist and/or the antagonist.
The presence of the gauze platform and lens tissue allowed the tissue to receive the
TCM through the capillary action of the lens paper without actually sitting in the
TCM. Endometrium and myometrium were cultured separately and the amount of
tissue in each dish ranged from 10-40 mg. Petri dishes were placed in racks
(maximum of 8 dishes per rack). A control Petri dish containing the tissue without
the agonist/antagonist was placed at the top and bottom of each rack. Racks were
placed in modified Kilner jars and incubated for 24 h (Fig. 2.1.2.1). Each Kilner jar
was pressurised to 0.7 kg cm"2 (10 lb in"2) with 95% 02: 5% C02 The small amounts
of C02 present allowed a C02/HC03" buffer system to be set up which helped
maintain the pH of the medium at 7.4. The TCM was removed from the dishes after
2, 8 and 24 h, and was replaced with fresh medium plus agonist and/or antagonist
after 2 and 8 h; the dishes were returned to the Kilner jars and re-gassed. After 24 h
all tissue was blotted dry and weighed. Samples of TCM were stored at -20°C before

















Figure 2.1.2.1 The arrangement for culturing uterine and placental tissue in a petri
dish, and how the petri dishes were stacked and gassed (via the inlet and outlet
tubes) in a Kilner jar.
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2.1.3 HOMOGENISATION OF GUINEA-PIG ENDOMETRIUM AND
MYOMETRIUM
These experiments were carried out using the endometrium and myometrium of the
guinea-pig uterus after 24 h culture with agonist. The tissue was blotted dry, weighed
and then homogenised using a Fisons glass homogeniser with 5 ml Krebs solution.
The homoginiser was washed with a further 5 ml Krebs' solution, which was then
combined with the original 5 ml (total volume of 10 ml) in a 25 ml conical flask.
Each sample was allowed to incubate for 60 min in a Grant water bath at 37°C and
230 oscillations/min. The pH of each sample was lowered to 4.0 using 1 M HC1.
Prostaglandins were extracted as described in Section 2.1.1 and the extract was
evaporated to dryness on a rotary evaporator. Samples were re-dissolved in 5 ml
ethyl acetate and were stored at -20°C until assayed for PGs.
2.1.4 CULTURE OF GUINEA-PIG PLACENTA AND SUB-PLACENTA
Animals were used on day 22 or 29 of pregnancy and killed as described in Section
2.1.1. The uterine horns were removed under aseptic conditions and placed in sterile
culture dishes containing TCM. Each uterine horn was cut open to reveal between 1
and 4 embryos. The placenta was cut away from each embryo with a pair of fine
dissection scissors. The placenta was then easily separated manually into the chorio¬
allantoic placenta (henceforth called the placenta) and the sub-placenta. Each tissue
was cut into small pieces approximately 1 mm3 and cultured for 24 h as described in
Section 2.1.2. Placenta and sub-placenta were cultured separately with or without the
drug treatment appropriate for the experiment. After 24 h all tissue was blotted dry
and weighed. Samples of culture medium were stored at -20°C until assayed for PGs.
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2.1.5 HOMOGENISATION OF GUINEA-PIG PLACENTA AND SUB-
PLACENTA
Guinea-pig placentae were used on day 22 or 29 of pregnancy. The placentae were
removed and separated from the sub-placenta as described in Section 2.1.4. Each
tissue was roughly divided into equal portions for each experiment, blotted dry and
weighed. The placentae were homogenised in 10 ml Krebs' solution containing a
specific treatment. Samples were incubated and PGs were extracted as described in
Section 2.1.1; the extracted PGs were re-dissolved in 5 ml ethyl acetate and stored at
-20°C before being assayed for their PG content.
2.1.6 RADIOIMMUNOASSAY (RIA) OF PROSTAGLANDINS
2.1.6.1 Assay Procedure
The amounts of PGF2c(, PGE2 and 6-keto-PGFIa present in all samples were
measured by radioimmunoassays (RIA). RIA was first developed in 1959 and is
based on the antigen-antibody equilibrium reaction. It depends on labelled and
unlabeled antigen competing for antibody binding sites.
The amount of tntiated prostaglandin [ TI]PG tracer used in each assay was sufficient
to obtain counts of 15000-20000 per tube when counted in a scintillation counter for
4 min (PGF2a), 8 min (6-keto-PGFia) and 10 min (PGE2). [3FI]PG solution for each
assay was made up from a stock solution of 5 pCi/ml stored in methanol or
acetonitrile:water (9:1) at -20°C. An aliquot was taken and the solvents were blown
off in a stream of warm air (45°C); the residue was re-dissolved in the appropriate
diluent (see Section 2.2.7b-d) to the appropriate concentration. This concentration
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was sufficient to allow 50 pi of the [H]PG solution to give the required number of
counts.
All antibodies used in these experiments were raised in this laboratory. Antiserum
was diluted to a concentration which gave 60 % - 80 % binding of [3H]PG in the
absence of non-radioactive PG (i.e. zero standards). The required dilution of
antiserum was made from a 1:100 stock solution stored at 4°C. The specific
concentration required for each assay was made up in the appropriate diluent.
Standard PG solutions were made from 1 pg/ml stock solutions in methanol stored at
-20°C. 200 pi of stock solution was evaporated in a warm stream of air (45°C) and
re-dissolved in 20 ml of the appropriate diluent (see Section 2.2.7) to give a final
concentration of 10 ng/ml. A series of dilutions (9 for PGE2 and 6-keto-PGF]a and 10
for PGF2a) were prepared from the 10 ng/ml solution. Standard solutions ranged
from 0.005 - 2.56 ng/ml (PGF2tl) or 0.02 - 5.12 ng/ml (PGE2 and 6-Keto-PGFla) and
were stored at -20°C until used. Standards were dispensed out in triplicate (0.5 ml)
into 3 ml plastic tubes (Table 2.1.6.1.1). Tubes 1-4 were non-specific binding
standards to determine the [3FI]PG binding to sites other than the specific PG binding
sites, which include the plastic tube, non-specific sites on the antiserum and on other
compounds in the assay. Tubes 5-8 were counting standards and together give an
average of the counts per tube. The non-specific binding was always less than 10 %
of the total binding for each assay. The last 4 tubes in each assay contained 0.5 ml of
the appropriate diluent in duplicate (zero standards) and 0.5 ml of the PG standard
solution (0.16 ng/ml or 0.32 ng/ml) also in duplicate so that the inter-assay
coefficient of variation could be calculated.
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The stored samples were dispensed out in duplicate in the appropriate volume. If
stored in ethyl acetate, this was blown off in a warm stream of air at 45°C. The
appropriate diluent was then added (0.5 ml) so that the volume was the same in the
standards and in the sample tubes. Samples stored in TCM were dispensed out
without extraction and 100 pi of TCM was added to all standards and the zero
standards to minimise the effect of the medium on the assay.
All tubes were then treated the same way throughout the assay. [3H]PG solution (50
pi) was added to all tubes (except to the counting standards), followed by 50 pi of
antibody. The tubes were then 'whirlimixed' and incubated at room temperature for 1
h (PGF2a) or 2 h (PGE2 and 6-keto-PGFla). After incubation, normal rabbit serum
(NRS; 50 pi; 1:140 dilution for the 6-keto-PGFi,x assay and 1:100 dilutions for the
PGF2a and PGE2 assays) and donkey anti-rabbit serum (DARS; 50 pi; 1:10 dilution
for all PG assays) were added; the tubes were 'whirlimixed' again and incubated
overnight at 4°C. NRS was added to ensure that, at dilutions of antisera used, there
was sufficient gamma-globulin present for adequate precipitation. DARS was added
to separate free PG from antibody-bound PG. After overnight incubation, tubes were
centrifuged at 13000 g for 30 min at 4°C. The supernatant was discarded and 2.5 ml
of scintillant was added. The tubes were then capped and 'whirlimixed' to re-suspend
the pellet, and the radioactivity in each tube was counted in a Packard Liquid
Scintillation Counter.
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The percentage of ['H]PG bound is calculated by the following formula:
% [3H]PG Bound = Counts in Tube x 100
Average Std Counts
where the average standard (Std) counts is the average of the counts in tubes 5-8
(counting standards).
Data from the counter were passed to an IBM-XT personal computer programmed
with the Packard Data Acquisition and Analysis system (PC-DAAS). The Spline
Curve-Fit programme was used which processes the standards according to a
Modified Smooth Spline Algorithm. The non-specific binding from all the standards
are subtracted by the programme which then calculates the co-ordinates for a curve
of the best fit (Figs. 2.1.6.1.1 - 2.1.6.1.3). The amount of PG in each sample tube is
calculated using this curve. The detection limit was 10-30 pg of PG per assay tube.
The intra-assay coefficient of variation was calculated using the formula:
Intra-assay coefficient of variation = standard deviation of sample duplicate x 100
mean value of sample duplicate
This coefficient was calculated by the computer for each unknown sample assayed in
duplicate. If the coefficient for the sample was greater than 12 %, the sample was re-
assayed.
The inter-assay coefficient of variation was calculated using the values obtained
from tubes containing a known standard amount of the appropriate PG (0.16 ng/ml
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0.001 0.01 0.1 1 10
ng PGF2cx / tube
Figure 2.1.6.1.1 Standard curve for PGF2a radioimmunoassay.
The data indicate the mean (± SEM, n=6).
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ng PGE2 / tube
Figure 2.1.6.1.2 Standard curve for PGE2 radioimmunoassay.
The data indicate the mean (± SEM, n=6).
62
ng 6-KETO-PGF1a / tube
Figure 2.1.6.1.3 Standard curve for 6-KET0-PGF-|a radioimmunoassay.
The data indicate the mean (± SEM, n=6).
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or 0.32 ng/ml), which were included at the end of the assay, according to the formula
below:
Inter-assay coefficient = standard deviation of known PG standard x 100
mean of know PG standard
This was < 10 % for all PGs measured.
2.1.6.2 Determination ofCross-Reactivities
The cross-reactivities for the prostaglandin antiserum used in these experiments had
been determined previously in this laboratory (Dighe et al., 1975; Poyser & Scott,
1980; Lytton & Poyser, 1982). The results of these experiments are shown in Tables
2.1.6.2.1 -2.1.6.2.3. Standard curves for the PGs and their metabolites were set up.
The concentration of PG or PG metabolite that produced a 50 % fall in binding from
the binding produced by the zero standard solution of the PG to which the antiserum
was raised and the cross-reactivities calculated.
Percentage cross-reactivity was calculated by the following formula:
% cross-reactivity = concentration PG (to which antisera was raised)
giving a 50 % fall in zero standard binding
x ioo
concentration of different PG or PG metabolite
giving a 50 % fall in zero standard binding
The PGF2a and PGE2 antibodies do not distinguish between the 1- and 2-series
prostaglandins. However, previous studies (Poyser, 1983) have shown little PGE]
and PGF]a to be produced by the guinea-pig uterus. In addition PGA2 and PGB2 are
not produced naturally and are therefore unlikely to interfere with the PGE2
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Table 2.1.6.2.1 Cross-reactivities with various prostanoids and their metabolites for
the PGF2a antiserum (rabbit 5, 6th bleed), measured at 30 % binding of tracer. (TxET
is thromboxane B2).
















Table 2.1.6.2.2 Cross-reactivities with various prostanoids and their metabolites for
the PGE2 antiserum (rabbit R5, 6th bleed), measured at 30 Vc binding of tracer. (TxB2
is thromboxane B2).
















Table 2.1.6.2.3 Cross-reactivities with various prostanoids and their metabolites for
the 6-keto-PGFia antiserum (rabbit NP1, 6th bleed), measured at 30 <7( binding of
tracer. (TxB2 is thromboxane EC).
















antiserum. Thus the PGF2a and PGE2 antibodies were removing predominantly the
PG to which they were raised.
2.1.7 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR PGFM
This technique is a variant ofRIA in which the label used is an enzyme rather than a
radioisotope. The ELISA used here was to measure the amount of prostaglandin
F2a metabolite called 13, 14-dihydro-15-keto-PGF2a (PGFM) in culture samples
already assayed for PG.
Plates were coated with DARS using direct y-globulin procedure and were washed
four times in wash buffer (for composition see Section 2.2.7e). The first two wells in
each plate contained 150 pi ELISA buffer (Section 2.2.7d) and were used to
calculate the non-specific binding. The next two wells contained 100 pi ELISA
buffer and were used to determine binding only. The final four wells in each assay
contained a quality control (QC) with a normal reading of approximately 200 pg/ml.
Ten standard solutions were prepared from a stock solution of 20 pg/ml stored at
-20°C. The standards were made up in ELISA buffer and concentrations ranged from
0.01-5.12 ng/ml. These were dispensed in duplicate in 100 pi. Samples were also
dispensed in duplicate in 100 pi at the appropriate dilution.
The required dilution of antiserum (1:100) was prepared from a stock solution of
1:50,000 in buffer. Antibodies were raised in the MRC Reproductive Biology Unit,
Edinburgh. The label used was a peroxidase conjugate (POX) and a 1:50 dilution
was made from a 1:40,000 stock solution. 50 pi of diluted antiserum was added to all
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wells except for the first two wells, and 50 pi of POX was added to all wells. The
plates were then allowed to incubate overnight at 4°C.
After overnight incubation, the plates were washed several times in wash buffer.
Tetramethyl benzidine substrate (TMB) was prepared from stable solutions; 2 ml of
urea-peroxidase (0.3g per 50 ml of 100 mM sodium acetate buffer pH 6.0) and 2 ml
of tetramethyl benzidine (2 mg/ml in dimethylformamide). These were added to 20
ml of 100 mM sodium acetate buffer (pH 6.0). TMB substrate (200 pi) was added
to all wells and the plates were left for approximately 10 min to allow colour to
develop. After this time, 50 pi of 2N sulphuric acid was added to quench
development of colour. The plates were read in a labsystems multiskan MCC/340
plate-reader and the results calculated on an assayzap program.
For this ELISA the inter-assay coefficient of variation was calculated as 14.7 %
while the intra-assay coefficient of variation was calculated as 6.8 % (see Section
2.1.6.1).
The cross-reactivities for the antiserum used in these experiments had been
determined previously in the Reproductive Biology Unit laboratory, Edinburgh
(Kelly et al., 1986). The results of these experiments are shown in Table 2.1.7.1.
2.1.8 STATISTICS
Statistical methods are used to analyse experimental results so that they can be
displayed in a way that is easy to comprehend. The arithmetic mean or the simple
'mean' of a population is usually the first thing calculated, otherwise known as the
'most typical value'. This is the same as the average. The mean is the summation of
the individual values divided by the number of values or the (n) number. The aim is
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Table 2.1.7.1 Cross-reactivities with various prostanoids and their metabolites for the
13,14-dihydro-15-keto-PGF2a (PGFM) antiserum.








to determine whether the hypothesis that the samples studied were drawn from the
same population is true. When there is more than two samples to compare, then a
multidimensional /-test is used which is called the analysis of variance (ANOVA)
but, while this test does tell you whether the groups are significantly different, it
doesn't tell you which groups differ from each other.
The purpose of the /-test is to assess the significance of the difference in the means
of two groups (e.g. the difference between a control group and a treated group).
Before calculating the value of /, the means and standard deviations of the two
groups being studied are required. The preconditions of doing a /-test are that the
distribution of the data should be normal, the number of groups to be compared
should be two and that there should be no significant difference in the variance of
the two groups being compared. The F-test is used to determine this and the formula
for this is shown below:
F test = population variance estimated from sample mean
population variance estimated as average of the sample variance
The difference between the /-test and the F-test is that the /-test compares the means
while the F-test compares variance (the square of the standard deviation). If the
hypothesis that all the samples in each experiment are drawn from the same
population is true, then the within group variance and between group variance are
both estimates of the same population variance and so should be about equal (Glantz,
1992). If 'F' is a big number then the variability between samples is larger than
expected from the variability within the samples and the hypothesis that the samples
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are drawn from the same population is rejected. If there is no significant difference
between standard deviations then we can go ahead and calculate the value ofV.
The formula for the t-test is shown below:
Mest = Difference in sample means
Standard error of difference of sample means
Values for V and T" are tabulated and depend on two factors. The first of these is the
number of samples in each experiment otherwise known as degrees of freedom (d.f.).
The greater the sample size, the more likely it is that there will be a significant
difference in the population. The d.f. is calculated by n-1 (where n is the number of
samples in each group). As the sample size increases then the value of 7' required to
reject the hypothesis that the samples came from the same population decreases. The
second factor is the level of confidence with which one rejects the hypothesis of no
difference. This is known as the P value, which stands for probability, and is
expressed either as a percentage or as a decimal. As the value of V increases, then the
P value decreases and thus becomes more significant.
'Duncan's Multiple Range Test' was used to test for significant differences of
increasing size in more than 2 samples analysed at the same time. In this test the
confidence levels are not appropriate and are replaced by 'protection levels' against
finding false significant differences. It uses a variable level depending on the number
of means involved at each stage. The idea is that as the number of means under test
increases, the smaller is the probability that they will be alike.
To summarise, since the interest was on the mean, which gives more information
about the samples tested, and the data were a continuous variable, the students t-test
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was therefore used. Where this was not appropriate Duncan's multiple range test was




The sources of the materials are as follows:
2.2.1 Solvents
Acetonitrile - Rathburn Chemicals Ltd, Walkerburn, Scotland, UK.
Ethyl acetate* - Prolabo, 54 rue Roger Salengro, 94120, Fontenay, S/Bois.
2-Ethoxyethanol - Fisher Scientific UK Ltd, Leicestershire, UK.
Methanol - Rathburn Chemicals Ltd, Walkerburn, Scotland, UK.
Toluene - Fisher Scientific UK Ltd, Leicestershire, UK.
* Redistilled before used
2.2.2 Chemicals
Actinomycin D - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
Adenosine - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
Amphotericin B - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
ATP (Adenosine 5'-triphosphate) - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
a,(3 Methylene ATP - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
P,y Methylene ATP - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
Calcium chloride - B.D.H. Laboratory Supplies, Poole, UK.
Cycloheximide - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
D-Glucose - B.D.H. Laboratory Supplies, Poole, UK.
EGTA (Ethyleneglycol-bis-(P-aminoethyl ether) N,N,N',N'-tetraacetic acid) -
Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
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Gonadotrophin releasing hormone - Sigma-Aldrich Company Ltd, Poole, Dorset,
UK.
Hydrochloric acid - B.D.H. Laboratory Supplies, Poole, UK.
Indomethacin - Merck, Sharpe & Dohme Ltd, Hoddesdon, Herts, UK.
Kanamycin - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
L-Glutamine - ICN, Oxfordshire, UK.
Magnesium sulphate - B.D.H. Laboratory Supplies, Poole, UK.
Medium 199 - ICN, Oxfordshire, UK.
2-Methylthio ATP - RBI, St Albans, Herts., UK.
Nifedipine - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
NS-398 (N-(2-cyclohexyloxy-4-nitrophenyl) methanesulphonamide) - Calbiochem,
Nottingham, UK.
Potassium chloride - Fisons Scientific Equipment, Loughborough, UK.
PPO (2,5-Diphenyloxazole) - Fisher Scientific UK Ltd, Leicestershire, UK.
Puromycin - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
Sodium chloride - Fisher Scientific UK Ltd, Leicestershire, UK.
Sodium hydrogen carbonate - B.D.H. Laboratory Supplies, Poole, UK.
8-Sulphophenyltheophylline - RBI, St Albans, Herts., UK.
Suramin - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
TFP (Trifluoperazine) - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
TMB-8 (3,4,5 Trimethoxybenzoic acid 8-(diethylamino) octyl ester hydrochloride) -
Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
TPA (Phorbol 12 myristate 13-acetate) - Sigma-Aldrich Company Ltd, Poole, Dorset,
UK.
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UTP (Uridine triphosphate) - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
Verapamil - Sigma-Aldrich Company Ltd, Poole, Dorset, UK.
W-7 (N-(6-aminohexyl)-5-chloro-l-naphthalene sulfonamide) - Sigma-Aldrich
Company Ltd, Poole, Dorset, UK.
2.2.3 Radioactive Compounds
[5,6, 8, 9,11,12, 14, 15(n)-3H] PGF2a
[5, 6, 8, 11, 12, 14, 15 (n) - 3H] PGE2
[5, 8, 9, 11, 12, 14, 15 (n) - 3H] 6-Keto-PGFla
All [3H]PG stock solutions were diluted to 5 pCi/ml and stored at -20°C before being
3 3diluted further and used for radioimmunoassay. [ H]PGF2a and [ H]PGE2 were
initially diluted in methanol and [ FI]6-keto-PGFia was diluted in a 1:9 mixture of
acetonitrile and water. All radioactive compounds were supplied by Amersham
International Ltd, Cardiff, UK.
2.2.4 Antibodies
Normal rabbit serum (NRS) and donkey anti-rabbit serum (DAR.S) - Scottish
Antibody Production Unit, Carluke, Scotland, UK.
PGF2a, PGE2 and 6-keto-PGFIa antibodies were all raised in this laboratory in rabbits
(Dighe et al., 1975; Dighe et al., 1978a; Dighe et al., 1978b).
2.2.5 Gases
95% 02: 5% C02 - British Oxygen Co. Ltd., Guildford, UK
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2.2.6 Other Materials
Plastic tubes (3 ml) and caps - Greiner, Gloucestershire, UK
Easy grip tissue culture dishes (sterile/gamma irradiated) - Becton Dickinson,
Plymouth, UK
Plastic blood containers (5 ml) - Sterelin Ltd, Teddington, UK
Stainless steel mesh - Advent Research Materials, Suffolk, UK
2.2.7 Composition of Solutions




Add 12 ml concentrated HC1 and check pH




Add 14.5 ml concentrated HC1 and check pH
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(c) Phosphate Diluent (0.05M, pH 7.5) used for PGE2 assay
NaHP04 (anhydrous) 34.5 g
H20 5 L
1M NaH2P042H20 56 ml
NaN3 0.5 g
Check pH
(d) ELISA Buffer (pH 7.2) used for PGFM assay
100 mM Tris pH 7.2
150 mg/litre 2-methylisothizolone
150 mg/litre Bromo nitro dioxane
2 mg/ml BSA
Phenol red 300 pi 0.5 % solution per litre
Sodium chloride 9 g/litre
EDTA 2 mM (4 ml/litre of 0.5 M stock)
Check pH
(e) ELISA wash buffer used for PGFM assay







10% KC1 solution 17.7 ml
10% MgS04.7H20 solution 14.5 ml
10% KH2P04 solution 8.0 ml
M CaCl2 solution 12.6 ml
Make up to 5 L with H20
(g) Scintillant
Toluene 1.5 L





This section deals, in full detail, with all the results obtained from the experiments
carried out for this thesis.
3A. AN INVESTIGATION INTO THE EFFECT OF ADENOSINE 5'-
TRIPHOSPHATE (ATP) ON PROSTAGLANDIN PRODUCTION BY THE
GUINEA-PIG UTERUS.
Introduction:
Previously it has been observed that adenosine and adenine nucleotides interact with
prostaglandins (PGs) in a number of tissues (Dozi-Vassilides et al., 1976) and in
particular cause contraction of the guinea-pig uterus (Moritoki et al., 1979; Smith et
al., 1988; Scheimann et al., 1991; Piper & Hollingsworth, 1996). Piper &
Hollingsworth (1996) have shown that adenosine 5'-triphosphate (ATP) and its
analogues contract the non-pregnant guinea-pig uterus in vitro. These spasmogenic
actions were inhibited by the prostaglandin H synthase (PGHS) inhibitor
indomethacin suggesting that PGs mediate this contractile effect (Piper &
Hollingsworth, 1996). Therefore, the effects of ATP, 2 methylthio-ATP, aP
methylene-ATP, Py methylene-ATP, UTP and adenosine on PG production by the
guinea-pig uterus have been investigated. Studies were carried out on non-pregnant
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guinea-pig uterus superfused in vitro and, on guinea-pig endometrium and
myometrium cultured for a period of 24 h.
These agonists act at adenosine (A, formerly PI) receptors and P2 purinoceptors.
ATP acts via P2 purinoceptors and, adenosine via A receptors. However, ATP can be
hydrolysed by ecto-nucleotidases and metabolised to adenosine (Paton, 1985), so it
could exert its effect via P2 and/or A receptors. P2 and A receptors have previously
been identified in the guinea-pig myometrium by Smith et al. (1988) and this group
have shown that ATP-induced contraction of guinea-pig myometrium is mediated by
both P2 and A receptors.
In this study the effects of an A receptor antagonist, 8-sulphophenyltheophylline, and
a P2 antagonist, suramin, have also been investigated on the uterus superfused in
vitro, and on the endometrium and myometrium cultured for 24 h.
8-Sulphophenyltheophylline and suramin are non-selective A and P2 antagonists,
respectively. These studies were carried out in the presence of ATP and adenosine.
This was to determine if the prostaglandin-releasing effects of ATP were mediated
via P2 purinoceptors or whether, after being broken down to adenosine, ATP could
act via adenosine receptors. Total PG production by the guinea-pig uterus was also
measured, using endometrial and myometrial homogenates, after the tissue had been
cultured for a period of 24 h with ATP or adenosine, either on their own or in the




For superfusion experiments, the guinea-pig uterus was removed on day 7 of the
oestrous cycle as described previously (Section 2.1.1), separated into 2 uterine horns,
blotted dry and weighed. Each horn was cut longitudinally along the anti-
mesometrial side and suspended in an organ bath with one end attached to an
isotonic lever. Each uterine horn was superfused independently with Krebs solution
at 5 ml/min at 37°C for a 60 min equilibration period. Samples where collected every
10 min for the next 80 min (8 samples per uterine horn) or 100 min (10 samples per
uterine horn). One of the uterine horns was untreated and acted as a control. The test
uterine horn was superfused with either ATP (100 pM), 2 methylthio-ATP (1 pM),
ap methylene-ATP (100 pM), Py methylene-ATP (100 pM), UTP (100 pM) or
adenosine (100 pM) between 30 and 50 min after equilibration (samples 4 and 5)
(for experiment 3A. 1). In experiment 3A.3, the test uterine horn was treated with
suramin (100 pM) or 8-sulphophenyltheophylline (140 pM) between 30-50 min after
equilibration (samples 4 and 5), followed by treatment with either suramin (100 pM)
plus ATP (100 pM) or adenosine (100 pM), or with 8-sulphophenyltheophylline
(140 pM) plus ATP (100 pM) or adenosine (100 mM) between 50-70 min after
equilibration (samples 6 and 7). Following treatment with the appropriate drug, all
samples were treated in the same way. The pH of each sample was lowered to 4.0
and the prostaglandins were extracted by shaking twice with 50 ml ethyl acetate,
according to the method described by Poyser (1972). The two ethyl acetate fractions
were combined and evaporated to dryness on a rotary evaporator. Samples were re-
dissolved in 10 ml ethyl acetate and stored at -20°C before assaying for their PGF2a,
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PGE? and 6-keto-Fla content. Changes in PG output with time were analysed by the
Duncan's multiple range test.
Culture experiments were carried out using the guinea-pig uterus on day 7 of the
oestrous cycle as described in Section 2.1.2. The endometrium and myometrium
were separated and prepared for culture as described in Section 2.1.2. The tissue was
cultured separately on raised platforms in Petri dishes containing tissue culture
medium (see Section 2.1.2). Kilner jars contained 8 Petri dishes (2 controls and 6
treated). The endometrium and myometrium in experiment 3A.2 were treated with
either ATP (10, 50 and 100 pM), 2 methylthio-ATP (1, 5, 10 and 25 pM), a|3
methylene-ATP (10, 50 and 100 pM), Py methylene-ATP (10, 50 and 100 pM), UTP
(10, 50 and 100 pM) or adenosine (10, 50 and 100 pM). In experiment 3A.4, the
endometrium and myometrium were treated with ATP (100 pM), ATP (100 pM)
plus suramin (100 pM), ATP (100 pM) plus 8-sulphophenyltheophylline (140 pM),
adenosine (100 pM), adenosine (100 pM) plus suramin (100 pM), or adenosine (100
pM) plus 8-sulphophenyltheophylline (140 pM). All samples were collected after 2,
8 and 24 h and stored at -20°C before being assayed for their PG content. The results
from these experiments were analysed by one-way analysis of variance (ANOVA)
and by the paired t-test.
PG production by homogenates of guinea-pig endometrium and myometrium was
measured using the tissue after 24 h culture with ATP (100 pM), adenosine (100
pM), and ATP (100 pM) or adenosine (100 pM) with either suramin (100 pM) or 8-
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sulphophenyltheophylline (140 pM). Control, untreated tissues were also used. The
tissue was blotted dry, weighed and then homogenised as described in Section 2.1.3.
Each sample was incubated for 60 min in a water bath at 37°C and 230
oscillations/min. The pH of each sample was lowered to 4.0 using 1 M HC1, and
prostaglandins were extracted as described in Section 2.1.1. The extracts were
evaporated to dryness on a rotary evaporator. Samples were re-dissolved in 5 ml
ethyl acetate and were stored at -20°C until assayed for their PG content. The results
from these experiments were analysed by one-way analysis of variance (ANOVA)
and by the paired t-test.
Results:
Experiment 3A.1 The Effects of ATP, Adenosine and ATP Analogues on
Prostaglandin Output From Day 7 Guinea-Pig Uterus Superfused In Vitro.
ATP (100 pM), 2 methylthio-ATP (1 pM), UTP (100 pM) and adenosine (100 pM)
significantly (P < 0.05, n=5) increased PGF2a output from the day 7 guinea-pig
uterus superfused in vitro (Figs. 3A.l.la, 3A. 1.3a, 3A.1.5a and 3A. 1.6a). aP
Methylene-ATP (100 pM) and Py methylene-ATP (100 pM) had no significant effect
on PGF2a output (Figs. 3A. 1.2a and 3A. 1.4a). PGE2 output from guinea-pig uterus
was unaffected by ATP (100 pM), aP methylene-ATP (100 pM), 2 methylthio-ATP
(1 pM), Py methylene-ATP (100 pM), UTP (100 pM) and adensoine (100 pM) (Figs.





























































Figure 3A.1.1 Effect of ATP (100 (jM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF1a
from day 7 superfused guinea-pig uterus.
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Figure 3A.1.2 Effect of aP methylene-ATP (100 pM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KET0-PGF1a from day 7
superfused guinea-pig uterus.
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Figure 3A.1.3 Effect of 2-methylthio-ATP (1 pM) on mean (±SEM, n=
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF1a from day 7
superfused guinea-pig uterus.
*Significantly higher, P < 0.05, than value immediately preceding
2 methylthio-ATP treatment.
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Figure 3A.1.4 Effect of (3ymethylene ATP (100 |iM) on mean (±SEM, n=5











































Figure 3A.1.5 Effect of UTP (100 pM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF-|a from
day 7 superfused guinea-pig uterus.
*Significantly higher, P < 0.05, than value immediately preceding
UTP treatment.
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Figure 3A.1.6 Effect of adenosine (100 |jM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF-|a from day
7 superfused guinea-pig uterus.
*Significantly higher, P < 0.05, than value immediately preceding
adenosine treatment.
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by ATP (100 |uM), 2 methylthio-ATP (1 pM) and adenosine (100 pM) (Figs.
3A. 1.1c, 3A. 1.3c and 3A.1.6c). a(3 Methylene-ATP (100 pM), py methylene-ATP
(100 pM) and UTP (100 pM) had no significant effect on the outputs of 6-keto-
PGFla (Figs. 3A. 1,2c, 3A. 1,4c and 3A. 1,5c).
Experiment 3A.2 The Effects of ATP, Adenosine and ATP Analogues on
Prostaglandin Output from Day 7 Guinea-Pig Endometrium and Myometrium
in Culture.
Endometrium
ATP (10, 50 and 100 pM) and 2 methylthio-ATP (1, 5, 10 and 25 pM) significantly
(P < 0.05, n=5) increased PGF2a outputs from guinea-pig endometrium after 24 h of
culture but had no effect after 2 h and 8 h of culture (Figs. 3A.2.1a and 3A.2.3a).
ATP (10, 50 and 100 pM) had no significant effect on PGE2 output from guinea-pig
endometrium (Fig. 3A.2.1b). 2 Methylthio-ATP (1, 5, 10 and 25 pM) had no effect
on PGE2 output, except for 5 pM 2 methylthio-ATP which significantly (P < 0.05,
n=5) decreased PGE2 output after 8 h of culture and 1 pM 2 methylthio-ATP which
significantly (P < 0.05, n=5) increased PGE2 output after 24 h (Figs. 3A.2.1b and
3A.2.3b). ATP (10, 50 and 100 pM) and 2 methylthio-ATP (5, 10 and 25 pM)
significantly (P < 0.05, n=5) decreased 6-keto-PGFla output after 8 h and 24 h of
culture, but had no effect during the first 2 h of culture (Fig. 3A.2.lc). 2 Methylthio-
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ATP (1 pM) had no significant effect on 6-keto-PGFla output from endometrium
cultured for 24 h (Fig. 3A.2.3c).
a(3 Methylene-ATP (10, 50 and 100 pM) had no effect on PGF2(X output after 2 h of
culture but significantly (P < 0.05, n=5) increased PGF2a output after 8 h and 24 h,
except for the 10 pM concentration after 8 h (Fig. 3A.2.3a). a(3 Methylene-ATP (10,
50 and 100 pM) significantly increased PGE2 output after 24 h but not after 2 and 8
h of culture (Figs. 3A.2.3a and b). 6-Keto-PGFla output was significantly (P < 0.05,
n=5) decreased by aP methylene-ATP (50 and 100 pM, but not by 10 pM) after 8 h
of culture (Fig. 3A.2.3c). aP Methylene-ATP had no effect on 6-keto-PGFia output
after 2 h and 24 h (Fig. 3A.2.3c).
py Methylene-ATP (10, 50 and 100 pM) had no significant effect on PGF2a output
after 2 h of culture but stimulated PGF2a output significantly (P < 0.05, n=5) after 8
and 24 h, except for 10 pM Py methylene-ATP after 8 h (Fig. 3A.2.5a). PGE2 output
was significantly (P < 0.05, n=5) increased by Py methylene-ATP (10, 50 and 100
pM) after 24 h of culture but had no effect after 2 h and 8 h of culture, except 50 pM
Py methylene-ATP which decreased PGE2 output significantly in the first 2 h (P <
0.05, n=5) (Fig. 3A.2.5b). 6-Keto-PGFia output was not affected by py methylene-
ATP except, after 24 h, 6-keto-PGFia output was significantly (P < 0.05, n=5)
increased by Py methylene-ATP (50 pM) (Fig.3A.2.5c).
Adenosine (10, 50 and 100 pM) and UTP (10, 50 and 100 pM) significantly (P <
0.05, n=5) stimulated PGF2a output after 24 h of culture, but not after 2 and 8 h (Fig.
3A.2.7a). PGE2 output was significantly (P < 0.05, n=5) reduced by adenosine (50
and 100 pM, but not 10 pM) and by UTP (10 pM, but not 50 and 100 pM) in the
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first 2 h of culture (Fig. 3A.2.7b). Adenosine (10, 50 and 100 pM) and UTP (10, 50
and 100 juM) had no effect on PGE2 output after 8 and 24 h of culture, except UTP
(100 pM) which significantly (P < 0.05, n=5) decreased PGE2 output after 8 h and
adenosine (100 pM) which significantly (P < 0.05, n=5) increased PGE2 output after
24 h of culture (Fig. 3A.2.7b). Adenosine (10, 50 and 100 pM) and UTP (10, 50 and
100 pM) had no effect on 6-keto-PGFla output, except adenosine (10 and 50 pM)
which increased 6-keto-PGFla output significantly (P < 0.05) after 24 h of culture
(Fig. 3A.2.7c).
Myometrium
ATP (10, 50 and 100 pM) and 2 methylthio-ATP (1,5, 10 and 25 pM) had no effect
on PGF2a output except, after 2 h, PGF2a output was significantly (P < 0.05, n=5)
increased by 5 pM 2 methylthio-ATP and, after 24 h, by 1 and 25 pM 2 methylthio-
ATP (Figs. 3A.2.2a and 3A.2.4a). PGE2 output was significantly (P < 0.05, n=5)
reduced by ATP (10 and 100 pM, but not 50 pM) throughout the 24 h culture period,
except by the 10 pM concentration after 8 h of culture (Fig. 3A.2.2b). 2 Methylthio-
ATP (1 pM, but not 5, 10 and 100 pM) significantly (P < 0.05, n=5) inhibited PGE2
output after 2 h but not after 8 and 24 h of culture (Figs. 3A.2.2b and 3A.2.4b). 2
Methylthio-ATP (5 and 10 pM, but not 1 and 25 pM) significantly (P < 0.05, n=5)
reduced PGE2 output after 8 and 24 h of culture (Figs. 3A.2.2b and 3A.2.4b). 6-Keto-
PGF!a output was significantly (P < 0.05, n=5) reduced by 2 methylthio-ATP (1 pM)
after the first 2 h of culture but not after 8 and 24 h of culture (Fig. 3A.2.4c). ATP
(10, 50 and 100 pM) and 2 methylthio-ATP (5, 10 and 25 pM) had no effect on 6-
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keto-PGFla output after 2 h of culture (Fig. 3A.2.2c). ATP (10, 50 and 100 pM) and
2 methylthio-ATP (5, 10 and 25 pM) significantly (P < 0.05, n=5) inhibited 6-keto-
PGF!a output after 8 and 24 h (Fig. 3A.2.2c).
ap Methylene-ATP (10, 50 and 100 pM) had no effect on PGF2ra output after 2 h and
8 h of culture, except for 50 pM aP methylene-ATP which increased PGF2a output
significantly (P < 0.05, n=5) after 8 h (Fig. 3A.2.4a). aP Methylene-ATP (10, 50 and
100 pM) significantly (P < 0.05, n=5) increased PGF2(X output after 24 h (Fig.
3A.2.4a). aP Methylene-ATP (10, 50 and 100 mM) had no significant effect on
PGE2 output throughout the 24 h culture period (Fig. 3A.2.4b). 6-Keto-PGFla output
was significantly (P < 0.05, n=5) increased by aP methylene-ATP (50 pM, but not
10 and 100 pM) in the first 2 h of culture and reduced by aP methylene-ATP (10 and
50 pM, but not 100 pM) after 24 h (Fig. 3A.2.4c).
PGF2(X output was significantly (P < 0.05, n=5) increased by Py methylene-ATP (50
pM, but not 10 and 100 pM) after 2 h of culture, by Py methylene-ATP (10 and 50
pM, but not 100 pM) after 8 h of culture and by py methylene-ATP (10, 50 and 100
pM) after 24 h of culture (Fig. 3A.2.6a). Py Methylene-ATP (10, 50 and 100 pM)
significantly (P < 0.05, n=5) increased PGE2 output after 24 h (Fig. 3A.2.6b). PGE2
output was reduced significantly (P < 0.05, n=5) by Py methylene-ATP (10 and 100
pM, but not 50 pM) alter 2 h (Fig. 3A.2.6b). Py methylene-ATP had no effect on
PGE2 output after 8 h of culture (Fig. 3A.2.6b). 6-Keto-PGFIa output was not
significantly affected by Py methylene-ATP throughouth the 24 h culture period (Fig.
3A.2.6c). UTP (10, 50 and 100 pM) and adenosine (10 and 100 pM, but not 50 pM)
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Figure 3A.2.1 Effects of ATP (10, 50 and 100 pm) and 2 methylthio-ATP
(5, 10 and 25 (xm) on mean (±SEM, n=5) outputs of (a) PGF2a, (b) PGE2
and (c) 6-KETO-PGF-|afrom guinea-pig endometrium cultured for
24 h.



























0-2 h 8-24 h2-8 h
Culture period
Figure 3A.2.2 Effects of ATP (10, 50 and 100 |im) and 2-methylthio-
ATP (5, 10 and 25|im) on mean (±SEM, n=5) outputs of (a) PGF2a,
(b) PGE2 and (c) 6-KETO-PGF-|afrom guinea-pig myometrium cultured
for 24 h.
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Figure 3A.2.3 Effects of aP methylene-ATP (10, 50 and 100 |iM) and
2 methylthio-ATP (1 pM) on mean (± SEM, n=5) outputs of (a) PGF2a,
(b) PGE2 and (c) 6-KETO-PGF-|afrom guinea-pig endometrium cultured
for 24 h.
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Culture period
Figure 3A.2.4 Effects of ap methylene-ATP (10, 50 and 100 (iM) and
2 methylthio-ATP (1 |iM) on mean (± SEM, n=5) outputs of (a) PGF2a,
(b) PGE2 and (c) 6-KETO-PGF1a from guinea-pig myometrium cultured
for 24 h.
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Figure 3A.2.5 Effect of Py methylene-ATP (10, 50 and 100 pM) on
mean (± SEM, n=5) outputs of (a) PGF2a, (b) PGE2 and
(c) 6-KETO-PGF-jafrom guinea-pig endometrium cultured for 24 h.
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Figure 3A.2.6 Effect of Py methylene-ATP (10, 50 and 100 |iM) on
mean (± SEM,n=5) outputs of (a) PGF2a, (b) PGE2 and
(c) 6-KETO-PGF-|afrom guinea-pig myometrium cultured for 24 h.
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Culture period
Figure 3A.2.7 Effects of adenosine (10, 50 and 100 pM) and UTP
(10, 50 and 100 pM) on mean (± SEM, n=5) outputs of (a) PGF2a,
(b) PGE2 and (c) 6-KETO-PGF1a from guinea-pig endometrium
cultured for 24 h.
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Figure 3A.2.8 Effects of adenosine (10, 50 and 100 pM) and UTP
(10, 50 and 100 pM) on mean (± SEM, n=5) outputs of (a) PGF2a,
(b) PGE2 and (c) 6-KETO-PGF-ja from guinea-pig myometrium
cultured for 24 h.
VfSignificantly higher/lower, P < 0.05, than corresponding control value.
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after 2 and 8 h of culture (Fig. 3A.2.8a). Adenosine (10, 50 and 100 mM) and UTP
(10, 50 and 100 mM) had no effect on the outputs of PGE2 and 6-keto-
PGFla throughout the culture preriod, except adenosine (10 pM) which significantly
(P < 0.05, n=5) reduced 6-keto-PGFia output after 2 and 8 h of culture (Fig.
3A.2.8c).
Experiment 3A.3 The Effects of Adenosine (A) Receptor and P2 Purinoceptor
Antagonists on ATP- and Adenosine-Induced Increased Prostaglandin Output
from Day 7 Guinea-Pig Uterus Superfused In Vitro.
Suramin (100 pM) or 8-sulphophenyltheophylline (140 pM) alone had no effect on
the outputs of any of the PGs measured (Figs. 3A.3.1-3A.3.4). ATP (100 pM) in the
presence of suramin (100 pM) produced no significant increase in PGF2a output
from the superfused guinea-pig uterus (Fig. 3A.3.1a). ATP (100 pM) significantly (P
< 0.05, n=5) stimulated PGF2a output in the presence of 8-sulphophenyltheophylline
(140 pM) (Fig. 3A.3.2a). ATP (100 pM) in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) had no significant effect on PGE2 output from
guinea-pig uterus (Figs. 3A.3.1b and 3A.3.2b). 6-Keto-PGFlaoutput was significantly
(P < 0.05, n=5) increased by ATP (100 pM) in the presence of suramin (100 pM) or
8-sulphophenyltheophylline (140 pM) (Figs. 3A.3. lc and 3A.3.2c).
PGF2a output was significantly (P < 0.05, n=5) increased by adenosine (100 pM) in




























































Figure 3A.3.1 Effects of suramin (100 pM) and ATP (100 pM) on mean
(±SEM, n=5) outputs of (a) PGF2a> (b) PGE2 and (c) 6-KETO-PGF1(t
from day 7 superfused guinea-pig uterus.
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Figure 3A.3.2 Effects of 8-sulphophenyltheophylline (140 pM) and ATP
(100 pM) on mean (±SEM, n=5) outputs of (a) PGF2ra, (b) PGE2 and
(c) 6-KETO-PGF1afrom day 7 superfused guinea-pig uterus.
*Significantly higher, P < 0.05, than value immediately preceding
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Figure 3A.3.3 Effects of suramin (100 gM) and adenosine (100 gM) on
mean (±SEM, n=5) outputs of (a) PGF2(x, (b) PGE2 and (c) 6-KETO-PGF1(i
from day 7 superfused guinea-pig uterus.
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Figure 3A.3.4 Effects of 8-sulphophenyltheophylline (140 pM)
and adenosine (100 pM) on mean (±SEM, n=5) outputs of
(a) PGF2ra, (b) PGE2and (c) 6-KETO-PGF1re from day 7
superfused guinea-pig uterus.
*Significantly higher, P < 0.05, than value immediately preceding
8-sulphophenyltheophylline plus adenosine treatment.
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sulphophenyltheophylline (140 pM) had no significant effect on PGF2a output (Fig.
3A.3.4a). Adenosine in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (100 pM) had no significant effect on PGE2 output from
superfused guinea-pig uterus (Figs. 3A.3.3b-3A.3.4b). 6-Keto-PGFla output was
increased significantly (P < 0.05, n=5) by adenosine (100 pM) in the presence of
suramin (100 pM) or 8-sulphophenyltheophylline (140 pM) (Figs. 3A.3.3c and
3A.3.4c).
Experiment 3A.4 The Effect of Adenosine (A) Receptor and P2 Purinoceptor
Antagonists on ATP- and Adenosine-Induced Increased Prostaglandin Output
from Day 7 Guinea-Pig Endometrium and Myometrium in Culture.
Endometrium
ATP (100 pM) alone significantly (P < 0.05, n=5) increased PGF2a output after 2 h
and 24 h of culture (Fig. 3A.4. la). Suramin (100 pM) had no effect on this ATP-
induced increase in PGF2a output after 2 h and 8-sulphophenyltheophylline had no
effect on this ATP-induced increase in PGF2a output after 2 h, and 24 h (Fig.
3A.4.la). Suramin (100 pM) significantly (P < 0.05, n=5) decreased the ATP-
induced increase in PGF2a output from the guinea-pig endometrium after 24 h of
culture although the output of PGF2ct in the presence of ATP and suramin was still
significantly (P < 0.05, n=5) higher than the control value (Fig. 3A.4.1a). ATP (100
pM) plus suramin (100 pM) decreased PGF2a output significantly (P < 0.05, n=5)
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after 8 h when compared to the effect of ATP (100 pM) alone or no treatment,
respectively (Fig. 3A.4. la). PGE2 output was significantly (P < 0.05, n=5) reduced by
ATP (100 pM) plus suramin (100 pM) in the first 2 h of culture in comparison with
the effect of ATP (100 pM) alone or no treatment. ATP (100 pM) plus 8-
sulphophenyltheophylline (140 pM) had no effect on PGE2 output during the first 2 h
of culture (Fig. 3A.4. lb). ATP (100 pM) alone and in the presence of suramin (100
pM) or 8-sulphophenyltheophylline (140 pM) significantly (P < 0.05, n=5) decreased
PGE2 output after 8 h and 24 h of culture (Fig. 3A.4.1b). After 8 and 24 h of culture,
ATP (100 pM) plus suramin (100 pM) or 8-sulphophenyltheophylline (140 pM) had
no significant effect on PGE2 output when compared to PGE2 output in the presence
of ATP alone. ATP (100 pM) plus 8-sulphophenyltheophylline (140 pM), but not
ATP plus suramin (100 pM) or ATP (100 pM) alone significantly (P < 0.05, n=5)
increased 6-keto-PGFlcx output during the first 2 h of culture (Fig. 3A.4. lc). ATP
(100 pM) alone and in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) significantly (P < 0.05, n=5) inhibited 6-keto-
PGFla output after 8 h of culture (Fig. 3A.4.1c). Furthermore, 6-keto-PGFla output
after 8 h of culture in the presence of ATP (100 pM) and suramin (100 pM), but not
in the presence of ATP (100 pM) and 8-sulphophenyltheophylline (140 pM), was
significantly (P < 0.05, n=5) lower than in the presence ofATP alone (Fig. 3A.4.1c).
ATP (100 pM) alone and in the presence of suramin (100 pM), but not in the
presence of 8-sulphophenyltheophylline (140 pM), significantly (P < 0.05, n=5)
reduced 6-keto-PGFla output after 24 h of culture (Fig. 3A.4.1c). The presence of 8-
sulphophenyltheophylline (140 pM) plus ATP (100 pM) had no significant effect on
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PGF2a , PGE2 or 6-keto-PGFla outputs when compared to the effects of ATP (100
pM) alone (Fig. 3A.4. la, b and c).
Adenosine (100 pM) alone and in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) significantly (P < 0.05, n=5) increased PGF2a
output from guinea-pig endometrium after 2 h and 24 h of culture (Fig. 3A.4.3a).
Adenosine (100 pM) plus suramin (100 pM) significantly (P < 0.05, n=5) reduced
the adenosine-induced increase in PGF2(X output after 2 and 24 h (Fig. 3A.4.3a). After
8 h of culture, adenosine (100 pM) plus suramin (100 pM), but not plus 8-
sulphophenyltheophylline (140 pM), significantly (P < 0.05, n=5) decreased PGF2a
output when compared to the no treatment control and to adenosine (100 pM) alone
(Fig. 3A.4.3a). PGE2 output was significantly (P < 0.05, n=5) reduced by adenosine
(100 pM) alone and in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) after 8 and 24 h, but not after 2 h, of culture
when compared to the no treatment control (Fig. 3A.4.3b). Adenosine (100 pM) plus
suramin (100 pM) or 8-sulphophenyltheophylline (140 pM) had no significant effect
on PGE2 output throughout the 24 h culture period when compared to the effect of
adenosine (100 pM) alone (Fig. 3A.4.3b). 6-Keto-PGFla output was significantly (P
< 0.05, n=5) increased after 2 h of culture by adenosine (100 pM) plus 8-
sulphophenyltheophylline (140 pM), but not by adenosine (100 pM) plus suramin
(100 pM) or by adenosine (100 pM) alone (Fig. 3A.4.3c). 6-Keto-PGFla output was
significantly (P < 0.05, n=5) reduced by adenosine (100 pM) alone and in the
presence of suramin (100 pM) or 8-sulphophenyltheophylline (140 mM) after 8 h of
culture (Fig. 3A.4.3c). After 24 h of culture, 6-keto-PGFla output was significantly (P
no
< 0.05, n=5) decreased by adenosine (100 pM) alone and in the presence of suramin
(100 pM), but not in the presence of 8-sulphophenyltheophylline (140 pM) (Fig.
3A.4.3c). Furthermore, 6-keto-PGFla output after 8 and 24 h of culture was
significantly (P < 0.05, n=5) lower in the presence of adenosine (100 pM) plus
suramin (100 pM) than in the presence of adenosine alone (Fig. 3A.4.3c).
Myometrium
ATP (100 pM) alone and in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) significantly (P < 0.05, n=5) increased
PGF2a output after 2 h of culture (Fig.3A.4.2a). PGF2a output was significantly (P <
0.05, n=5) decreased after 8 h by ATP (100 pM) plus suramin (100 pM), but not by
ATP (100 pM) alone or in the presence of 8-sulphophenyltheophylline (140 pM),
when compared to the no treatment controls (Fig.3A.4.2a). ATP (100 pM) plus
suramin (100 pM) significantly (P < 0.05, n=5) reduced PGF2a output after 8 h of
culture when compared to the effect of ATP (100 pM) alone (Fig.3A.4.2a). ATP
(100 pM) alone and plus suramin (100 pM) or 8-sulphophenyltheophylline (140 pM)
had no significant effect on PGF2(X output after 24 h of culture (Fig.3A.4.2a). PGE2
output was inhibited significantly (P < 0.05, n=5) by ATP (100 pM) alone, and in the
presence of suramin (100 pM) throughout the 24 h culture period, and by ATP (100
pM) in the presence of 8-sulphophenyltheophylline (140 pM) after 8 h of culture but
not after 2 and 24 h (Fig. 3A.4.2b). ATP in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) had no significant effect on PGE2 output when
compared to the effect of ATP (100 pM) alone (Fig. 3A.4.2b). 6-Keto-PGFla output
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was increased significantly (P < 0.05, n=5) in the first 2 h of culture and decreased
significantly (P < 0.05, n=5) after 24 h by ATP (100 pM) alone, and in the presence
of suramin (100 pM) or 8-sulphophenyltheophylline (140 pM) (Fig. 3A.4.2c). After
8 h of culture, 6-keto-PGF1(X output was reduced significantly (P < 0.05, n=5) by ATP
(100 pM) plus suramin (100 pM), but not by ATP (100 pM) alone or in the presence
of 8-sulphophenyltheophylline (140 pM) (Fig. 3A.4.2c). 6-Keto-PGFla output after
24 h, but not after 2 and 8 h, was significantly (P < 0.05, n=5) decreased further by
ATP (100 pM) plus suramin (100 pM) but not plus 8-sulphophentltheophylline (140
pM) when compared to 6-keto-PGFla output in the presence of ATP (100 pM) alone
(Fig. 3A.4.2c). ATP (100 pM) plus 8-sulphophenyltheophylline (140 pM) had no
significant effect on 6-keto-PGFia output when compared to ATP (100 pM) alone
throughout the 24 h culture period (Fig. 3A.4.2c).
Adenosine (100 pM) alone and in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) significantly ( P < 0.05, n=5) stimulated PGF2a
output in the first 2 h of culture (Fig.3A.4.4a). Adenosine (100 pM) alone but not in
the presence of suramin (100 pM) or 8-sulphophenyltheophylline (140 pM)
increased PGF2a output significantly (P < 0.05, n=5) after 8 and 24 h of culture
(Fig.3A.4.4a). Adenosine (100 pM) plus suramin (100 pM) significantly (P < 0.05,
n=5) reduced this adenosine-induced increase in PGF2a output after 8 and 24 h of
culture (Fig.3A.4.4a). 8-Sulphophenyltheophylline (140 pM) had no significant
effect on adenosine-induced increased PGF2a output from guinea-pig myometrium
(Fig. 3A.4.4a). PGE2 output was significantly (P < 0.05, n=5) decreased by adenosine
(100 pM) alone and in the presence of suramin (100 pM) or 8-
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sulphophenyltheophylline (140 pM) after 8 h of culture (Fig.3A.4.4b). PGE2 output
was reduced significantly (P < 0.05, n=5) by adenosine (100 pM) plus suramin (100
pM), but not by adenosine plus 8-sulphophenyltheophylline (140 pM) or by
adenosine (100 pM) alone, after 2 h and 24 h of culture (Fig.3A.4.4b). ATP in the
presence of suramin (100 pM), or 8-sulphophenyltheophylline (140 pM) had no
significant effect on PGE2 output when compared to the effect of ATP (100 pM)
alone (Fig.3A.4.4b). 6-Keto-PGFla output was increased significantly (P < 0.05, n=5)
by adenosine (100 pM) alone and in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) after 2 h, but not after 8 and 24 h, of culture
(Fig. 3A.4.4c). Adenosine (100 pM) alone had no significant effect on 6-keto-PGFia
output after 8 and 24 h of culture (Fig. 3A.4.4c). Adenosine (100 pM) plus suramin
(100 pM) significantly (P < 0.05, n=5) decreased 6-keto-PGFla output after 8 and 24
h of culture and adenosine (100 pM) plus 8-sulphophenyltheophylline (140 pM)
significantly (P < 0.05, n=5) inhibited output after 24 h but not after 8 h, when
compared to untreated controls (Fig. 3A.4.4c). Adenosine (100 pM) plus suramin
(100 pM) significantly (P < 0.05, n=5) decreased 6-keto-PGFIa output after 8 h and
24 h when compared to the effect of adenosine (100 pM) alone (Fig. 3A.4.4c).
Adenosine (100 pM) plus 8-sulphophenyltheophylline (140 pM) reduced 6-keto-
PGFia output significantly (P < 0.05, n=5) after 24 h, but not after 2 and 8 h, when











































0-2 h 2-8 h 8-24 h
Culture period
Figure 3A.4.1 Effects of ATP (100 jiM) plus suramin (100 pM) or
8-sulphophenyltheophylline (140 pM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF-|a from
guinea-pig endometrium cultured for 24 h.
*Significantly different, P < 0.05, than corresponding control value.


























































0-2 h 2-8 h 8-24 h
Culture period
Figure 3A.4.2 Effects of ATP (100 |iM) plus suramin (100 mM) or
8-sulphophenyltheophylline (140 pM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF-|a from
guinea-pig myometrium cultured for 24 h.
*Significantly different, P < 0.05, than corresponding control value.



























































0-2 h 2-8 h 8-24 h
Culture period
Figure 3A.4.3 Effects of adenosine (100 4M) plus suramin (100 mM)
or 8-sulphophenyltheophylline (140 pM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF-|a from
guinea-pig endometrium cultured for 24 h.
*Significantly different, P < 0.05, than corresponding control value.


















































0-2 h 2-8 h 8-24 h
Culture period
Figure 3A.4.4 Effects of adenosine (100 (iM) plus suramin (100 mM)
or 8-sulphphenyltheophylline (140 pM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF-|a from
guinea-pig myometrium cultured for 24 h.
*Significantly different, P < 0.05, than corresponding control value.
tSignificantly lower, P < 0.05, than corresponding adenosine value.
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Experiment 3A.5 Prostaglandin Production by Homogenates of Day 7 Guinea-
Pig Endometrium and Myometrium after 24 h of Culture.
Endometrium
PGF2a production by homogenates of endometrium was significantly (P < 0.05, n=4)
increased following 24 h culture of the endometrium with ATP (100 pM) or
adenosine (100 pM) alone, and by ATP (100 pM) and adenosine (100 pM) in the
presence of suramin (100 pM) or 8-sulphophenyltheophylline (140 pM) (Fig.
3A.5.1a). There were no significant differences between PGF2(1 production following
treatment with ATP (100 pM) or adenosine (100 pM) alone when compared to
PGF2a production with ATP or adenosine in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) (Fig. 3A.5.1a). ATP (100 pM) and adenosine
(100 pM) on their own or in the presence of suramin (100 pM) had no significant
effect on PGE2 production (Fig. 3A.51b). PGE2 production was significantly (P <
0.05, n=4) increased following 24 h culture in the presence of ATP (100 pM) plus 8-
sulphophenyltheophylline (140 pM) and adenosine (100 pM) plus 8-
sulphophenyltheophylline (140 pM) when compared to the untreated control (Fig.
3A.5.1b). ATP in the presence of suramin (100 pM) or 8-sulphophenyltheophylline
(140 pM) had no significant effect on PGE2 production when compared to the effect
of ATP (100 pM) or adenosine (100 pM) alone (Fig. 3A.5.1b). None of the
treatments used had any significant effect on 6-keto-PGFla production by



























Con. Aden. Aden.+S Aden.+8S
ATP ATP+S ATP+8S
Figure 3A.5.1 Production of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF1a
by endometrial homogenates after 24 h in culture with ATP (100 |iM) and
adenosine (100 pM) alone and plus either suramin (100 pM) or 8-sulpho-
phenyltheophylline (140 pM).
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Con. Aden. Aden.+S Aden.+8S
ATP ATP+S ATP+8S
Figure 3A.5.2 Production of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF1re
by myometrial homogenates after 24 h in culture with ATP (100 pM) and
adenosine (100 pM) alone and plus either suramin (100 pM) or 8-sulpho-
phenyltheophylline (140 pM).
*Significantly higher, P < 0.05, than corresponding control value.
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Myometrium
PGF2a production by homogenates of the myometrium was significantly (P < 0.05,
n=4) increased following 24 h culture with ATP (100 pM) and adenosine (100 pM)
alone and in the presence of suramin (100 pM) or 8-sulphophenyltheophylline (140
pM), except with ATP (100 pM) plus 8-sulphophenyltheophylline (140 pM) (Fig.
3A.5.2a). There were no significant differences between PGF2a production following
treatment with ATP (100 pM) or adenosine (100 pM) alone when compared to
PGF2a production with ATP or adenosine in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) (Fig. 3A.5.2a). PGE2 production by
homogenates was increased significantly (P < 0.05, n=4) following treatment with
ATP (100 pM) and adenosine (100 pM) alone, but not by ATP and adenosine in the
presence of suramin (100 pM) or 8-sulphophenyltheophylline (140 pM) (Fig.
3A.5.2b). There were no significant differences between PGE2 production following
ATP (100 pM) or adenosine (100 pM) treatment alone when compared to treatment
with ATP and adenosine in the presence of suramin (100 pM) or 8-
sulphophenyltheophylline (140 pM) (Fig. 3A.5.2b). 6-Keto-PGFla output was not
significantly affected by any of the treatments used (Fig. 3A.5.2c).
Discussion:
This study has shown that ATP, 2 methylthio-ATP and adenosine stimulate
PGF2a and PGI2 (measured as 6-keto-PGF]a) outputs from the non-pregnant guinea-
pig uterus superfused in vitro. PGF2a output was also stimulated by UTP while 6-
keto-PGFla output was not. a(3 Methylene-ATP and Py methylene-ATP had no
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significant effect on the outputs of either PGF2a or 6-keto-PGFla at the
concentrations used. The ATP analogues that did not stimulate PGF2c( and 6-keto-
PGF]a outputs may be less potent than ATP and may therefore require even higher
concentrations than those used to stimulate PGF2a and 6-keto-PGF]a outputs
significantly. Piper & Hollingsworth (1996) observed that Py methylene-ATP was
less effective at contracting the guinea-pig uterus when compared to the effects of
ATP and other ATP analogues. ATP, analogues of ATP, adenosine and UTP had no
effect on PGE2 output from the superfused guinea-pig uterus.
Both adenosine and ATP stimulated PGF2ct and 6-keto-PGFla outputs suggesting the
presence of A and P2 receptors in the guinea-pig uterus. However, stimulation of
PGF2aand 6-keto-PGFla outputs by ATP is not enough to prove that P2 receptors are
present in the guinea-pig uterus as ATP is rapidly metabolised to adenosine, which
acts at A receptors. Studies with P2 and A receptor antagonists, suramin and 8-
sulphophenyltheophylline, respectively, were performed to determine whether ATP
or adenosine increased PGF2a and 6-keto-PGFla outputs from the superfused uterus
by acting on P2 purinoceptors or A receptors, respectively. Suramin or 8-
sulphophenyltheophylline treatment alone had no effect on PGF2a or 6-keto-
PGFla outputs from the superfused uterus. Suramin inhibited the stimulatory effect of
ATP on PGF2ct output from the superfused guinea-pig uterus while 8-
sulphophenyltheophylline had no such effect. Therefore, this indicates that ATP acts
via P2 purinoceptors and not on A receptors, even though ATP may be broken down
rapidly by ecto-nucleotidases to adenosine. The stimulatory effect of adenosine on
PGF2a output from superfused uterus was inhibited by 8-sulphophenyltheophylline
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while suramin had no effect on adenosine stimulated PGF2a output which suggests
that A receptors are also present in guinea-pig uterus and mediate the effect of
adenosine. These results are consistent with the work of Smith et al. (1988) who
observed that both A and P2 receptors were present in the guinea-pig myometrium.
The stimulation of 6-keto-PGFia output by ATP and adenosine from superfiised
uterus was not affected by the presence of suramin or 8-sulphophenyltheophylline.
Therefore, ATP- and adenosine-induced increases in 6-keto-PGFla output appear to
be via a different mechanism than their stimulation of PGF2a output from superfused
guinea-pig uterus. The stimulatory effects of ATP and adenosine on 6-keto-PGFia
output from the superfused uterus may be receptor mediated but may require high
concentrations of antagonist to block the 6-keto-PGFla pathway compared to the
concentration required to block the PGF2a pathway. Alternatively, stimulation of 6-
keto-PGFla output from the superfused guinea-pig uterus may be non-receptor
mediated and this might explain why suramin and 8-sulphophenyltheophylline, P2
and A receptor anatagonists respectively, have no effect on ATP and adenosine
stimulated 6-keto-PGFia output. ATP could be stimulating 6-keto-PGFla output from
the superfused uterus by phosphorylating PLA2. PLA2 is the enzyme responsible for
arachidonic acid release from membrane phospholipids. However, this does not
account for the stimulatory action of adenosine. The mechanism for 6-keto-PGFIa
production by the superfused guinea-pig uterus remains unclear and requires further
investigation.
None of the treatments used had any effect on PGE2 output suggesting a different
mechanism for PGE2 production by the guinea-pig uterus in the short-term
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superfusion experiments from the mechanisms for PGF2a and 6-keto-PGFlc(
production. There is evidence that different pools of arachidonic acid exist in tissues
and that these pools are specifically channelled to different PGHS enzymes (Reddy
& Herschman, 1994). These pools of arachidonic acid could also be channelled to
specific types of PG synthesis depending on which PG is required. Naraba et al.
(1998) demonstrated that the constitutive enzyme, PGHS-1, and the inducible
enzyme, PGHS-2, are preferentially coupled to distinct prostanoid synthases in rat
peritoneal macrophages. This could also be the case in guinea-pig uterus.
The increased PG outputs from superfused guinea-pig uterus observed in the
presence of adenosine, ATP and ATP analogues is probably due to an increase in
arachidonic acid release from the sn-2 position of membrane phospholipids. The
release of arachidonic acid is attributed to the enzyme, phospholipase A2 (PLA2)
(Flower & Blackwell, 1976). This is the rate-limiting step in PG production (Vogt,
1978). Addition of exogenous arachidonic acid and PLA2 have been observed to
stimulate PG synthesis from the superfused guinea-pig uterus (Poyser, 1987a).
Previous work has also shown that melittin, a PLA2 activator, stimulates PG output
from the guinea-pig uterus (Johnson & Poyser, 1991), while aristolochic acid, a
PLA2 inhibitor, reduces PG output from cultured cells from the guinea-pig
endometrium (Naderali & Poyser, 1996b). At least three phospholipase A2 enzymes
have been implicated in the mobilisation of arachidonic acid from phospholipids
(Balsinde & Dennis, 1996). However, cytosolic PLA2 (cPLA2) is selective for the
hydrolysis of phospholipid containing arachidonic acid (Clark et al., 1991; Kramer et
al., 1991) and can be quickly activated by post-translational mechanisms to rapidly
mobilise arachidonic acid for eicosanoid production (Leslie, 1997). It remains to be
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seen which of the PLA2 enzymes are present in the guinea-pig uterus and which are
involved in PG production. However, it seems likely that ATP, ATP analogues, UTP
and adenosine stimulate PG output from the superfused guinea-pig uterus by
activating one or more types ofPLA2.
After 24 h of culture ATP, aP methylene-ATP, 2 methylthio-ATP, Py methylene-
ATP, UTP and adenosine stimulated PGF2a output from guinea-pig uterus,
particularly from the endometrium. As very little stimulation was observed after 2
and 8 h of culture, it appears that the mechanism for increased PGF2a production
after 24 h of culture is different than the one involved in increased PGF2ot production
by guinea-pig uterus in the short-term superfusion experiments. While it appears
likely that increased mobilisation of arachidonic acid is the reason for increased PG
production from the superfused uterus, increased PG production from the cultured
uterus, particularly the endometrium after 24 h of culture, is probably due to
stimulation of PGHS synthesis, the enzyme responsible for PG synthesis from
arachidonic acid (Lands, 1979). Homogenisation of endometrium and myometrium
showed an increase in PGF2a production following 24 h treatment with adenosine
and ATP. These homogenisation experiments are an indication of PG synthesising
capacity and therefore the amount of PGHS present in the tissue before
homogenisation. These results suggest that ATP and adenosine stimulate PGHS
synthesis, the conversion of arachidonic acid to PGH2 and an increase in PGF2cc
production from the guinea-pig endometrium and myometrium after 24 h culture.
This may not be the mechanism for increased PGF2a output in short-term superfusion
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experiments as it is unlikely that any increase in PGHS synthesis would be observed
in such a short period of time. A decrease in PGF2ct metabolism may also be the
cause of the increase in PGF2a output observed after 24 h of culture. Levels of 13, 14-
dihydro-15-keto-PGF2c( (PGFM), the metabolite of PGF2a, were measured in the
control samples of culture medium following 24 h of culture, by ELISA assay and
were found to be undetectable in control tissues, suggesting that metabolism of
PGF2a after 24 h of culture was low. This observation is consistent with metabolism
by guinea-pig uterus homogenates being low (< 5%; Poyser, 1979). Therefore, these
results suggest that increased PGF2a production by the guinea-pig uterus following
24 h of culture with ATP and adenosine is due to increased synthesis, probably
through the increased production of PGHS. ATP or adenosine-induced increases in
PGF2ct production by homogenates of the guinea-pig uterus (endometrium and
myometrium) were not inhibited in the presence of either suramin or 8-
sulphophenyltheophylline after 24 h of culture. This suggests that ATP- and
adenosine-induced increase in PGHS synthesis may not have been mediated by
receptor activation at P2 and A receptors, respectively.
The effects of adenosine, ATP and ATP analogue treatment on PGE2 and 6-keto-
PGFla outputs from guinea-pig uterus after 24 h culture were variable. Short-term
superfusion of the guinea-pig uterus in the presence of adenosine, ATP and ATP
analogues showed no stimulation of PGE2 output. However, following 24 h of
culture, PGE2 output from the guinea-pig uterus, particularly from the endometrium,
was significantly increased by aP methylene-ATP and Py methylene-ATP. These
compounds were ineffective at stimulating PG outputs from superfused guinea-pig
126
uterus. Following 24 h of culture, an increase in PGHS synthesis may be directed
towards PGE2 production as well as PGF2a production. Homogenates of
endometrium and myometrium following 24 h of culture in the presence of
adenosine and ATP, with or without suramin or 8-sulphophenyltheophylline, showed
an increase in PGE2 production, although this was not always significantly. This
indicates increased capacity to synthesise PGE2 and therefore increased PGHS
present in the tissue before homogenisation. Therefore, it appears likely that
increased PGE2 output after 24 h of culture in the presence of aP methylene-ATP
and Py methylene-ATP is a result of increased PGHS synthesis. PGE2 output from
the myometrium was inhibited by ATP and 2 methylthio-ATP throughout culture,
and 6-keto-PGFlo( output from the endometrium and myometrium was inhibited in
the long-term culture experiments in the presence of ATP, and 2 methylthio-ATP
and, to some extent by aP methylene-ATP. Homogenates of endometrium and
myometrium following 24 h culture with ATP or adenosine alone or with either
suramin or 8-sulphophenyltheophylline showed no significant increase in 6-keto-
PGFla production following 24 h incubation. This suggests that the synthesising
capacity for 6-keto-PGFIa production was not increased following 24 h culture. It
appears that most of the increased PGH2 produced by the increase in PGHS is
directed into the PGF2a-forming pathway and this channelling of PGH2 towards
PGF2a formation may explain why PGE2 and 6-keto-PGFia outputs decreased after
24 h of culture.
Culture experiments with ATP and adenosine alone and in the presence of suramin
and 8-sulphophenyltheophylline, showed increased PGF2(1 output from the
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endometrium and the myometrium and increased 6-keto-PGFla output from the
myometrium after 2 h of culture. Increased PGF2a and 6-keto-PGF]a outputs in the
presence ofATP and adenosine after 2 h of culture were not seen in previous culture
experiments and the reason for this is not clear. Some inhibition of the ATP-induced
stimulation of PGF2a output was observed in the presence of suramin from
endometrium after 24 h of culture. However, suramin was also seen to decrease
PGF2aand 6-keto-PGFl0( outputs from endometrium and myometrium when there
was no ATP-induced stimulation and also when in the presence of adenosine. This
suggests that, in long-term culture experiments, suramin may be inhibiting PGF2a and
6-keto-PGFla outputs by itself. Since suramin alone was not included in the
experimental set-up, it is not clear whether suramin really does have any significant
effect on PG output from guinea-pig uterus after 24 h of culture. ATP plus 8-
sulphophenyltheophylline or adenosine plus 8-sulphophenyltheophylline had very
little inhibitory effect on PG production by endometrium and myometrium in 24 h
culture experiments when compared to the effect of adenosine alone. This suggests
that this effect of adenosine may not be mediated via A receptors in the guinea-pig
uterus during 24 h of culture.
ATP and adenosine were observed to decrease PGE2 and 6-keto-PGFla outputs from
guinea-pig endometrium and myometrium, particularly between 2 and 24 h of
culture. The same effect on PGE2 and 6-keto-PGFla outputs from the guinea-pig
endometrium and myometrium were observed in previous culture experiments in the
presence of ATP, especially from the myometrium, and were attributed to an
increase in the channelling of PGH2 towards the PGF2(X synthesising pathway.
Suramin and 8-sulphophenyltheophylline had little effect on ATP and adenosine-
induced increases in PG outputs after 24 h of culture. This suggests that ATP and
adenosine-induced increases in PG production were non-receptor-mediated events.
However, the effect of suramin on PG output, particularly PGF2a output remains
unclear and P2 receptor-mediated stimulation of PGF2a cannot be ruled out.
These present findings support the view that adenosine, ATP and it analogues
stimulate PG output (particularly PGF2a) from the superfused guinea-pig uterus and
from guinea-pig endometrium and myometrium cultured for 24 h. This was more
pronounced in the endometrium which is the main site of prostanoid synthesis in the
guinea-pig uterus (Poyser, 1983). Scheimann et al. (1991) and Suzuki (1991) both
observed increased PGF2a and 6-keto-PGFia outputs from the uterus from guinea-pig
and rabbit respectively, following treatments with A and P2 agonists. The increase in
PGF2a output could be responsible for stimulating uterine contraction in the guinea-
pig uterus as suggested by Smith et al. (1988) and Piper & Hollingsworth (1996).
The effects of the P2 antagonist, suramin, on ATP stimulated PGF2(X production from
superfused guinea-pig uterus suggests that ATP exerts its effect via P2 receptors. A
and P2 receptors have previously been observed in guinea-pig uterus (Smith et. al.,
1988). However, as well as acting on P2 receptors, ATP may indirectly be
stimulating adenosine receptors after being broken down to adenosine by ecto-
nucleotidases especially after 24 h of culture. However, the A receptor antagonist, 8-
sulphophenyltheophylline, had no effect on ATP-induced PGF2ct output from guinea-
pig uterus suggesting that ATP was exerting its action predominantly by activating
P2 receptors.
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Previous workers have disagreed over the involvement of PGs in spasm of the
guinea-pig uterus mediated by A receptors (Scheimann et al., 1991; Bradley et al.,
1993). Scheimann et al. (1991) proposed that cyclooxygenase products are involved
in adenosine-induced contractions of the non-pregnant guinea-pig uterus, while
Bradley et al. (1993) dispute this fact. The present study indicates that PGs may be
involved in adenosine-induced spasm of the guinea-pig uterus, as adenosine was
observed to stimulate PGF2ct output from guinea-pig uterus superfused in vitro and
this stimulation by adenosine was inhibited by the A receptor antagonist, 8-
sulphophenyltheophylline. Therefore, it is clear that ATP- and adenosine-induced
increases in PGF2a output from the superfused guinea-pig uterus are receptor
mediated responses as the actions of ATP and adenosine were significantly reduced
by the P2 and A receptor antagonists, suramin and 8-sulphophenyltheophylline
respectively. P2Y purinoceptors have previously been observed in the guinea-pig
uterus and more specifically in the endometrium (Piper & Plollingsworth). P2Y
receptors are G protein-linked receptors (Webb et al., 1993). They have been
observed to couple via G proteins to phospholipase A2 (PLA2) (see Axelrod et al.,
1988) and phospholipase C (PLC) in a number of tissues (Piper & Hollingsworth,
1996). PLA2 is well documented as the enzyme responsible for arachidonic acid
release from membrane phospholipids, and it is possibly responsible for increased
PG synthesis from the superfused guinea-pig uterus stimulated by adenosine, ATP
and ATP analogues. However, PLC can also mobilise arachidonic acid from inositol
phospholipids (IP). Diacylglycerol (DAG) is one of the breakdown products of PI
hydrolysis. Arachidonic acid can be released from DAG by the sequential action of
diacylglycerol lipase and monoacylglycerol lipase. Previous workers have suggested
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that adenosine and ATP-induced stimulation of PG synthesis could be linked to IP
hydrolysis in the guinea-pig and rabbit uterus (Scheimann et al., 1991; Suzuki,
1991). ATP has been observed to stimulate DAG formation, indicative of PLC
activation (Suzuki, 1991) and stimulation of adenosine receptors leads to rapid
accumulation of inositol phosphates (Scheimann et al., 1991).
Diacylglycerol (DAG) can also activate protein kinase C (PKC), another second
messenger system that has been implicated in stimulation of PGHS expression
(DeWitt, 1991), which can stimulate a kinase cascade leading to mitogen-activated
protein kinase (MAPK) activation (Qiu & Leslie, 1994). MAPK can activate
transcription factors (Karin & Hunter, 1995), and in particular NF-kB which leads to
induction of expression ofmany immediate early genes (Baeuerle, 1991). NF-kB has
been observed to increase PGHS-2 synthesis in lipopolysaccharide (LPS)-stimulated
macrophages (Hwang et al., 1997). This may be the mechanism for increased PGHS
synthesis by the guinea-pig uterus observed after 24 h of culture. Previous studies
have shown the presence of PGHS-2 in the guinea-pig endometrium by western
blotting (Naderali & Poyser, 1994) and have demonstrated that PGHS-2 is the main
functional form of PGHS in the guinea-pig endometrium and myometrium (Naderali
& Poyser, 1996a).
MAPK also activates cPLA2 (Lin et al., 1993) which could also result in increased
PG synthesis. Inositol 1,4,5-triphosphate (IP3) is a specific breakdown product of
PLC-mediated PIP2 hydrolysis and is a unique second messenger that releases
calcium from the endoplasmic reticulum of several cell types, including the
sarcoplasmic reticulum of smooth muscle cells (Schrey et al., 1988). Scheimann et
al. (1991) suggest that IP3 is capable of releasing calcium from the guinea-pig
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uterine intracellular stores. Increased calcium concentration can activate PLA2
enzymes and stimulate arachidonic acid mobilisation and increased PG synthesis.
Therefore, there are a number of possible mechanisms for arachidonic acid release
and stimulation ofPG synthesis in the guinea-pig uterus by ATP, ATP analogues and
adenosine. Further studies are required to elucidate which pathways are actually
involved.
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3B. A STUDY OF PROSTAGLANDIN PRODUCTION BY THE GUINEA-
PIG PLACENTA
3B.1 BASAL PROSTAGLANDIN PRODUCTION AND THE EFFECTS OF
PROSTAGLANDIN H SYNTHASE (PGHS) INHIBITORS
Introduction:
The placenta is a major site of prostaglandin (PG) biosynthesis during pregnancy
(Keirse, 1979). PG production by the placenta has been reported to increase during
pregnancy and particularly towards parturition in many animal species (Challis &
Olson, 1988; Mitchell, 1988). PG production by the guinea-pig placenta and sub-
placenta has been investigated during early to mid pregnancy. The basal outputs of
PGF2a, PGE2 and 6-keto-PGFla were measured on day 22 and day 29 of gestation
following a 24 h culture period. PGF2acan be metabolised to 13, 14-dihydro-15-keto-
PGF2a (PGFM). The output of this metabolite was also measured to determine
whether any increase in PGF2(I output from guinea-pig placenta was accompanied by
an increase in PGF2a metabolism.
Prostaglandins of the 2-series are synthesised from arachidonic acid and the first step
in this synthesis is the conversion of arachidonic acid to PGH2 by prostaglandin H
synthase (PGHS). Recently two PGHS enzymes have been identified, cloned and
sequenced (DeWitt & Smith, 1988; Merlie et al., 1988; Kujubu et al., 1991;
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O'Banion et al., 1992): they are called PGHS-1 and PGHS-2. This raises the question
as to which form is responsible for PG production by the guinea-pig placenta and
sub-placenta? Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the
cyclooxygenase activity of PGHS. The effects of indomethacin, a non-selective
inhibitor of PGHS, and the PGHS-2 selective inhibitor NS-398 (N(2-cyclohexyloxy-
4-nitrophenyl)methanesulphonamide), have been investigated. Both compounds have
similar potencies at inhibiting PGHS-2 but, in contrast to indomethacin, NS-398 has
no inhibitory effect on PGHS-1 (Futaki et al., 1993, 1994). It has also been reported
that indomethacin is more potent at inhibiting PGHS-1 than PGHS-2 (Mitchell et al.,
1993). The effects of indomethacin and NS-398 on PG output from day 22 and day
29 guinea-pig placenta and sub-placenta cultured for 24 h were observed. In
addition, the effects of these two inhibitors on PG production by homogenates of
guinea-pig placenta on days 22 and 29 of pregnancy were studied.
Methods:
In tissue culture experiments, the placentae of day 22 and 29 pregnant guinea-pigs
were removed and separated as described in Section 2.1.4. The placenta and sub-
placenta were cut into small pieces approximately 1 mm3, and placed on lens tissue
on the top of raised, gauze platforms in culture dishes. Each dish contained 4 ml
tissue culture medium (TCM). In experiment 3B.1.1, day 22 and 29 placenta and
sub-placenta were cultured in TCM only, in order to obtain basal PG outputs.
Experiments 3B. 1.3-5 were carried out in the presence of indomethacin (5, 20 and 40
pM) or NS-398 (5, 20 and 40 pM) which was added to the TCM in each Petri dish.
The Petri dishes were placed in modified Kilner jars, which were gassed and
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incubated as previously described (Section 2.1.2). Culture medium was removed
after 2, 8 and 24 h. The samples of culture medium were stored at -20°C and assayed
for their PGF2tx, PGE2 and 6-keto-PGFja content by radioimmunoassay (RIA).
Enzyme-linked immunosorbent assay (ELISA) was used to measure PGFM content
in the culture medium obtained from day 22 and 29 control placenta. Statistical
analyses were carried out using a one-way analysis of variance (ANOVA) and the
paired t-test.
Homogenisation experiments were carried out using the placenta from day 29
pregnant guinea-pigs. Tissue was removed and prepared as described in Section
2.1.4. The tissue was blotted dry, weighed and then homogenised as described in
Section 2.1.3 with Krebs solution containing either indomethacin (40 jliM) or NS-398
(40 pM). One sample in each experiment was untreated and acted as a control. Each
sample was allowed to incubate for 60 min in a water bath at 37°C (see Section
2.1.3), and prostaglandins were then extracted as described in Section 2.1.1.
Samples were evaporated to dryness on a rotary evaporator, re-dissolved in 5 ml
ethyl acetate and stored at -20°C until assayed for their PG content. Statistical




Experiment 3B.1.1 Prostaglandin Output from Day 22 and 29 Guinea-Pig
Placenta and Sub-Placenta in Culture.
Placenta
The outputs of PGF2a, PGE2 and 6-keto-PGFla from guinea-pig placenta decreased
significantly (P < 0.05, n=5) with time during the 24 h culture period on both days 22
and 29 of pregnancy (Figs. 3B. 1.1.1a, b and c). PGF2ot and 6-keto-Fla outputs from
day 29 guinea-pig placenta were significantly (P < 0.05, n=5) higher than PGF2a and
6-keto-PGFla outputs from the day 22 guinea-pig placenta, respectively, throughout
the 24 h culture period (Figs. 3B.l.l.la and c). PGE2 output from guinea-pig
placenta did not change significantly between days 22 and 29 of pregnancy
throughout culture (Fig. 3B. 1.1.1b).
Sub-Placenta
The outputs of PGF2ct, PGE2 and 6-keto-PGFla from guinea-pig sub-placenta
decreased significantly (P < 0.05, n=5) with time during the 24 h culture period on
both days 22 and 29 of pregnancy (Figs. 3B.1.1.2a, b and c). PGF2a output from day
22 guinea-pig placenta was not significantly different from PGF2a output from day
22 sub-placenta (Figs. 3B. 1.1.1, 3B. 1.1.2a and c). PGE2 and 6-keto-PGFta outputs
from day 22 placenta were significantly (P < 0.05, n=5) higher than PGE2 and 6-
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Figure 3B. 1.1.1 Mean (±SEM, n=5) outputs of (a) PGF2a,
(b) PGE2 and (c) 6-KETO-PGF^ from day 22 and 29
guinea-pig placenta cultured for 24 h.






Figure 3B.1.1.2 Mean (±SEM, n=5) outputs of (a) PGF2a,
(b) PGE2 and (c) 6-KETO-PGF1a from day 22 and day 29
guinea-pig sub-placenta cultured for 24 h.
*
Significantly higher, P < 0.05, than corresponding day 22 value.
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of culture (Fig. 3B. 1.1.2b). PGF2a, PGE2 and 6-keto-PGFla outputs from day 29
guinea-pig placenta were significantly (P < 0.05, n=5) higher than PGF2ct, PGE2 and
6-keto-PGFla outputs from day 29 sub-placenta, 6-keto-PGFla output after 2 h of
culture (Figs. 3B. 1.1.1, 3B. 1.1.2a, b and c). PGF2ct, output from day 29 guinea-pig
sub-placenta was significantly (P < 0.05, n=5) increased after 2 h of culture but not
after 8 and 24 h, when compared to PGF2a output from day 22 sub-placenta (Fig.
3B. 1.1.2a). PGE2 output was significantly (P < 0.05, n=5) higher on day 29 of
pregnancy after 2 h and 8 h of culture but not after 24 h (Fig. 3B.1.1.2b). 6-Keto-Fla
output from day 29 sub-placenta was significantly (P < 0.05, n=5) higher throughout
the 24 h culture period compared to 6-keto-PGFia output from day 22 guinea-pig
sub-placenta (Fig. 3B. 1.1,2c).
Experiment 3B.1.2 PGFM Output from Day 22 and 29 Guinea-Pig Placenta.
The output of PGFM from guinea-pig placenta decreased with time during the
culture period on both day 22 and day 29 of pregnancy (Fig. 3B. 1.2.1). PGFM output
from the guinea-pig placenta was significantly (P < 0.05, n=5) higher on day 29 of
pregnancy compared to day 22 during the first 2 h of culture, but not after 8 h and 24
h of culture (Fig. 3B. 1.2.1). PGF2a output from day 29 placenta was 8-fold higher
compared to PGF2a output from day 22 placenta during the first 2 h of culture.
PGFM output from day 29 placenta was 2.5-fold higher compared to PGFM output
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Figure 3B. 1.2.1 Mean (± SEM, n=5) output of PGFM from day 22
and 29 guinea-pig placenta cultured for 24 h.
*Significantly higher, P < 0.05, than corresponding day 22 value.
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culture PGF2ct and PGFM outputs from day 29 placenta had increased 2-fold
compared to outputs from day 22 placenta (Figs. 3B.l.l.la and 3B.1.2.1). After 24 h
of culture, there was very little difference between the output of PGFM from day 22
and 29 placenta, while PGF2a output from day 29 guinea-pig placenta was
significantly (P < 0.05, n=5) higher than the day 22 PGF2(X output (Figs. 3B. 1.1.1a
and 3B. 1.2.1).
Experiment 3B.1.3 The Effects of Indomethacin and NS-398 on PG Output from
Day 29 Guinea-Pig Placenta and Sub-Placenta in Culture.
Placenta
Indomethacin (20 pM, but not 5 p.M) significantly (P < 0.05, n=5) reduced PGF2a
output from day 29 guinea-pig placenta after 2 h of culture (Fig. 3B.1.3.1a). After 8
and 24 h of culture, indomethacin (5 and 20 pM) significantly (P < 0.05, n=5)
inhibited PGF2a output (Fig. 3B.1.3.1a). NS-398 (5 and 20 pM) significantly (P <
0.05, n=5) reduced PGF2a output throughout the 24 h culture period (Fig. 3B. 1.3. la).
PGF2a output was significantly (P < 0.05, n=5) higher in the presence ofNS-398 (20
pM, but not 5 pM) when compared to the corresponding indomethacin treatment
after 24 h of culture but not after 2 and 8 h (Fig. 3B. 1.3.1a). PGE2 output from day
29 guinea-pig placenta was significantly (P < 0.05, n=5) reduced by indomethacin
(20 pM, but not 5 pM) and NS-398 (20 pM, but not 5 pM) after 2 h, and by
indomethacin (5 and 20 pM) after 8 h but not after 24 h (Fig. 3B.1.3.1b). NS-398 (5
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and 20 pM) had no effect on PGE2 output from day 29 guinea-pig placenta after 8 h
and 24 h of culture (Fig. 3B.1.3.1b). There was no significant difference between
PGE2 output from the placenta in the presence of indomethacin (5 and 20 pM)
compared to PGE2 output in the presence ofNS-398 (5 and 20 pM) (Fig. 3B.1.3.1b).
Indomethacin (5 and 20 pM) significantly (P < 0.05, n=5) inhibited 6-keto-Fia output
from day 29 placenta throughout the 24 h culture period (Fig. 3B. 1.3.1c). NS-398 (5
and 20 pM) significantly (P < 0.05, n=5) reduced 6-keto-PGFla output in the first 2 h
of culture but not after 8 h (Fig. 3B. 1.3.1c). After 24 h of culture, NS-398 (5 pM, but
not 20 pM) significantly (P < 0.05, n=5) reduced 6-keto-PGFla output (Fig.
3B. 1.3.1c). 6-Keto-Fla output was significantly (P < 0.05, n=5) higher in the
presence of NS-398 (20 pM, but not 5 pM) when compared to treatment with
indomethacin (20 pM) after 8 and 24 h of culture but not in the first 2 h (Fig.
3B.1.3.1c).
Sub-Placenta
PGF2a output from day 29 guinea-pig sub-placenta was significantly (P < 0.05, n=5)
reduced by indomethacin (5 and 20 pM) after 2 and 24 h of culture, but not after 8 h
of culture (Fig. 3B. 1.3.2a). NS-398 (5 and 20 pM) had no effect on PGF2a output,
except NS-398 (20 pM) which significantly (P < 0.05, n=5) decreased PGF2a output
after 24 h of culture (Fig. 3B. 1.3.2a). PGF2a output in the presence of NS-398 (20
pM, but not 5 pM) was significantly (P < 0.05, n=5) higher than PGF2(X output in the
presence of indomethacin (20 pM, but not 5 pM) (Fig. 3B. 1.3.2a). Indomethacin (5
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Figure 3B.1.3.2 Effects of indomethacin (5 and 20 (iM) and NS-398
(5 and 20 (iM) on mean (±SEM, n=5) outputs of (a) PGF2a, (b) PGE2
and (c) 6-KETO-PGF-jafrom day 29 guinea-pig sub-placenta cultured
for 24 h.
*Significantly lower, P < 0.05, than corresponding control value.







































Figure 3B. 1.3.1 Effects of indomethacin (5 and 20 |iM) and NS-398
(5 and 20 |iM) on mean (± SEM, n=5) outputs of (a) PGF2a, (b) PGE2
and (c) 6-KETO-PGF-^from day 29 guinea-pig placenta cultured
for 24 h
*Significantly lower, P < 0.05, than corresponding control value.
fSignificantly higher, P < 0.05, than corresponding value obtained
from indomethacin treatment.
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throughout the 24 culture period; indomethacin (20 pM) significantly (P < 0.05, n=5)
inhibited PGE2 output after 24 h, but not after 2 and 8 h of culture (Fig. 3B. 1.3.2b).
NS-398 (5 and 20 pM) had no significant effect on PGE2 output (Fig. 3B. 1.3.2b)
from day 29 guinea-pig sub-placenta. PGE2 output was significantly greater (P <
0.05, n=5) in the presence of NS-398 (5 pM, but not 20 pM) after 2 and 8 h but not
after 24 h of culture, when compared to the corresponding value obtained for
indomethacin treatment (Fig. 3B. 1.3.2b). 6-Keto-PGFla output was significantly (P <
0.05, n=5) reduced throughout the 24 h culture period by indomethacin (5 and 20
pM) and by NS-398 (20 pM, but not 5 pM) after 8 h and 24 h but not in the first 2 h
of culture (Fig. 3B. 1.3.2c). 6-Keto-PGFlct output in the presence of NS-398 (20 pM,
but not 5 pM) was significantly (P < 0.05, n=5) higher than 6-keto-PGFla output in
the presence of indomethacin (20 pM) after 24 h but not after 2 and 8 h of culture
(Fig. 3B. 1.3.2c).
Experiment 3B.1.4 The Effects of Indomethacin (40 pM) and NS-398 (40 pM) on
Prostaglandin Output from Day 29 Guinea-Pig Placenta and Sub-Placenta in
Culture.
Placenta
Indomethacin (40 pM) significantly (P < 0.05, n=5) inhibited PGF2a throughout the
24 h culture period (Fig. 3B. 1.4.1a). NS-398 (40 pM) significantly (P < 0.05, n=5)
reduced PGF2ct output after 24 h, but not after 2 and 8 h of culture (Fig. 3B. 1.4.1a).
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After 8 and 24 h of culture, but not after 2 h, PGF2a output was significantly (P <
0.05, n=5) higher in the presence of NS-398 (40 pM) when compared to PGF2a
output in the presence of indomethacin (40 pM) (Fig. 3B. 1.4.1a). PGE2 output was
reduced significantly (P < 0.05, n=5) by indomethacin (40 pM) throughout the 24 h
culture period (Fig. 3B.1.4.1b). NS-398 (40 pM) significantly (P < 0.05, n=5)
decreased PGE2 output after 2 and 8 h of culture, but had no effect after 24 h (Fig.
3B. 1.4.1b). Throughout the 24 h culture period, PGE2 output was significantly (P <
0.05, n=5) greater in the presence of NS-398 (40 pM) when compared to the PGE2
output in the presence of indomethacin (40 pM) (Fig. 3B. 1.4.1b). 6-Keto-PGFla
output was reduced significantly (P < 0.05, n=5) by indomethacin (40 pM)
throughout the 24 h culture period, and by NS-398 (40 pM) after 2 and 8 h, but not
after 24 h of culture (Fig. 3B. 1.4.1c). 6-Keto-PGFia output was significantly (P <
0.05, n=5) higher after 8 and 24 h, but not in the first 2 h, in the presence ofNS-398
(40 pM) when compared to the corresponding value obtained for indomethacin (40
pM) treatment (Fig. 3B. 1,4.1c).
Sub-Placenta
PGF2a output from day 29 sub-placenta was significantly (P < 0.05, n=5) decreased
by indomethacin (40 pM) and NS-398 (40 pM) throughout the 24 h culture period
(Fig. 3B. 1.4.2a). After 8 h, but not after 2 and 24 h of culture, PGF2ct output in the
presence of NS-398 (40 pM) was significantly (P < 0.05, n=5) higher than PGF2a
output in the presence of indomethacin (40 pM) (Fig. 3B. 1.4.2a). Indomethacin (40
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Culture period
Figure 3B. 1.4.1 Effects of indomethacin (40 (iM) and NS-398 (40 |iM)
on mean (±SEM, n=5) outputs of (a) PGF2a> (b) PGE2 and
(c) 6-KETO-PGF-|afrom day 29 guinea-pig placenta cultured for 24 h.
*Significantly lower, P < 0.05, than corresponding control value.
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Figure 3B. 1.4.2 Effects of indomethacin (40 pM) and NS-398 (40 pM)
on mean (±SEM, n=5) outputs of (a) PGF2a, (b) PGE2 and
(c) 6-KETO-PGF-j a from day 29 guinea-pig sub-placenta cultured for 24 h.
*Significantly lower, P < 0.05, than corresponding control value.
fSignificantly higher, P < 0.05, than corresponding value obtained
from indomethacin treatment.
148
period (Fig. 3B. 1.4.2b). NS-398 (40 pM) significantly (P < 0.05, n=5) reduced PGE2
output after 2 h of culture, but not after 8 and 24 h (Fig. 3B. 1.4.2b). PGE2 output in
the presence of NS-398 (40 pM) was significantly (P < 0.05, n=5) greater than PGE2
output in the presence of indomethacin (40 pM) after 8 h, but not after 2 h and 24 h
of culture (Fig. 3B. 1.4.2b). 6-Keto-Fla output was inhibited significantly (P < 0.05,
n=5) throughout the 24 h culture period by indomethacin (40 pM) and by NS-398
(40 pM) (Fig. 3B. 1.4.2c). There were no significant differences when 6-keto-PGFia
output from the sub-placenta in the presence NS-398 (40 pM) was compared to the
corresponding output in the presence of indomethacin (40 pM) (Fig. 3B. 1.4.2c).
Experiment 3B.1.5 The Effect of Indomethacin and NS-398 on Prostaglandin
Output from Day 22 Guinea-Pig Placenta and Sub-Placenta in Culture,
Placenta
Indomethacin (5, 20 and 40 pM) significantly (P < 0.05, n=5) reduced PGF2a
throughout the 24 h culture period (Fig. 3B.1.5.1a). NS-398 (5, 20 and 40 pM)
significantly (P < 0.05, n=5) inhibited PGF2a output after 2 h of culture (Fig.
3B. 1.5.1a). After 8 h, NS-398 (40 pM, but not 5 and 20 pM) significantly (P < 0.05,
n=5) decreased PGF2(X output and, after 24 h, PGF2a output was reduced significantly
(P < 0.05, n=5) by NS-398 (5 and 40 pM, but not 20 pM) (Fig. 3B.1.5.1a). PGF2a
output was significantly (P < 0.05, n=5) higher in the presence of NS-398 (40 pM,
but not 5 and 20 pM) after 8 h, but not after 2 and 24 h of culture, when compared to
149
the corresponding indomethacin (40 pM) treatment (Fig. 3B. 1.5.1a). PGE2 output
was reduced significantly (P < 0.05, n=5) by indomethacin (5, 20 and 40 pM) and by
NS-398 (5, 20 and 40 pM) throughout the 24 h culture period, except for 20 pM NS-
398 after 8 h (Fig. 3B. 1.5.1b). PGE2 output from day 22 guinea-pig placenta was
significantly (P < 0.05, n=5) higher in the presence ofNS-398 (5 and 40 pM, but not
20 pM) when compared to PGE2 output in the presence of the corresponding
indomethacin concentration (5 and 40 pM, but not 20 pM) treatments after 2 and 8 h
(Fig. 3B. 1.5.1b). After 24 h of culture, PGE2 output was significantly (P < 0.05, n=5)
higher in the presence ofNS-398 (40 pM, but not 5 and 20 pM) compared to output
in the presence of indomethacin (40 pM, but not 5 and 20 pM) (Fig. 3B. 1.5. lb). 6-
Keto-PGFla output was significantly (P < 0.05, n=5) reduced by indomethacin (5 and
40 pM, but not 20 pM) in the first 2 h of culture and by indomethacin (5, 20 and 40
pM) after 8 h (Fig. 3B. 1.5.1c). After 24 h, 6-keto-PGF1(X output was reduced
significantly (P < 0.05, n=5) by indomethacin (40 pM, but not 5 and 20 pM) (Fig.
3B. 1.5.1c). NS-398 (5, 20 and 40 pM) had no effect on 6-keto-PGFla output, except
for 40 pM NS-398 which significantly (P < 0.05, n=5) decreased output after 2 and 8
h of culture, and 5 pM NS-398 which reduced 6-keto-PGFIcx output significantly (P <
0.05, n=5) after 24 h (Fig. 3B. 1,5.1c). After 8 h, but not after 2 and 24 h of culture, 6-
keto-PGFla output was significantly (P < 0.05, n=5) higher in the presence of NS-
398 (20 and 40 pM, but not 5 pM) when compared to the corresponding 6-keto-




PGF2a output from day 22 sub-placenta was inhibited significantly (P < 0.05, n=5)
by indomethacin (5, 20 and 40 pM) and by NS-398 (5, 20 and 40 pM) throughout the
24 h culture period (Fig. 3B. 1.5.2a). After 2 and 24 h of culture, PGF2a output was
significantly (P < 0.05, n=5) higher in the presence of NS-398 (20 pM, but not 5 and
40 pM) when compared to PGF2a output in the presence of indomethacin (20 pM,
but not 5 and 40 pM) (Fig. 3B. 1.5.2a). PGF2a output was significantly (P < 0.05,
n=5) higher after 8 h, in the presence of NS-398 (5, 20 and 40 pM) when compared
to the corresponding output in the presence of indomethacin (5, 20 and 40 pM) (Fig.
3B. 1.5.2a). Indomethacin (5, 20 and 40 pM) and NS-398 (5 and 40 pM, but not 20
pM) significantly (P < 0.05, n=5) reduced PGE2 output throughout the culture period
(Fig. 3B. 1.5.2b). PGE2 output was significantly (P < 0.05, n=5) greater in the
presence of NS-398 (20 pM, but not 5 and 40 pM) compared to the corresponding
PGE2 output in the presence of indomethacin (20 pM, but not 5 and 40 pM)
throughout the culture period (Fig. 3B. 1.5.2b). 6-Keto-F1(X output was inhibited
significantly (P < 0.05, n=5) by indomethacin (5, 20 and 40 pM) throughout the 24 h
culture period (Fig. 3B. 1.5.2c). NS-398 (40 pM, but not 5 and 20 pM) significantly
(P < 0.05, n=5) decreased 6-keto-PGFla output after 2 h of culture, and NS-398 (5
and 40 pM, but not 20 pM) decreased 6-keto-PGFla output significantly (P < 0.05,
n=5) after 8 and 24 h (Fig. 3B. 1.5.2c). 6-Keto-PGFla output from the sub-placenta in
the presence of NS-398 (20 pM, but not 5 and 40 pM) was significantly (P < 0.05,





























































0-2 h 2-8 h 8-24 h
Culture period
Figure 3B. 1.5.1 Effects of indomethacin (5, 20 and 40 (iM) and NS-398
(5, 20 and 40 |iM) on mean (±SEM, n=5) outputs of (a) PGF2a, (b) PGE2
and (c) 6-KETO-PGF1afrom day 22 guinea-pig placenta cultured for 24 h.
*Significantly lower, P < 0.05, than corresponding control value.








































Figure 3B.1.5.2 Effects of indomethacin (5, 20 and 40 (iM) and NS-398
(5, 20 and 40 (iM) on mean (±SEM, n=5) outputs of (a) PGF2a, (b) PGE2
and (c) 6-KETO-PGF1afrom day 22 guinea-pig sub-placenta cultured
for 24 h.
^Significantly lower, P < 0.05, than corresponding control value.
ISignificantly higher, P , 0.05, than corresponding value obtained
from indomethacin treatment.
153
PGFlct output in the presence of indomethacin (20 pM, but not 5 and 40 pM) (Fig.
3B.F5.2c).
Experiment 3B.1.6 The Effects of Indomethacin and NS-398 on Prostaglandin
Production by Day 22 and 29 guinea-Pig Placental Homogenates.
Day 22
The amount of PGF2a produced by day 22 guinea-pig placental homogenates was
significantly (P < 0.05, n=5) greater than the amounts of PGE2 and 6-keto-PGFla
produced (Fig. 3B.1.6. la). The amounts of PGF2ct, PGE2 and 6-keto-PGFlc( produced
by homogenates of day 22 placenta incubated for 1 h were significantly (P < 0.05,
n=5) inhibited by indomethacin (40 pM) (Fig. 3A. 1.6.1a). The presence of NS-398
(40 pM) had no significant effect on the production of PGF2a, PGE2 or 6-keto-PGFia
by day 22 placental homogenates although PGF2a production tended to be decreased
(Fig. 3A. 1.6.1a). The amounts of PGF2a and PGE2 (but not of 6-keto-PGFia) formed
were significantly (P < 0.05, n=5) higher in the presence of NS-398 (40 pM) when
compared to the corresponding amounts produced in the presence of indomethacin
(40 pM) (Fig. 3A. 1.6. la).
Day 29
PGF2a production by day 29 guinea-pig placental homogenates was significantly (P <





































































Figure 3B. 1.6.1 Effects of indomethacin (40 pM) and NS-398 (40 pM)
on mean (±SEM, n=5) amounts of PGF2a, PGE2 and 6-KETO-F-|a
produced by (a) day 22 and (b) day 29 guinea-pig placenta homogenates
following 1 h incubation.
*Significantly lower, P < 0.05, than corresponding control value.
tSignificantly higher, P < 0.05, than correponding value obtained
from indomethacin treatment.
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3B. 1.6. la and b). The basal amounts of PGF2a and 6-keto-PGFla produced by day 29
guinea-pig placenta were not significantly different from the amounts of PGF2a and
6-keto-PGFla produced by day 22 placenta (Figs. 3B.1.6. la and b). Basal PGE2
production by day 29 placenta was significantly (P < 0.05, n=5) higher than PGE2
production by day 22 placenta (Figs. 3B.1.6.1a and b). The amounts of PGF2a, PGE2
and 6-keto-PGFla produced by day 29 placental homogenates were significantly (P <
0.05, n=5) reduced following 1 h incubation with indomethacin (40 pM) (Fig.
3B.1.6.1b). NS-398 (40 pM) significantly (P < 0.05, n=5) inhibited PGF2a and PGE2
production while having no significant effect on 6-keto-PGFla production (Fig.
3B.1.6. lb). PGE2 and 6-keto-PGFla production (but not PGF2a production) was
significantly (P < 0.05, n=5) higher in the presence of NS-398 (40 pM) when
compared to production in the presence of indomethacin (40 pM) (Fig. 3B. 1.6. lb).
Discussion:
This study has shown that PGF2a and 6-keto-Fla outputs from the mid-pregnant day
29 guinea-pig placenta were significantly higher than outputs from day 22 placenta,
which is consistent with the work of Csapo et al. (1981) who reported increased
tissue concentrations of PGF2ct in guinea-pig placenta from day 30 of pregnancy that
remained unchanged during the second half of gestation. PGF2a, PGE2 and 6-keto-
PGF[a outputs from guinea-pig sub-placenta were also increased on day 29 of
pregnancy when compared to day 22, particularly in the first 2 h of culture. PG
output from guinea-pig placenta was greater than PG output from the sub-placenta in
culture, particularly PGF2a output. These results essentially confirm the previous
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study of Norman & Poyser (1998b). It has been suggested that the guinea-pig
placenta has a decreased capacity for PG metabolism the final third of gestation
(Moussard et al., 1986). This study has shown that the PGFM output from the
guinea-pig placenta was very high. This high output of PGFM could mean that the
basal PGF2a outputs from day 22 and day 29 guinea-pig placentae have been
underestimated and that perhaps the metabolite levels should have been measured
throughout along with PG outputs. When the outputs of PGF2a from day 22 and day
29 are considered together with the PGFM outputs from day 22 and day 29 placenta,
it does appear that there may be a decrease in metabolism within the first 2 h of
culture. After 2 h of culture, metabolism does appear to increase with increase PGF2a
production by the day 29 guinea-pig placenta. The metabolism of PGF2c( may be an
important mechanism for maintaining pregnancy and may act as a barrier to prevent
primary active PGs getting to the myometrium and causing unwanted contraction of
the mid-pregnant uterus. The present results have shown an increase in PGF2a output
from the guinea-pig placenta between day 22 and day 29 of pregnancy. Further
investigation is required to determine whether metabolism does actually decrease as
pregnancy proceeds. Rice et al. (1988) observed increased PG output from the sheep
placenta in the final third of gestation and it has been suggested that this may be in
preparation for parturition (Thorburn, 1991). This could also be the case for
increased PG output from the guinea-pig placenta. However, further investigation is
required as this study has only investigated PG outputs from day 29 of pregnancy
(gestation normally 65-70 days).
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Homogenisation of day 22 and 29 placenta gave an indication of PG synthesising
capacity. Basal PGF2a, PGE2 and 6-keto-PGFla production by day 29 placenta tended
to increase compared to PGF2a, PGE2 and 6-keto-PGF1(X production by day 22
guinea-pig placenta. This is consistent with the work ofMoussard et al. (1986), who
observed a further 3-fold increase in production rates of PGE2 and PGF2a by guinea-
pig placental homogenates after day 50 of pregnancy. These results suggest that an
increase in PGHS synthesis is responsible for increased PGF2a, PGE2 and 6-keto-
PGF]a production by day 29 guinea-pig placenta. Schellenberg & Kirby (1997)
demonstrated that the administration of exogenous arachidonic acid had no effect on
PG output from guinea-pig placenta on days 45 to 65 of pregnancy, which indicates
that there is a large pool of free endogenous arachidonic acid available for PG
synthesis. This has also been observed in the human placenta (Ogburn et al., 1988;
Walsh, 1985) and suggests that the amount of PGHS is the rate limiting step for PG
production by the placenta.
Indomethacin is a non-selective inhibitor of PGHS and NS-398 is selective for
PGHS-2, but both have been shown to have similar potencies on PGHS-2 activity
(Futaki et al., 1993, 1994). After 22 days of gestation, PGF2a output from the guinea-
pig placenta was significantly reduced by indomethacin and NS-398. There was very
little difference between treatment with indomethacin and NS-398 suggesting that
PGHS-2 is the predominant enzyme involved in PGF2a synthesis from day 22 guinea-
pig placenta. Indomethacin (5 and 20 pM) and NS-398 (5 and 20 pM) were
equipotent at inhibiting PGF2ot output from day 29 guinea-pig placenta which
indicates that PGHS-2 is the predominant enzyme in the synthesis of PGF2a from day
29 guinea-pig placenta. However, at a higher concentration of 40 p.M, indomethacin
was significantly greater at inhibiting PGF2a output from day 29 placenta suggesting
that both PGHS-1 and PGHS-2 are controlling PGF2a synthesis. These results suggest
that although PGHS-2 is the predominant enzyme responsible for PGF2a synthesis in
the guinea-pig placenta after 22 days of pregnancy, the increase in PGF2a output at
day 29 may also involve PGHS-1. Although PGE2 output from day 22 guinea-pig
placenta was significantly inhibited by both indomethacin and NS-398, treatment
with indomethacin was significantly better. Indomethacin and NS-398 at low
concentrations (5 and 20 pM) showed very little effect on PGE2 output from day 29
guinea-pig placenta. At a higher concentration (40 pM), both indomethacin and NS-
398 significantly reduced PGE2 output. PGE2 output from day 29 placenta in the
presence of indomethacin was significantly lower than in the presence of NS-398.
This suggests that both PGHS-1 and PGHS-2 enzymes are responsible for PGE2
output from day 22 and day 29 guinea-pig placenta. After 22 days of gestation, 6-
keto-PGFIa output from guinea-pig placenta was inhibited slightly more by
indomethacin than by NS-398, possibly indicating that both PGHS enzymes are
involoved in 6-keto-PGFla synthesis. 6-Keto-PGFI(X output from day 29 guinea-pig
placenta was inhibited by indomethacin and NS-398 throughout the 24 h culture
period, and was significantly lower in the presence of indomethacin compared to
NS-398 treatment. Therefore, both PGHS-1 and PGHS-2 appear to be responsible for
6-keto-PGFia synthesis from day 29 guinea-pig placenta as well as from day 22
placenta. As NS-398 has no significant inhibitory effect on PGHS-1 (Futaki et al.,
1993, 1994; Masferrer et al., 1994) and indomethacin has a more potent action on
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PGHS-1 than on PGHS-2 (Mitchell et al., 1993), it appears that PGE2 and 6-keto-
PGFlo( synthesis from day 29 guinea-pig placenta is controlled by both PGHS
enzymes.
PGF2a and PGE2 outputs from guinea-pig sub-placenta after 29 days of pregnancy
were inhibited by indomethacin and NS-398. Indomethacin appeared to be more
effective at inhibiting PGF2ra and PGE2 outputs from the sub-placenta, which suggests
that both forms of the PGHS enzyme are responsible for their outputs. 6-Keto-PGFia
output from day 29 guinea-pig sub-placenta was inhibited throughout culture by
indomethacin and NS-398. At smaller concentrations (5 and 20 pM), indomethacin
appeared to be more effective at inhibiting 6-keto-PGFla output but, at 40 pM,
indomethacin and NS-398 were equipotent. PGF2a, PGE2 and 6-keto-PGFla outputs
from day 22 guinea-pig sub-placenta were significantly reduced throughout the 24 h
culture period by both indomethacin and NS-398. All PGs measured were inhibited
to a greater extent by indomethacin compared to treatment with NS-398. After 22
days of gestation PGF2a, PGE2 and 6-keto-PGFla outputs from guinea-pig sub-
placenta appear to be controlled by both forms of the PGHS enzyme and, after 29
days of pregnancy, this does not appear to change.
Previous studies have provided evidence which suggests that PGHS activity in the
guinea-pig, sheep and pig placenta gradually increases during pregnancy (Moussard
et al., 1986; Rice et al., 1988, 1989). The amounts of PGF2a, PGE2 and 6-keto-PGFla
produced by homogenates of day 22 placenta incubated for 1 h were reduced by
indomethacin. Treatment of day 22 placenta homogenates with NS-398 showed no
significant decrease in PGF2a, PGE2 and 6-keto-PGFlcx production although
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production tended to decrease. PGF2a and PGE2 production was significantly higher
in the presence of NS-398 when compared to treatment with indomethacin. The
previous culture experiments suggested that PGHS-2 was the predominant enzyme
responsible for PGF2a production by day 22 guinea-pig placenta. However,
homogenisation of this tissue indicates that both PGHS-1 and PGHS-2 are involved
in PGF2ct production by day 22 placenta. Therefore, PG production by the day 22
guinea-pig placenta, cultured for 24 h, appears to be dependent on PGHS-2, while
PG production by homogenates of day 22 placenta is dependent on both PGHS-1 and
PGHS-2. The reason for this is not clear. Homogenisation of day 22 guinea-pig
placenta suggest that PGHS-1 and PGHS-2 are responsible for PGE2 and 6-keto-
PGF]a production. Indomethacin is a non-selective inhibitor of PGHS although it has
previously been reported that it is more effective at inhibiting PGHS-1 than PGHS-2
(Mitchell et a/., 1993). NS-398 is a selective inhibitor of PGHS-2 (Futaki et al.,
1993, 1994). Both compounds were capable of inhibiting PGE2 and 6-keto-PGFla
production by homogenates of day 22 guinea-pig placenta, suggesting that PGHS-1
and PGHS-2 are responsible for PGE2 and 6-keto-PGFla synthesis by this tissue.
Indomethacin and NS-398 significantly reduced PGF2c( and PGE2 production by
homogenates of day 29 guinea-pig placenta, while 6-keto-PGFla production was
inhibited by indomethacin only. Indomethacin was significantly greater at inhibiting
PGE2 and 6-keto-PGFla production suggesting that both PGHS-1 and PGHS-2 are
responsible for their production. Indomethacin and NS-398 were equipotent at
inhibiting PGF2a production by placental homogenates, which is consistent with the
tissue culture experiments that suggested PGHS-2 is the predominant enzyme
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responsible for PGF2a production. These results suggest that both isoforms of the
PGHS enzyme are responsible for PGE2 and 6-keto-PGFla production by day 29
guinea-pig placenta and that PGHS-2 is the predominant enzyme involved in PGF2a
production by day 29 placenta.
Up-regulation ofPGHS expression is a common effect ofmany agents that stimulate
PG synthesis including growth factors, hormones, interleukins and phorbol esters
(DeWitt, 1991), but no one signal transduction mechanism has been implicated in
increased PGHS expression. However, activation of protein kinase C (PKC) has been
observed to lead to increased PGHS expression in many cases including interleukin-
1 (IL-1) stimulation of human dermal and endothelial cells (Raz et al., 1988; Maier
et al., 1990). PKC has also been observed to stimulate mitogen-activated protein
kinase (MAPK) (Qiu & Leslie, 1994) which stimulates PGHS-2 expression in
macrophages (Hwang et al., 1997).
In summary, this work has shown that PG output from guinea-pig placenta and sub-
placenta increases between day 22 and 29 of pregnancy. Metabolism of PGF2ct by the
guinea-pig placenta requires further investigation as it was not clear from this study
whether metabolism decreases or increases between day 22 and day 29 of pregnancy.
The finding that the PG synthesising capacity of placental homogenates increases
between days 22 and 29 of pregnancy suggests that the increase in placental PG
output between these two days was due to increased PGHS synthesis. It has been
suggested that PGHS activity plays a key role in the maintenance of pregnancy
(Kelly, 1994). PGHS is required for PG production. Previous workers have suggested
that PGE2 may be the important PG as pregnancy proceeds (see Thorbum, 1991).
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PGE2 output from the guinea-pig placenta and sub-placenta did not increase
significantly between day 22 and day 29 of pregnancy. However, whether PGE2
output from the guinea-pig placenta and sub-placenta increases after day 29 requires
further investigation. At day 29, PGF2a appears to be the important PG produced by
the guinea-pig placenta and sub-placenta.
Previous workers have observed PGHS-2 to be the predominant enzyme in PG
synthesis from the ovine and human placenta (Wimsatt et al., 1993; Freed et al.,
1995; Rice et al., 1995; Macchia et al., 1997). This functional study showed that
PGHS-2 is the predominant enzyme responsible for PGF2a synthesis by day 22 and
29 guinea-pig placenta and sub-placenta, and that both isoforms of the PGHS
enzyme are involved in PGE2 and 6-keto-PGFia synthesis from day 22 and day 29
guinea-pig placenta and sub-placenta. PGHS-1 and PGHS-2 are often co-expressed
in the same cell, and it has been proposed that PGHS-2 may co-localise with PGHS-1
to augment the function of PGHS-1 or substitute for it ifPGHS-1 is lacking (Smith et
al., 1996). PGHS-2 is also associated with cell differentiation and replication (Otto
& Smith, 1995) which could be an advantage for the developing fetus and placenta.
The signal transduction mechanism responsible for stimulation of PGHS expression
and increased PG synthesis from the guinea-pig placenta and sub-placenta as
pregnancy proceeds requires further investigation.
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3B.2 PROTEIN SYNTHESIS INHIBITORS
Introduction:
While synthesis of prostaglandins is regulated acutely by the activation of
phospholipases and release of arachidonic acid from membrane phospholipids, net
prostanoid production is dependent on the level of expression of prostaglandin H
synthase (PGHS). Prostaglandin production by the guinea-pig placenta and sub-
placenta has been observed to increase as pregnancy proceeds (see Section 3B.1.1).
This increase has been attributed to stimulation of PGHS synthesis, which is
dependent on the synthesis of proteins. PGHS is destroyed during PG biosynthesis,
therefore, fresh enzyme must be provided if biosynthesis is to be maintained (Lands
et al., 1973). Continued protein synthesis is necessary for PGHS and PG synthesis in
both cell types of guinea-pig endometrium (Naderali & Poyser, 1996b). Protein
synthesis inhibitors have previously been observed to inhibit the output of PGs,
particularly of PGF2a from guinea-pig endometrium on days 7 and 15 of the oestrous
cycle (Riley & Poyser, 1989). In addition, the protein synthesis inhibitors prevented
the synthesis of PGHS in the guinea-pig endometrium during culture (Riley &
Poyser, 1989).
Three different protein synthesis inhibitors with different mechanisms of action were
chosen. The effects of actinomycin D (a DNA-dependent RNA synthesis inhibitor),
puromycin (a releaser of nascent polypeptide chains before their synthesis is
complete) and cycloheximide (an inhibitor of elongation step of transcription) on PG
production by day 29 guinea-pig placenta and sub-placenta have been investigated.
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Methods:
The placentae from day 29 pregnant guinea-pigs were removed, separated and
prepared as described in section 2.1.4. The placenta and the sub-placenta were
cultured separately in Petri dishes containing TCM plus cycloheximide (5, 10, 100
and 200 pM), puromycin (5, 10, 100 and 200 pM) or actinomycin D (10, 20, 50 and
100 pM). Dishes were placed in Kilner jars, gassed and incubated as described in
Section 2.1.4. The TCM was removed and replaced after 2, 8 and 24 h. Samples
were stored at -20°C and assayed for their PGF2a, PGE2 and 6-keto-PGFia content.
Statistical analyses were carried out using a one-way analysis of variance (ANOVA)
and the paired t-test.
Results:
Experiment 3B.2.1 The Effects of Cycloheximide, Puromycin and Actinomycin
D on Prostaglandin Output from Day 29 Guinea-Pig Placenta and Sub-Placenta
in Culture.
Placenta
Low Concentrations of Protein Synthesis Inhibitors
PGF2a output was unaffected by cycloheximide (5 and 10 pM) and puromycin (5 and
10 pM) after 2 and 8 h of culture (Fig. 3B.2.1.1a). After 24 h of culture,
cycloheximide (10 pM, but not 5 pM) and puromycin (5 pM, but not 10 pM)
significantly (P < 0.05, n=5) inhibited PGF2a output (Fig. 3B.2.1.1 a). After 2 and 8 h
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of culture, PGF2a output was significantly (P < 0.05, n=5) inhibited by actinomycin
D (10 and 20 pM), but not after 24 h of culture (Fig. 3B.2.1.1a). None of the protein
synthesis inhibitors used had any significant effect on PGE2 output from the placenta
throughout the 24 h culture period (Fig. 3B.2.1.1b). 6-Keto-PGFla output was
unaffected by cycloheximide (5 and 10 pM), puromycin (5 and 10 pM) and
actinomycin D (10 and 20 pM) after 2 h of culture (Fig. 3B.2.1.1c). 6-Keto-PGFla
output was reduced significantly (P < 0.05, n=5) by cycloheximide (5 and 10 pM)
after 8 h and 24 h of culture (Fig. 3B.2.1.1c). Puromycin (5 and 10 pM) significantly
(P < 0.05, n=5) reduced 6-keto-PGFla output after 8 h and 24 h, except 5 pM
puromycin after 8 h of culture (Fig. 3B.2.1.1c). Actinomycin D (10 and 20 pM) had
no effect on 6-keto-PGFla output after 8 h. After 24 h of culture actinomycin D (20
pM, but not 10 pM) significantly (P < 0.05, n=5) reduced 6-keto-PGFla output (Fig.
3B.2.1.1c).
High Concentrations of Protein Synthesis Inhibitors
Cycloheximide (200 pM, but not 100 pM) significantly (P < 0.05, n=5) increased
PGF2a output from the guinea-pig placenta after 2 and 8 h of culture, but had no
effect after 24 h (Fig. 3B.2.1.3a). PGF2a output was increased significantly (P < 0.05,
n=5) by cycloheximide (100 pM) after 8 h and 24 h of culture, but had no effect after
2 h of culture (Fig. 3B.2.1.3a). Puromycin (100 and 200 pM) and actinomycin D (50
and 100 pM) had no effect on PGF2a output except, after 2 h of culture, 200 pM
puromycin and 100 pM actinomycin D significantly (P < 0.05, n=5) increased PGF2cx
output (Fig. 3B.2.1.3a). PGE2 output was significantly (P < 0.05, n=5) reduced by
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cycloheximide (100 and 200 pM) after 2 and 8 h of culture, and by cycloheximide
(100 pM, but not 200 pM) after 24 h of culture (Fig. 3B.2.1.3b). Puromycin (100
pM, but not 200 pM) and actinomycin D (50 pM, but not 100 pM) significantly (P <
0.05, n=5) inhibited PGE2 output after 2 and 8 h of culture, but had no effect after 24
h of culture (Fig. 3B.2.1.3b). 6-Keto-PGFia output was significantly (P < 0.05, n=5)
inhibited by cycloheximide (100 and 200 p.M) and actinomycin D (50 pM, but not
100 pM) after 2 and 8 h of culture, but had no significant effect after 24 h (Fig.
3B.2.1.3c). After 24 h of culture, but not after 2 and 8 h of culture, cycloheximide
(200 pM, but not 100 pM) significantly (P < 0.05, n=5) increased 6-keto-PGFla
output (Fig. 3B.2.1.3c). Puromycin (100 and 200 pM) had no effect on 6-keto-PGFla
output throughout the culture period, except 100 pM puromycin which significantly
(P < 0.05, n=5) reduced 6-keto-PGFla output after 8 h of culture (Fig. 3B.2.1.3c).
Sub-Placenta
Low Concentrations of Protein Synthesis Inhibitors
Cycloheximide (5 and 10 pM) had no significant effect on PGF2C( output from the
sub-placenta after 2 and 8 h of culture (Fig. 3B.2.1.2a). After 24 h of culture
cycloheximide (5 and 10 pM) significantly (P < 0.05, n=5) increased PGF2a output
(Fig. 3B.2.1.2a). Puromycin (5 pM, but not 10 pM) and actinomycin D (10 pM, but
not 20 pM) significantly reduced PGF2a output from the guinea-pig sub-placenta
after 2 h of culture (Fig. 3B.2.1.2a). PGF2a output was increased significantly (P <
0.05, n=5) by puromycin (5 and 10 pM) after 8 h and 24 h of culture, and by
actinomycin D (10 and 20 pM) after 24 h, but not after 8 h of culture (Fig.
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3B.2.1.2a). Cycloheximide (5 pM, but not 10 pM) significantly (P < 0.05, n=5)
reduced PGE2 output after 2 and 8 h of culture, but not after 24 h (Fig. 3B.2.1.2b).
After 24 h, PGE2 output was increased significantly (P < 0.05, n=5) by
cycloheximide (10 pM, but not 5 pM) and puromycin (10 pM, but not 5 pM) (Fig.
3B.2.1,2b). Puromycin (5 and 10 pM) had no effect on PGE2 output after 2 h and 8 h
of culture (Fig. 3B.2.1.2b). Actinomycin D (10 and 20 pM) reduced PGE2 output
significantly (P < 0.05, n=5) after 2 and 8 h of culture, except 10 pM actinomycin D
which had no effect on PGE2 output after 8 h (Fig. 3B.2.1.2b). Actinomycin D (10
and 20 pM) had no effect on PGE2 output after 24 h of culture (Fig. 3B.2.1.2b).
None of the protein synthesis inhibitors used had any significant effect on 6-keto-
PGFlc( output from the guinea-pig sub-placenta throughout the 24 h culture period
(Fig. 3B.2.1.2c).
High Concentrations of Protein Synthesis Inhibitors
PGF2a output was significantly (P < 0.05, n=5) inhibited after 2 h and 24 h of culture
by cycloheximide (100 pM, but not 200 pM), and after 8 h by cycloheximide (100
and 200 pM) (Fig. 3B.2.1.4a). After 24 h of culture, but not after 2 and 8 h of
culture, cycloheximide (200 pM, but not 100 pM) significantly (P < 0.05, n=5)
increased PGF2a output from the sub-placenta (Fig. 3B.2.1.4a). Puromycin (100 and
200 pM) significantly (P < 0.05, n=5) decreased PGF2a output from the sub-placenta
after 2 and 8 h of culture, but had no significant effect after 24 h (Fig. 3B.2.1.4a).
Actinomycin D (50 pM, but not 100 pM) significantly (P < 0.05, n=5) decreased
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Figure 3B.2.1.1 Effects of cycloheximide (5 and 10 |iM), puromycin
(5 and 10 pM) and actinomycin D (10 and 20 pM) on mean (±SEM, n=
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF1afrom day 29
guinea-pig placenta cultured for 24 h.
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Figure 3B.2.1.2 Effects of cycloheximide (5 and 10 pM), puromycin
(5 and 10 pM) and actinomycin D (10 and 20 pM) on mean
(± SEM, n=5) outputs of (a) PGF2a C3) PGE2 and (c) 6-KETO-PGF-|a
from day 29 guinea-pig sub-placenta cultured for 24 h.













y// Cyc. 100 pM
v\\\ Cyc. 200 pM
E229 Puro. 100 pM
■■■ Puro. 200 pM
llll Ac. D 50 uM


















0-2 h 2-8 h 8-24 h
Culture period
Figure 3B.2.1.3 Effects of cycloheximide (100 and 200 pM), puromycin
(100 and 200 pM) and actinomycin D (50 and 100 pM) on mean
(±SEM, n=5) outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF1a
from day 29 guinea-pig placenta cultured for 24 h.
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Figure 3B.2.1.4 Effects of cycloheximide (100 and 200 |uM), puromycin
(100 and 200 pM) and actinomycin D (50 and 100 |iM) on mean
(±SEM, n=5) outputs of (a) PGF2a,(b) PGE2 and (c) 6-KETO-PGF1a
from day 29 guinea-pig sub-placenta cultured for 24 h.
*/t Significantly lower/higher, P < 0.05, than corresponding control
value.
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Cycloheximide (100 and 200 pM) had no effect on PGE2 output after 2 h of culture,
but after 8 h and 24 h of culture, cycloheximide (100 pM, but not 200 pM) reduced
PGE2 output significantly (P < 0.05, n=5) (Fig. 3B.2.l.4b). After 24 h, but not after 2
and 8 h of culture, cycloheximide (200 pM, but not 100 pM) significantly (P < 0.05,
n=5) stimulated PGE2 output (Fig. 3B.2.1.4b). Puromycin (100 pM, but not 200 pM)
significantly (P < 0.05, n=5) decreased PGE2 output after 2 and 8 h of culture, but
had no effect after 24 h of culture (Fig. 3B.2.1.4b). PGE2 output was unaffected by
actinomycin D (50 and 100 pM) throughout the 24 h culture period, except after 24 h
of culture, PGE2 output was significantly (P < 0.05, n=5) increased by 50 pM
actinomycin D (Fig. 3B.2.1.4b). 6-Keto-PGFla output was unaffected by the protein
synthesis inhibitors used throughout culture, except by 100 pM cycloheximide which
significantly (P < 0.05, n=5) reduced 6-keto-PGFla output after 8 h, and by 100 pM
puromycin which significantly (P < 0.05, n=5) increased 6-keto-PGFia output after
24 h of culture (Fig. 3B.2.1.4c).
Discussion:
Cycloheximide and puromycin at low concentrations of 10 pM and 5 pM,
respectively, inhibited PGF2cx output from day 29 guinea-pig placenta after 24 of
culture. Actinomycin D at low concentrations also inhibited PGF2a output from the
guinea-pig placenta after 2 h and 8 h of culture. These results suggest that
PGF2a production by day 29 guinea-pig placenta may be dependent on protein
synthesis. The effects of cycloheximide, puromycin and actinomycin D were not
pronounced and this may have been due to the low concentrations used. However, at
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higher concentrations, cycloheximide, puromycin and actinomycin D stimulated
PGF2a output from the guinea-pig placenta, particularly cycloheximide. Riley &
Poyser (1989) have previously observed that protein synthesis inhibitors stimulate
PG output from day 7 and day 15 superfused guinea-pig uterus, with cycloheximide
having a particularly strong stimulatory effect on PGE2 output. It has also been
shown that PGHS mRNA can be superinduced by cycloheximide (DeWitt et a/.,
1990; Maier et al., 1990). This stimulation of PGHS, the enzyme responsible for the
conversion of arachidonic acid to PGs, may account for the observed increase in
PGF2a output from day 29 guinea-pig placenta in the presence of cycloheximide.
PGE2 output from the guinea-pig placenta was unaffected by the lower
concentrations of cycloheximide, puromycin and actinomycin D used. Higher
concentrations of these treatments inhibited PGE2 output significantly, especially
during the first 8 h of culture. This suggests that PGE2 output from the guinea-pig
placenta is dependent on the synthesis of proteins. The presence of protein synthesis
inhibitors at low concentrations significantly inhibited 6-keto-PGFla output from the
guinea-pig placenta, especially after 24 h of culture. Higher concentrations of
cycloheximide, puromycin and actinomycin D also inhibited 6-keto-PGFla output
from the placenta, but had a more pronounced effect at the beginning of the culture
period. These results show that both low and high concentrations of cycloheximide,
puromycin and actinomycin D were capable of inhibiting 6-keto-PGFla output from
the guinea-pig placenta, and suggest that 6-keto-PGF1(X production by the placenta
requires protein synthesis. After 24 h of culture, 6-keto-PGFla output was
significantly increased by the presence of cycloheximide (200 pM). Naderali &
174
Poyser (1996b) observed that cycloheximide was not as effective at inhibiting PG
output from cultured guinea-pig endometrium as actinomycin D and puromycin
because it had a short-term stimulatory effect. A similar action may account for the
effect of cycloheximide on the placenta.
Low concentrations of puromycin and actinomycin D inhibited PGF2a output from
day 29 guinea-pig sub-placenta after 2 h of culture. However, after 24 h of culture,
all treatments used significantly stimulated PGF2a output from the sub-placenta. This
effect was not so pronounced when higher concentrations of these compounds were
used. At these higher concentrations, cycloheximide, puromycin and actinomycin D
inhibited PGF2a output from the sub-placenta after 8 h of culture, while only
cycloheximide significantly increased PGF2a output after 24 h of culture. High
concentrations of puromycin and actinomycin D had no significant stimulatory effect
on PGF2ct output from the guinea-pig sub-placenta after 24 h of culture. These results
suggest that PGF2a production by the sub-placenta may be dependent on protein
synthesis. Cycloheximide and actinomycin D (low concentrations) significantly
inhibited PGE2 output from the sub-placenta after 2 and 8 h of culture, but had little
effect at higher concentrations. Puromycin had no inhibitory effect on PGE2 output at
low concentrations of 5 and 10 pM, but significantly reduced PGE2 output after 2
and 8 h of culture at a higher concentration of 100 pM. The inhibitory effects of
cycloheximide, puromycin and actinomycin D on PGE2 output from the sub-placenta
suggests that protein synthesis is necessary for PGE2 production. PGE2 output from
the sub-placenta was stimulated after 24 h of culture in the presence of
cycloheximide at both high and low concentrations, puromycin at a low
175
concentration and by actinomycin D at a high concentration. Cycloheximide has
previously been observed to stimulate PGE2 output from the superfused guinea-pig
uterus (Riley & Poyser, 1989) and is known to induced PGHS mRNA (DeWitt et al.,
1990; Maier et al., 1990). 6-Keto-PGFla output from day 29 sub-placenta was
unaffected by the presence of low concentrations of cycloheximide, puromycin and
actinomycin D. However, at higher concentrations, cycloheximide was observed to
inhibit 6-keto-PGFla output after 8 h of culture, while puromycin was observed to
stimulate 6-keto-PGFia output after 24 h of culture. It remains unclear whether 6-
keto-PGFia production by the guinea-pig sub-placenta is dependent on the
production of proteins. The stimulatory effects of the compounds used, previously
observed when measuring PGF2(X and PGE2 outputs from the guinea-pig placenta and
sub-placenta, may explain why no inhibitory effect on 6-keto-PGFia output from the
sub-placenta was seen. Cycloheximide, puromycin and actinomycin D may have
opposing action with regards to PG production by the guinea-pig placenta and sub-
placenta.
In summary, these results suggest that PG production by the day 29 guinea-pig
placenta and sub-placenta may be dependent to a limited extent on the synthesis of
proteins. PGHS is destroyed during PG biosynthesis, therefore fresh enzyme must be
provided if biosynthesis is to be maintained (Lands et al., 1973). Therefore, the
process of protein synthesis may be necessary for the production of PGHS, the
enzyme responsible for the conversion of arachidonic acid to PGs.
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3B.3 AN INVESTIGATION INTO THE ROLE OF CALCIUM IN
PROSTAGLANDIN PRODUCTION BY THE GUINEA-PIG PLACENTA.
Introduction;
'Phospholipase A2' consists of a family of enzymes, some ofwhich are dependent on
calcium. Phospholipase A2 is the enzyme responsible for arachidonic acid release
from membrane phospholipids, and it is well documented that arachidonic acid
release for PG synthesis is triggered in cells by many calcium mobilising agonists
(Clark et al., 1995). PG production by the guinea-pig placenta and sub-placenta has
been observed to increase as pregnancy proceeds (see Section 3B.1.1). The calcium
(Ca2+) requirement for this increased PG synthesis by guinea-pig placenta and sub-
placenta has been investigated. Day 29 guinea-pig placenta and sub-placenta were
cultured in calcium-depleted medium to determine if extracellular calcium is
required for prostaglandin production.
It has previously been observed that raising the intracellular free calcium
concentration stimulates PGF2a synthesis by, and release from, the guinea-pig uterus
(Poyser & Brydon, 1983). The effect of 8-(N,N-diethylamino)-octyl-3,4,5-
trimethoxybenzoate hydrochloride (TMB-8; an intracellular Ca2+ antagonist) on PG
production by the day 29 guinea-pig placenta and sub-placenta have been examined.
This was to establish whether or not intracellular calcium is required for PG
synthesis by these tissues. The effect of EGTA (a calcium chelator) on PG
production by the day 29 guinea-pig placenta and sub-placenta were also studied.
Riley & Poyser (1987b) have observed that EGTA, when cultured with the guinea-
pig endometrium, acts intracellularly as well as extracellularly.
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Calmodulin is a cytosolic calcium-binding protein through which the action of
calcium on various enzymes is mediated. Calmodulin functions in a variety of cells
(Cheung, 1980) and, in some tissues, PLA2 is a calmodulin-dependent enzyme
(Wong & Cheung 1979, Maskowitz et al., 1983). Calmodulin has previously been
observed to play a role in PG synthesis in the guinea-pig uterus (Poyser, 1985a, b;
Riley & Poyser, 1987b). Day 29 guinea-pig placenta and sub-placenta were cultured
for 24 h in the presence of trifluoperazine (TFP; a calmodulin antagonist) and N-(6-
aminohexyl)-5-chloro-l-naphthalenesulphonamide (W-7; a calmodulin antagonist)
and PG output was observed. This experiment was carried out to determine whether
calcium exerts its effect on the guinea-pig placenta and sub-placenta by combining
with the intracellular calcium binding protein, calmodulin.
It is well documented that phorbol esters stimulate the activation of protein kinase C
(PKC) in a number of tissues. Protein kinase C has been observed to increase
arachidonic acid release in, and PGF2a and PGE2 production by human decidual cells
(Schrey & Read, 1986). Phorbol esters also stimulate PGHS-2 mRNA expression in
cultured human amnion cells (Zakar et al., 1996). The effect of phorbol 12-myristate
13-acetate (TPA; a stimulator of protein kinase C) on PG output from day 29 guinea-
pig placenta and sub-placenta was investigated. TPA mimics the action of
diacylglycerol, thereby activating PKC. Anteby et al. (1997) have observed that
PGF1S-2 expression was increased in the presence of TPA, as was PGE2 output, from
human trophoblasts.
The effects of nifedipine and verapamil (voltage-dependent Ca2+ channel blockers)
on PG outputs from day 29 guinea-pig placenta and sub-placenta were also
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investigated. This was to determine whether any influx of calcium from outside the
cells was via voltage-dependent channels.
The effects of EGTA, TMB-8, nifedipine and verapamil were also investigated in
homogenates of day 29 guinea-pig placenta and sub-placenta to observe whether
these treatments had any effect on the PG synthesising capacity.
Methods:
Day 29 guinea-pig placentae were removed and prepared as described in Section
2.1.4. In experiment 3B.3.1, the day 29 placenta and sub-placenta were cultured for
24 h in Medium 199 or in calcium-depleted Medium 199. These dishes were placed
in modified Kilner jars, gassed and incubated as previously described (Section 2.1.4).
The culture medium in each dish was changed and collected after 2, 8 and 24 h.
Samples were stored at -20°C before being assayed for PGF2a, PGE2 and 6-keto-
PGFla content. Statistical analyses were carried out using a one-way analysis of
variance (ANOVA) and the paired t-test.
In experiments 3B.3.2-4, the placentae from day 29 pregnant guinea-pigs were
removed and separated as described in Section 2.1.4. The placenta and sub-placenta
were cut into small pieces and placed on lens tissue on top of raised gauze platforms
in culture dishes containing tissue culture Medium 199 (TCM). In experiment
3B.3.2, day 29 guinea-pig placenta and sub-placenta were cultured separately in
TCM containing EGTA (2 mM), TMB-8 (30 and 100 pM), TFP (100 and 200 pM)
or W-7 (150 and 300 pM). Experiment 3B.3.3 was carried out similarly in the
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presence of nifedipine (1, 10 and 100 pM) or verapamil (1, 10 and 100 pM). In
experiment 3B.3.4, placenta and sub-placenta were cultured in the presence of TPA
(1.5, 8 and 40 nM). In all three experiments dishes were placed in modified Kilner
jars, and were gassed and incubated as previously described in Section 2.1.4. Culture
medium was collected after 2, 8 and 24 h. Samples were stored at -20°C. PGF2a,
PGE2 and 6-keto-PGFla content in each sample was measured using
radioimmunoassay. Statistical analyses were carried out using a one-way analysis of
variance (ANOVA) and the paired t-test.
Homogenisation experiment 3B.3.5 was carried out using day 29 guinea-pig
placenta. The tissue was blotted dry, weighed and then homogenised as described in
Section 2.1.3 with Krebs solution containing either EGTA (2 mM), TMB-8 (30 and
100 pM), nifedipine (10 and 100 pM) or verapamil (10 and 100 pM). One sample in
each experiment was untreated and acted as a control. Each sample was allowed to
incubate for 60 min at 37°C (see Section 2.1.3), and prostaglandins were then
extracted as described in Section 2.1.1. The ethyl acetate extracts were evaporated
to dryness on a rotary evaporator, and the residues were each re-dissolved in 5 ml
ethyl acetate and stored at -20°C until assayed for their PG content. Statistical




Experiment 3B.3.1 The Effect of Ca2+-Depleted Medium on Prostaglandin
Output from Day 29 Guinea-Pig Placenta and Sub-Placenta in Culture.
Placenta
PGF2a and PGE2 outputs from guinea-pig placenta were unaffected by culturing the
tissue in calcium-depleted medium for 24 h (Fig. 3B.3.1.1a and b). Calcium-depleted
medium significantly (P < 0.05, n=5) reduced 6-keto-PGFia output from placenta
throughout the 24 h culture period compared to culturing the placenta in Medium
199 (Fig. 3B.3.1. lc).
Sub-Placenta
Calcium-depleted medium significantly (P < 0.05, n=5) inhibited the PGF2a output
from the sub-placenta after 2 h of culture but, after 8 and 24 h, the presence of
calcium-depleted medium had no significant effect (Fig. 3B.3.1.2a). PGE2 output
was reduced significantly (P < 0.05, n=5) throughout the 24 h culture period in the
presence of calcium-depleted culture medium compared to culturing the tissue in
Medium 199 (Fig. 3B.3.1.2b). 6-Keto-PGFla output was unaffected by calcium-
depleted medium after 2 and 8 h of culture, but was significantly (P < 0.05, n=5)
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Figure 3B.3.1.1 Effect of calcium-depleted Medium (Ca^+ D.M.) on mean
(±SEM, n=5) outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF1a
from day 29 guinea-pig placenta cultured for 24h.
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Figure 3B.3.1.2 Effect of calcium-depleted Medium (Ca2+ D.M.) on mean
(±SEM, n=5) outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF1oc
from day 29 guinea-pig sub-placenta cultured for 24 h.
*Significantly, P < 0.05, lower than corresponding control value.
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Experiment 3B.3.2 The Effects of a calcium chelator (EGTA), an intracellular
antagonist (TMB-8) and calmodulin inhibitors (TFP and W-7) on Prostaglandin
Output from Day 29 Guinea-Pig Placenta and Sub-Placenta in Culture.
Placenta
PGF2(X output from the guinea-pig placenta was significantly (P < 0.05, n=5)
decreased by EGTA (2 mM) after 8 and 24 h of culture, but EGTA (2 mM) had no
effect on PGF2a output after 2 h of culture (Fig. 3B.3.2.1a). TMB-8 (30 and 100 pM)
had no significant effect on PGF2cx output in the first 2 h of culture (Fig. 3B.3.2. la).
After 24 h of culture, but not after 8 h, TMB-8 (30 pM, but not 100 pM)
significantly (P < 0.05, n=5) inhibited PGF2ci output. After 8 and 24 h, TMB-8 (100
pM, but not 30 pM) stimulated PGF2a ouput significantly (P < 0.05, n=5) (Fig.
3B.3.2.la). TFP (100 and 200 pM) had no effect on PGF2a output, except after 8 h,
when 200 pM TFP significantly (P < 0.05, n=5) increased PGF2a output (Fig.
3B.3.2.1a). W-7 (150 and 300 pM) had no effect on PGF2a output after 2 h of culture
(Fig. 3B.3.2.1a). PGF2a output was significantly (P < 0.05, n=5) increased after 8 h
by W-7 (150 and 300 pM), and after 24 h by W-7 (300 pM, but not 150 pM) (Fig.
3B.3.2.1a).
PGE2 output from the placenta was unaffected by any of the treatments used, except
TMB-8 (30 pM) which significantly (P < 0.05, n=5) reduced PGE2 throughout the 24
h culture period (Fig. 3B.3.2.1 b).
6-Keto-PGFla output was not affected by any of the treatments used after 2 h of
culture (Fig. 3B.3.2.1c). 6-Keto-PGFla output was decreased significantly (P < 0.05,
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n=5) by EGTA (2 mM) and TMB-8 (30 pM, but not 100 pM) after 8 and 24 h of
culture (Fig. 3B.3.2. lc). TFP (100 pM, but not 200 pM) significantly (P < 0.05, n=5)
inhibited 6-keto-PGFia output after 8 and 24 h of culture (Fig. 3B.3.2.1c). W-7 (150
and 300 pM) decreased 6-keto-PGFia output significantly (P < 0.05, n=5) after 8 h of
culture, but not after 24 h (Fig. 3B.3.2.1c).
Sub-Placenta
EGTA (2 mM) had no significant effect on PGF2a output from the guinea-pig sub-
placenta throughout the 24 h culture period (Fig. 3B.3.2.2a). TMB-8 (100 p.M, but
not 30 pM) significantly (P < 0.05, n=5) reduced PGF2a output after 2 h of culture
(Fig. 3B.3.2.2a). After 8 and 24 h of culture, TMB-8 (30 pM, but not 100 pM)
significantly (P < 0.05, n=5) inhibited PGF2a output from the sub-placenta (Fig.
3B.3.2.2a). PGF2aoutput was increased significantly (P < 0.05, n=5) by TFP (200
pM, but not 100 pM) after 8 h and 24 h of culture, but had no effect after 2 h of
culture (Fig. 3B.3.2.2a). W-7 (150 and 300 pM) had no effect on PGF2a output after
2 h of culture (Fig. 3B.3.2.2a). PGF2a output was significantly (P < 0.05, n=5)
increased by W-7 (300 pM, but not 150 pM) after 8 h, and by W-7 (150 and 300
pM) after 24 h of culture (Fig. 3B.3.2.2a and b).
PGE2 output was significantly (P < 0.05, n=5) reduced after 2 h of culture by EGTA
(2 mM) and TMB-8 (30 pM, but not 100 pM). PGE2 output was not affected by
EGTA or TMB-8 after 8 and 24 h of culture (Fig. 3B.3.2.2b). TFP (100 and 200 pM)
had no significant effect on PGE2 output after 2 and 8 h of culture (Fig. 3B.3.2.2b).
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Figure 3B.3.2.1 Effects of EGTA (2 mM), TMB-8 (30 and 100 pM), TFP
(100 and 200 pM) and W-7 (150 and 300 pM) on mean (±SEM, n=5)
outputs of (a) PGF2oc , (b) PGE2 and (c) 6-KETO-PGF1afrom day 29
guinea-pig placenta cultured for 24 h.
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Figure 3B.3.2.2 Effects of EGTA (2 mM), TMB-8 (30 and 100^ M), TFP
(100 and 200 |iM) and W-7 (150 and 300 (llM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-PGF-^ from day 29
guinea-pig sub-placenta cultured for 24 h.
VfSignificantly lower/higher, P < 0.05, than corresponding
control value.
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0.05, n=5) (Fig. 3B.3.2.2b). W-7 (150 and 300 pM) had no effect on PGE2 output
after 2 h of culture (Fig. 3B.3.2.2b). After 8 h of culture, W-7 (300 pM, but not 150
pM) significantly (P < 0.05, n=5) stimulated PGE2 output, and after 24 h of culture
W-7 (150 and 300 pM) increased PGE2 output significantly (P < 0.05, n=5) (Fig.
3B.3.2.2b).
6-Keto-PGFla output was unaffected by EGTA (2 mM) and TMB-8 (30 and 100 pM)
after 2 h of culture (Fig. 3B.3.2.2c). EGTA (2 mM) and TMB-8 (30 and 100 pM)
reduced 6-keto-PGFia output significantly (P < 0.05, n=5) after 8 h and 24 h of
culture (Fig. 3B.3.2.2c). TFP (100 and 200 pM) had no effect on 6-keto-PGF1(X
output throughout the culture period, except TFP (200 pM) which significantly (P <
0.05, n=5) increased 6-keto-PGFia output after 24 h in culture (Fig. 3B.3.2.2c). W-7
(150 and 300 pM) had no significant effect on 6-keto-PGFIa output from the guinea-
pig sub-placenta throughout the 24 h culture period (Fig. 3B.3.2.2c).
Experiment 3B.3.3 The Effects of Calcium Channel Blockers (Nifedipine and
Verapamil) on Prostaglandin Output from Day 29 Guinea-Pig Placenta and
Sub-Placenta in Culture.
Placenta
Nifedipine (10 and 100 pM, but not 1 pM) significantly (P < 0.05, n=5) reduced
PGF2o( output after 2 h of culture (Fig. 3B.3.3.1a). Nifedipine (1, 10 and 100 pM)
significantly (P < 0.05, n=5) inhibited PGF2a output after 8 and 24 h of culture (Fig.
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3B.3.3.1a). Verapamil (1, 10 and 100 pM) had no significant effect on PGF2a output
from the guinea-pig placenta after 2 h of culture (Fig. 3B.3.3.1a). Verapamil (1 pM,
but not 10 and 100 pM) significantly (P < 0.05, n=5) reduced PGF2tx output from the
placenta after 8 and 24 h of culture, while verapamil (100 pM, but not 1 and 10 pM)
increased output significantly (P < 0.05, n=5) after 24 h but had no significant effect
after 8 h of culture (Fig. 3B.3.3.1a).
Nifedipine (1, 10 and 100 pM) had no significant effect on PGE2 output from the
guinea-pig placenta after 2 h of culture (Fig. 3B.3.3.1b). PGE2 output was reduced
significantly (P < 0.05, n=5) by nifedipine (10 and 100 pM, but not 1 pM) after 8 h
of culture, and by nifedipine (1, 10 and 100 pM) after 24 h of culture (Fig.
3B.3.3. lb). Verapamil (1, 10 and 100 pM) had no significant effect on PGE2 output
after 2 and 8 h of culture, except 1 pM verapamil which significantly (P < 0.05, n=5)
inhibited PGE2 output after 2 h (Fig. 3B.3.3.1b). PGE2 output was significantly (P <
0.05, n=5) inhibited by verapamil (1 pM, but not 10 and 100 pM), and significantly
(P < 0.05, n=5) increased by verapamil (100 pM, but not 1 and 10 pM) after 24 h of
culture (Fig. 3B.3.3.1b).
Nifedipine (1,10 and 100 pM) had no significant effect on 6-keto-PGF)a output after
2 h and 8 h of culture (Fig. 3B.3.3.1c). 6-Keto-PGF]a output was significantly (P <
0.05, n=5) inhibited by nifedipine (1 and 10 pM, but not 100 pM) after 24 h of
culture (Fig. 3B.3.3.1c). 6-Keto-PGFla output from the placenta was unaffected by
verapamil (1,10 and 100 pM) throughout the 24 h culture period, except after 24 h,




PGF2a output from the guinea-pig sub-placenta was unaffected by nifedipine (1, 10
and 100 pM) after 2 and 24 h of culture (Fig. 3B.3.3.2a). PGF2(X output was
significantly (P < 0.05, n=5) reduced by nifedipine (1 and 100 pM, but not 10 pM)
after 8 h of culture (Fig. 3B.3.3.2a). PGF2a output was unaffected by verapamil (1,
10 and 100 pM) throughout the culture period, except for 100 pM verapamil which
significantly (P < 0.05, n=5) increased PGF2a output after 24 h of culture (Fig.
3B.3.3.2a).
Nifedipine (1, 10 and 100 pM) had no effect on PGE2 output after 2 h of culture (Fig.
3B.3.3.2b). PGE2 output was reduced significantly (P < 0.05, n=5) after 8 h and 24 h
of culture by nifedipine (1 and 10 pM, but not 100 pM) (Fig. 3B.3.3.2b). Verapmail
(1 pM, but not 10 and 100 pM) significantly (P < 0.05, n=5) reduced PGE2 output
after 2 h of culture (Fig. 3B.3.3.2b). After 8 and 24 h of culture, verapamil (10 pM,
but not 1 and 100 pM) significantly (P < 0.05, n=5) inhibited PGE2 output (Fig.
3B.3.3.2b). After 24 h of culture, PGE2 output was increased significantly (P < 0.05,
n=5) by verapamil (100 pM, but not 1 and 10 pM) (Fig. 3B.3.3.2a).
6-Keto-PGFla output was unaffected by nifedipine (1, 10 and 100 pM) after 2 h of
culture (Fig. 3B.3.3.2c). Nifedipine (10 and 100 pM, but not 1 pM) significantly (P <
0.05, n=5) inhibited 6-keto-PGFia output after 8 h of culture, and nifedipine (1 and
10 pM, but not 100 pM) significantly (P < 0.05, n=5) inhibited 6-keto-PGFla output
after 24 h (Fig. 3B.3.3.2c). 6-Keto-PGFla output was unaffected by verapamil (1, 10
and 100 pM) after 2 h and 24 h of culture (Fig. 3B.3.3.2c). Verapamil (10 pM, but
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Figure 3B.3.3.1 Effects of nifedipine (1,10 and 100 pM), verapamil
(1,10 and 100 pM) on mean (± SEM, n=5) outputs of (a) PGF2a,
(b) PGE2 and (c) 6-KETO-PGF-)a from day 29 guinea-pig placenta
cultured for 24 h.
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Figure 3B.3.3.2 Effects of nifedipine (1, 10 and 100 pM), verapamil
(1,10 and 100 pM) on mean (± SEM, n=5) outputs of (a) PGF2a,
(b) PGE2 and (c) 6-KETO-PGF1a from day 29 guinea-pig
sub-placenta cultured for 24 h.
VtSignificantly lower/higher, P < 0.05, than corresponding control
value.
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h of culture (Fig. 3B.3.3.2c).
Experiment 3B.3.4 The Effect of a Stimulator of Protein Kinase C (TPA) on
Prostaglandin Output from Day 29 Guinea-Pig Placenta and Sub-Placenta in
Culture.
Placenta
TPA (1.5, 8 and 40 nM) had no effect on PGF2(X output after 2 h of culture (Fig.
3B.3.4.1a). TPA (1.5 nM, but not 8 and 40 nM) significantly (P < 0.05, n=5) reduced
PGF2a output from the guinea-pig placenta after 8 h of culture (Fig. 3B.3.4. la). After
24 h of culture, TPA (1.5 and 40 nM, but not 8 nM) significantly (P < 0.05, n=5)
reduced PGF2a output (Fig. 3B.3.4. la).
PGE2 output was inhibited significantly (P < 0.05, n=5) by TPA (1.5 nM) throughout
the 24 h culture period (Fig. 3B.3.4. lb). TPA (40 nM, but not 8 nM) significantly (P
< 0.05, n=5) inhibited PGE2 output after 24 h of culture, but not after 2 and 8 h (Fig.
3B.3.4. lb).
TPA (1.5, 8 and 40 nM) had no significant effect on 6-keto-PGFla output from the
guinea-pig placenta after 2 h of culture (Fig. 3B.3.4. lc). After 8 and 24 h of culture,
TPA (1.5 nM) significantly (P < 0.05, n=5) inhibited 6-keto-PGF1(X output (Fig.
3B.3.4. lc). TPA (40 nM, but not 8 nM) significantly (P < 0.05, n=5) inhibited 6-
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Figure 3B.3.4.1 Effect of TPA (1.5, 8 and 40 nM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-F-|a from day 29
guinea-pig placenta cultured for 24 h.
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Figure 3B.3.4.2 Effect of TPA (1.5, 8 and 40 nM) on mean (±SEM, n=5)
outputs of (a) PGF2a, (b) PGE2 and (c) 6-KETO-F1a from day 29
guinea-pig sub-placenta cultured for 24 h.
'Significantly lower, P < 0.05, than corresponding control value.
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Sub-Placenta
TPA (1.5, 8 and 40 nM) had no effect on PGF2(X output from the guinea-pig sub-
placenta throughout the 24 h culture period (Fig. 3B.3.4.2a).
PGE2 output was significantly (P < 0.05, n=5) reduced after 2 h of culture by TPA
(40 nM, but not 1.5 and 8 nM), and after 8 h of culture by TPA (1.5 nM, but not 8
and 40 nM) (Fig. 3B.3.4.2b). After 24 h of culture, PGE2 output was significantly (P
< 0.05, n=5) inhibited by TPA (1.5, 8 and 40 nM) (Fig. 3B.3.4.2b).
6-Keto-PGF]a output was unaffected by TPA (1.5, 8 and 40 nM) after 2 h of culture
(Fig. 3B.3.4.2c). 6-Keto-PGFla output was significantly (P < 0.05, n=5) reduced by
TPA (1.5 nM, but not 8 and 40 nM) after 8 and 24 h of culture (Fig. 3B.3 .4.2c).
Experiment 3B.3.5 The Effects of EGTA, TMB-8, Nifedipine and Verapamil on
Prostaglandin Production by Day 29 Guinea-Pig Placental Homgenates.
PGF2ci production by placental homogenates was unaffected by treatment with
EGTA (2 mM), TMB-8 (30 and 100 pM), nifedipine (10 and 100 pM) or verapamil
(10 and 100 pM) (Fig. 3B.3.5.1a). PGE2 production was significantly (P < 0.05, n=5)
inhibited in the presence of EGTA (2 mM) or TMB-8 (30 pM), but treatment with
TMB-8 (100 pM), nifedipine (10 and 100 pM) or verapamil (10 and 100 pM) had no
significant effect (Fig. 3B.3.5.1b). 6-Keto-PGF]a production by placental
homogenates was unaffected by treatment with EGTA (2 mM), TMB-8 (30 and 100































Figure 3B.3.5.1 Mean (±SEM, n=5) (a) PGF2w, (b) PGE2 and (c) 6-KETO-PGF1f
production by guinea-pig placental homogenates in the presence of EGTA
(2 mM), TMB-8 (30 and 100 pM), nifedipine (10 and 100 pM) or verapamil
(10 and 100 pM).
*Significantly lower, P < 0.05, than corresponding control value.
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Discussion:
The absence of calcium from tissue culture medium had no effect on basal outputs of
PGF2a and PGE2 from day 29 guinea-pig placenta, cultured for 24 h. However, 6-
keto-PGFla output was inhibited throughout the 24 h culture period, in the presence
of calcium-depleted medium. This suggests that 6-keto-PGFia synthesis by the
guinea-pig placenta is dependent on extracellular calcium, while PGF2(X and PGE2
outputs are not. Calcium-depleted Krebs solution has previously been observed to
inhibit 6-keto-PGF)(X output from superfused guinea-pig uterus, while having no
affect on PGF2a and PGE2 outputs (Poyser, 1984). In contrast, calcium-depleted
medium significantly reduced PGF2a, PGE2 and 6-keto-PGFlc( outputs from day 29
guinea-pig sub-placenta, particularly PGE2 output, suggesting that the synthesis of
these three PGs by this tissue is dependent on extracellular calcium. Although
extracellular calcium appears to be necessary for 6-keto-PGFla production by the day
29 guinea-pig placenta and for PGF2a, PGE2 and 6-keto-PGFia production by the
guinea-pig sub-placenta, it may only be required to replenish intracellular calcium
stores.
Calcium may stimulate PLA2 to release arachidonic acid from phospholipids in the
placenta. The free arachidonic acid may then be available for PG synthesis. There
are several different PLA2 enzymes, some which rely on calcium and some which do
not. The presence of a diverse family of PLA2 enzymes provides multiple
differentially regulated pathways for the important process of fatty acid turnover
(Leslie, 1997).
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There was very little change in PGF2a, PGE2 or 6-keto-PGFla outputs from day 29
guinea-pig placenta and sub-placenta after 2 h of culture, in the presence of EGTA,
TMB-8, TFP, W-7, nifedipine, verapamil or TPA. This suggests that the treatments
used had no immediate effect on PG production and required a longer period of time
to exert their effects. EGTA inhibited PGF2a and 6-keto-PGFia outputs from the day
29 placenta but had no effect on PGE2 output. TMB-8 (30 pM), an intracellular
calcium antagonist, inhibited PGE2 output from day 29 placenta and also inhibited
PGF2a and 6-keto-PGFla outputs, but to a lesser extent. This suggests that
intracellular calcium is necessary for PGF2a, PGE2 and 6-keto-PGFia production by
the day 29 guinea-pig placenta. However, PGF2ct output from the placenta was
significantly increased by TMB-8 (100 pM), which had no effect on PGE2 and 6-
keto-PGFla outputs. Therefore, these results suggest that TMB-8 has opposing
actions on PG production by the guinea-pig placenta following 24 h of culture.
Poyser (1985b) observed TMB-8 to have a similar stimulatory effect on PG output
from the superfused guinea-pig uterus. The opposing actions of TMB-8 on PG
production by the guinea-pig placenta, particularly at the higher concentration of 100
pM, could explain why this treatment had no inhibitory effect on PGE2 and 6-keto-
PGFla output from the day 29 placenta, while at a lower concentration of 30 pM,
TMB-8 significantly inhibited PGE2 and 6-keto-PGFla outputs. These results indicate
that PG production by the day 29 guinea-pig placenta is dependent on intracellular
calcium. 6-Keto-PGFla output from the guinea-pig placenta also requires
extracellular calcium for its synthesis. The intracellular calcium stores may be
replenished by influx of calcium from the extracellular compartment.
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EGTA had no significant effect on PG output from day 29 guinea-pig sub-placenta.
TMB-8 (30 pM) inhibited PGF2a, PGE2 and 6-keto-PGFlct outputs from the sub-
placenta which suggests that intracellular calcium is required for their synthesis. At a
higher concentration of 100 pM, TMB-8 also inhibited PGF2ot and 6-keto-
PGF1(X outputs from the sub-placenta but had no significant effect on PGE2 output.
TMB-8 had no stimulatory effect on PG output from the sub-placenta. However, the
opposing actions of TMB-8 on PG production by the guinea-pig placenta may also
occur in the sub-placenta and account for the lack of effect of TMB-8 on PGE2
output. Intracellular calcium appears to be necessary for PG production by the day 29
guinea-pig sub-placenta. Therefore, PG production by the guinea-pig sub-placenta
appears to be dependent on both extracellular and intracellular calcium.
TFP a calmodulin antagonist, had no effect on PGF2a or PGE2 output from the day 29
guinea-pig placenta, except TFP (200 pM), which significantly stimulated PGF2ct
output. TFP has been observed to have opposing actions on PG output from the
superfused guinea-pig uterus, and the guinea-pig endometrium maintained in culture
(Poyser, 1985a; Riley & Poyser, 1987b). TFP has also been observed to stimulate
arachidonic acid release from phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) in guinea-pig macrophages (Takenawa et ai, 1982).
The opposing actions of TFP may account for the stimulation of PG synthesis
observed from the guinea-pig placenta. W-7, another calmodulin antagonist, had no
significant effect on PGE2 output from the day 29 placenta, while PGF2ot output from
the day 29 guinea-pig placenta was increased significantly in the presence of W-7.
Riley & Poyser (1987b) also demonstrated that W-7 has opposing actions on PG
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outputs from the cultured guinea-pig endometrium. TFP (100 pM) significantly
reduced 6-keto-PGFla output, while at a higher concentration of 200 pM, TFP had
no effect on 6-keto-PGF,a output from the guinea-pig placenta. The opposing actions
of TFP could explain why 6-keto-PGFla output from the guinea-pig placenta was
significantly inhibited in the presence of TFP (100 pM), while TFP (200 pM) had no
effect. 6-Keto-PGFla output was also significantly inhibited in the presence ofW-7.
These results suggest that 6-keto-PGFla production by the day 29 guinea-pig placenta
may be dependent on calmodulin. Flowever, PGF2a and PGE2 outputs were not
inhibited by the presence of either of the calmodulin antagonists used, and so it is
unlikely that calmodulin is necessary for their production. TFP and W-7 had
opposing actions on PGF2a output from the day 29 placenta and it remains unclear
whether the treatments used had any inhibitory effect.
TFP had no inhibitory effect on PGF2ct, PGE2 and 6-keto-PGFia outputs from the day
29 guinea-pig sub-placenta after 24 h of culture. However, PGF2ct, PGE2 and 6-keto-
PGFla outputs were significantly stimulated by TFP, particularly at the 200 pM
concentration, and after 24 h of culture. W-7 had no effect on 6-keto-PGFla output
but significantly increased the outputs of PGF2(X and PGE2 from the guinea-pig sub-
placenta. TFP and W-7 had no inhibitory effect on any of the PGs measured which
suggests that calmodulin is not a requirement for PGF2a, PGE2 and 6-keto-PGF1(X
production by the day 29 sub-placenta.
Nifedipine significantly inhibited all PG outputs measured from day 29 guinea-pig
placenta to some extent, particularly PGF2a output. Verapamil (1 pM) inhibited
PGF2a and PGE2 outputs but had no effect on 6-keto-PGFla output. Low
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concentrations of nifedipine and verapamil are normally sufficient to block voltage-
dependent calcium channels. These results suggest that the guinea-pig placenta does
rely on voltage-dependent calcium channels to transport extracellular calcium to the
inside of cells, even though previous experiments have shown that PGF2ct and PGE2
production by the guinea-pig placenta is not dependent on extracellular calcium. At a
concentration of 100 pM, verapamil significantly increased PGF2ct, PGE2 and 6-keto-
PGFla outputs, after 24 h of culture. Verapamil has opposing actions on PG
production by the guinea-pig endometrium after 3 days of culture (Riley & Poyser,
1987b), and this also appears to be true of PG production by the guinea-pig placenta
after 24 h of culture. Verapamil was observed to inhibit PG output from the placenta
at a low concentration, while stimulating PG output at higher concentrations. The
opposing actions of verapamil could account for the lack of inhibitory effect,
especially at 10 pM. Riley & Poyser (1987b) demonstrated that nifedipine and
verapamil inhibited PG output from the guinea-pig uterus and observed that these
treatments may have intracellular actions on PG production by the guinea-pig uterus.
This may be the case here. This could explain why extracellular calcium was not
required for PGE2 and 6-keto-PGFia synthesis by the placenta, while nifedipine and
verapamil inhibited their outputs from the guinea-pig placenta.
Nifedipine reduced PGF2a, PGE2 and 6-keto-PGFla outputs from day 29 sub-
placenta. Verapamil had no inhibitory effect on PGF2(X ouput, while at a
concentration of 10 pM, verapamil reduced PGE2 and 6-keto-PGFla outputs from the
day 29 sub-placenta. These results suggest that extracellular calcium required for the
activation of PLA2, and hence PG synthesis does enter the guinea-pig sub-placenta
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via voltage-dependent calcium channels. Verapamil has previously been observed to
reduce calcium uptake by the ovine placenta by > 70% (Jones et al., 1997). At a
higher concentration of 100 p.M, verapamil significantly increased PGF2(X and PGE2
outputs from the sub-placenta, after 24 h of culture. This effect was also observed in
the day 29 guinea-pig placenta and was attributed to the opposing effects of
verapamil on PG production. The inhibitory effect of nifedipine and verapamil may
also be due to an intracellular action. This has previously been observed in culture
guinea-pig endometrium (Riley & Poyser, 1987b).
PGF2a, PGE2 and 6-keto-PGFIa outputs from the day 29 placenta were inhibited in
the presence of TPA, particularly at the lowest concentration used. TPA had no
effect on PGF2a output from the day 29 guinea-pig sub-placenta but significantly
reduced PGE2 and 6-keto-PGFla outputs. TPA is a stimulator of protein kinase C,
which has previously been observed to activate PLA2s and the mobilisation of
arachidonic acid from membrane phospholipids in many tissues. However, the
inhibitory action of TPA on PG output from the guinea-pig placenta and sub-placenta
does not indicate activation by PKC. Therefore, it is unlikely that PKC is necessary
for PG production by the guinea-pig placenta and sub-placenta. The inhibitory effect
of TPA on PG output from the guinea-pig placenta and sub-placenta indicates that
either PKC inhibits PG synthesis by these tissues or that TPA has an inhibitory action
independent ofPKC.
Since PGHS is destroyed during the synthesis of PGs (Lands, 1979), the total amount
of PGs synthesised by tissue homogenates is indicative of the amount ofPGHS in the
tissue. The presence of EGTA, TMB-8, nifedipine or verapamil had no significant
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effect on PGF2a or 6-keto-PGFla production by homogenates of the guinea-pig
placenta after 1 h incubation. PGE2 production was reduced significantly in the
presence of EGTA and TMB-8 (30 pM). These results suggest that PGHS activity
was unaffected by the presence of EGTA, TMB-8, nifedipine and verapamil.
Therefore, the inhibitory and the stimulatory effects on PG output from guinea-pig
placenta and sub-placenta were not due to inhibition or stimulation ofPGHS.
In summary, these results have shown that 6-keto-PGFlct production by the day 29
guinea-pig placenta is dependent on extracellular as well as intracellular calcium and
calmodulin may also be necessary for its synthesis. PGF2ct and PGE2 production by
the day 29 guinea-pig placenta appears to be dependent on intracellular calcium, but
does not appear to require calmodulin. PG output from the placenta also appears to
be dependent on calcium entry via voltage-dependent calcium channels. The calcium
may stimulate PLA2 to release arachidonic acid from phospholipids in the placenta.
However, previous experiments have shown that extracellular calcium was not
necessary for PGE2 and 6-keto-PGFia production by the placenta. Therefore, it is
possible that nifedipine and verapamil may be having intracellular effects on PG
production by the guinea-pig placenta. It has previously been observed that
nifedipine and verapamil have similar effects on PG production by the guinea-pig
endometrium (Riley & Poyser, 1987b). The activation of PKC appears not to be a
requirement for PGF2ct, PGE2 or 6-keto-PGFla synthesis by the placenta.
PG production by the day 29 guinea-pig sub-placenta appears to require extracellular
and intracellular calcium, probably for the activation of PLA2 and the mobilisation of
arachidonic acid from membrane phospholipids. Calcium influx may be via voltage-
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dependent calcium channels. PLA2 does not appear to be calmodulin-dependent in
the guinea-pig sub-placenta as the calmodulin antagonists used had no inhibitory
effect. TPA, a PKC activator, was ineffective at stimulating PG output from the
guinea-pig sub-placenta, indicating that PKC is not required for PGF2a, PGE2 or 6-
keto-PGFla synthesis.
PG production by the guinea-pig placenta and sub-placenta appears to be dependent
on extracellular and/or intracellular calcium. Secretory and cytosolic PLA2 enzymes
can be dependent on calcium for their activation. Mitogen-activated protein kinase
(MAPK) may also be involved in PLA2 activation particularly cytosolic PLA2, and
this may or may not require PKC for its activation (Lin et al., 1992; Qiu et al., 1993;
de Carvahlo et al., 1996). If such a cytosolic PLA2 is involved in PG production by
guinea-pig placenta and sub-placenta, it appears to be PKC-independent. Not all
PLA2 enzymes have substrate preference for arachidonic acid but many of them have
been observed to release arachidonic acid from membrane phospholipids. Several
PLA2 enzymes have been identified in the human placenta including cytosolic PLA2
(cPLA2), type II secretory PLA2 (type II sPLA2) and type IV sPLA2 (Freed et al.,
1997; Rice et al., 1994; Buhl et al., 1995). Which PLA2 enzymes are present in the
guinea-pig placenta and sub-placenta and which of these are responsible for PG
2~b
synthesis and which are Ca -dependent require further investigation.
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3B.4 THE ROLE OF GnRH IN PROSTAGLANDIN PRODUCTION BY THE
GUINEA-PIG PLACENTA.
Introduction:
Fetal pituitary hormones, particularly gonadotrophins regulate steroid and PG
synthesis by the placenta (Thorburn el al., 1989). It has been speculated that
gonadotropin releasing hormone (GnRH) or luteinising hormone releasing hormone
(LHRH) may have a role in the maintenance of pregnancy (Kang et al., 1991).
Abnormally low levels of circulating immunoreactive GnRH were observed to be
associated with preterm labour and high levels of immunoreactive GnRH were
observed in patients who later had post-term pregnancies (Siler-Khodr et al., 1984,
1991). Previous workers have observed that GnRH stimulated PGF2a production by
human placental homogenates (Hanig et al., 1982). The effects of GnRH on mid-
pregnant day 29 guinea-pig placenta and sub-placenta have therefore been
investigated.
Methods:
The guinea-pig placentae were removed on day 29 of pregnancy as described in
Section 2.1.4. The placenta and sub-placenta were separated manually and cut into
small pieces. The tissue was cultured separately on raised platforms in Petri dishes
containing TCM plus gonadotrophin releasing hormone (GnRH) (see Section 2.1.2).
Kilner jars contained 8 Petri dishes (i.e. 2 controls and 6 treated). The placenta and
sub-placenta were treated with GnRH (100 pM, 1 nM, 10 nM, 100 nM or 1 pM).
Samples were collected after 2, 8 and 24 h and stored at -20°C before being assayed
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for PGs. Statistical analyses were carried out using a one-way analysis of variance
(ANOVA) and the paired t-test.
Results:
Experiment 3B.4.1 The Effect of GnRH on Prostaglandin Output from Day 29
Guinea-Pig Placenta and Sub-Placenta in Culture.
Placenta
PGF2a output from the guinea-pig placenta was unaffected by GnRH (100 pM, 1, 10
and 100 nM and 1 pM) after 2 and 8 h of culture (Fig. 3B.4.1a). PGF2a output was
significantly (P < 0.05, n=5) decreased by GnRH (100 pM and 1 nM, but not by 10
and 100 nm or 1 pM) after 24 h of culture (Fig. 3B.4. la). GnRH (100 pM, 1, 10 and
100 nM and 1 pM) had no effect on PGE2 output, except GnRH (10 nM) which
reduced PGE2 output signifcantly (P < 0.05, n=5) after 2 and 8 h of culture (Fig.
3B.4. lb). 6-Keto-PGFla output was reduced significantly (P < 0.05, n=5) after 2 h of
culture by GnRH (100 pM, 100 nM and 1 pM, but not by 1 and 10 nM) (Fig.
3B.4.1c). GnRH (100 pM, 1, 10 and 100 nM and 1 pM) had no effect on 6-keto-
PGFia output after 8 and 24 h of culture, except GnRH (10 nM) which significantly

















0 - __m mmLCl
.T
t
0-2 h 2-8 h 8-24 h
Culture period
Figure 3B.4.1 Effect of GnRH (100 pM, 1 nM, 10 nM, 100 nM and
1 pM) on mean (± SEM, n=5) outputs of (a) PG^a- (b) PGE2 and
(c) 6-KETO-PGF1afrom day 29 guinea-pig placenta cultured
for 24 h.
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Figure 3B.4.2 Effect of GnRH (100 pM, 1 nM, 10 nM, 100 nM and
1 pM) on mean (± SEM, n=5) outputs of (a) PGF2a, (b) PGE2 and
(c) 6-KETO-PGF1rv from day 29 guinea-pig sub-placenta cultured
for 24 h.
VfSignificantly lower/higher, P < 0.05, than corresponding control value.
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Sub-Placenta
PGF2a output was significantly (P < 0.05, n=5) inhibited by GnRH (100 pM, 100 nM
and 1 pM, but not 1 and 10 nM) after 2 h of culture (Fig. 3B.4.2a). GnRH (100 pM
and 10 nM, but not 1 and 100 nM and 1 pM) significantly (P < 0.05, n=5) increased
PGF2a output from the guinea-pig sub-placenta after 8 h in culture (Fig. 3B.4.2a).
After 24 h of culture, GnRH (100 pM, 1 nM, 10 nM and 1 pM, but not 100 nM)
increased PGF2a output significantly (P < 0.05, n=5) (Fig. 3B.4.2a). PGE2 output was
unaffected in the presence of GnRH (100 pM, 1, 10 and 100 nM and 1 pM)
throughout the 24 h culture period, except 10 nM GnRH which significantly (P <
0.05, n=5) increased PGE2 output after 8 h of culture, and by 100 pM GnRH which
increased PGE2 output significantly (P < 0.05, n=5) after 24 h (Fig. 3B.4.2b). 6-Keto-
PGF]a output was unaffected by GnRH (100 pM, 1, 10 and 100 nM and 1 pM)
treatment throughout the 24 h culture period, except by 100 nM GnRH which
significantly (P < 0.05, n=5) reduced 6-keto-PGFIa output after 2 h of culture (Fig.
3B.4.2c).
Discussion:
GnRH had no significant effect on PGF2ct output from day 29 guinea-pig placenta
after 2 and 8 h of culture. However, after 24 h of culture, PGF2ct output was inhibited
by the lower concentrations of GnRH used. Kang et al. (1991) observed that
treatment of the human placenta with GnRH significantly reduced PGF and PGE
outputs from the human placenta, particularly by the lower, more physiological
levels of GnRH. Previous studies by the same group demonstrated that GnRH could
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stimulate as well as inhibit PG output from the human placenta (Siler-Khodr et al.,
1986a, b). The effect ofGnRH on the guinea-pig sub-placenta was more pronounced
that that of the guinea-pig placenta. GnRH was observed to decrease PGF2a output
after 2 h of culture, while stimulating PGF2a output from the sub-placenta after 8 h,
and particularly after 24 h of culture. PGF2a output from the human placenta has also
been observed to increase in the presence of GnRH (Hanig et al., 1982). The
stimulation of PGF2ot output from the sub-placenta in the presence of GnRH may be
due to an increase in PGHS synthesis as suggested by Thorburn (1991).
PGE2 output from the placenta and the sub-placenta was largely unaffected by the
presence of GnRH. GnRH had some inhibitory effect on PGE2 output from the
placenta and some stimulatory effect on PGE2 output from the sub-placenta.
Therefore, GnRH had the same effects on PGE2 output from the placenta and the
sub-placenta but to a lesser extent. GnRH significantly inhibited 6-keto-PGF la output
from the guinea-pig placenta after 2 h of culture, but had no inhibitory effects after
this time. Stimulation of 6-keto-PGFla output from the placenta was observed after
24 h of culture in the presence of 10 nM GnRH. 6-Keto-PGFla output from the
guinea-pig sub-placenta was mostly unaffected by the GnRH treatments used.
Bland & Donovan (1969a) postulated that placental hormones may be responsible
for luteal function in the guinea-pig. It has also been suggested that these hormones
may be related to human chorionic gonadotrophin. Davies et al. (1961) concluded
that the guinea-pig sub-placenta was the source of a gonadotrophin responsible for
the maintenance of pregnancy. GnRH may be stimulating the production of this
gonadotrophin by the guinea-pig placenta. Humphreys et al. (1982) observed the
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presence of gonadotrophin in the guinea-pig placenta and sub-placenta from day 10
of pregnancy, which reached a maximum after 3 weeks of gestation. This
gonadotrophin could help reduce the luteolytic effects of PGF2a. Siler-Khodr et al.
(1983, 1986a) observed an increase in PG output from the human placenta in the
presence of GnRH and North et al. (1991) concluded that GnRH may mediate its
effect via hCG. Specific binding sites (receptors) for GnRH have been demonstrated
in the human placenta (Currie et al., 1989) and bioactive GnRH and GnRH mRNA
have also been observed (Gibbons et al., 1975; Kelly et al., 1991). Whether specific
binding sites for GnRH are present in the guinea-pig placenta and sub-placenta





Prostaglandins (PGs) regulate physiological and pathological processes in all body
systems including the reproductive tract. Therefore, the uterus and the placenta have
been extensively studied in this thesis with respect to factors controlling PG
production. In the studies presented in this thesis, Adenosine, ATP and its analogues
stimulated PG production (particularly PGF2a) from day 7 superfused guinea-pig
uterus and from day 7 endometrium and myometrium cultured for 24 h. This was
more pronounced in the endometrium which is the main site of prostanoid synthesis
in the guinea-pig uterus (Poyser, 1983). Scheimann et al. (1991) and Suzuki (1991)
both observed increased PGF2(X and 6-keto-PGF]a outputs from the guinea-pig and
the rabbit uterus respectively, following treatments with adenosine (A) and P2
receptor agonists. This increase in PGF2a output could be responsible for stimulating
uterine contraction in the guinea-pig uterus as suggested by Smith et al. (1988) and
Piper & Hollingsworth (1996). Piper & Hollingsworth (1996) proposed that PGs
produced by the endometrium are involved in ATP-induced contractions of the non¬
pregnant guinea-pig uterus after demonstrating that indomethacin, a non-selective
PGHS inhibitor, and removal of the endometrium inhibited ATP-induced contraction
of the guinea-pig uterus. Suramin, a non-selective P2 receptor antagonist,
significantly inhibited the ATP-induced increase in PGF2a output from the
superfused guinea-pig uterus (see Section 3A.3). This effect of suramin on ATP-
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stimulated PGF2ct production suggests that ATP exerts its effect via P2 receptors. A
and P2 receptors have previously been observed in the guinea-pig uterus (Smith et.
al., 1988). However, as well as acting on P2 receptors, ATP may indirectly be
stimulating adenosine receptors after being broken down to adenosine by ecto-
nucleotidases, especially after 24 h of culture (see Section 3A.4). However, the non¬
selective A receptor antagonist, 8-sulphophenyltheophylline, had no effect on ATP-
induced PGF2a output from guinea-pig uterus (see Section 3A.3 and 3A.4),
suggesting that ATP was probably exerting its action predominantly by activating P2
receptors.
Previous workers have disagreed over the involvement of PGs in spasm of the
guinea-pig uterus mediated by A receptors (Scheimann et ai., 1991; Bradley et al.,
1993). Bradley et al. (1993) proposed that cyclooxygenase products were not
involved in adenosine-induced contractions of the non-pregnant guinea-pig uterus,
while Scheimann et al. (1991) concluded that activation of A receptors in the non¬
pregnant guinea-pig uterus leads to stimulation of a cyclooxygenase product,
resulting in contraction of uterine smooth muscle. The present study indicates that
PGs may be involved in adenosine-induced spasm of the guinea-pig uterus.
Adenosine was observed to stimulate PGF2a output from the guinea-pig uterus
superfused in vitro (see Section 3A. 1), and this stimulation by adenosine was
inhibited by the A receptor antagonist, 8-sulphophenyltheophylline. Therefore, it is
clear that ATP- and adenosine-induced increases in PGF2a output from the
superfused guinea-pig uterus are receptor mediated responses as the actions of ATP
and adenosine were significantly reduced by the P2 and A receptor antagonists,
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suramin and 8-sulphophenyltheophylline, respectively (see Section 3A.3). P2Y
purinoceptors have previously been observed in the guinea-pig uterus and, more
specifically, in the endometrium (Piper & Hoi lingsworth, 1996). P2Y receptors are G
protein-linked receptors (Webb et al., 1993). They have been observed to couple via
G proteins to phospholipase A2 (PLA2) (see Axelrod et al., 1988) and phospholipase
C (PLC) in a number of tissues (see Piper & Hollingsworth, 1996). PLA2 is well
documented as the enzyme responsible for arachidonic acid release from membrane
phospholipids, and it is possibly responsible for increased PG synthesis from the
superfused guinea-pig uterus stimulated by adenosine, ATP and ATP analogues.
However, activation ofPLC can also lead to the mobilisation of free arachidonic acid
from inositol phospholipids (IP). Diacylglycerol (DAG) is one of the breakdown
products of IP hydrolysis by PLC. Arachidonic acid can be released from DAG by
the sequential action of diacylglycerol lipase and monoacylglycerol lipase. Previous
workers have suggested that adenosine- and ATP-induced stimulation of PG
synthesis could be linked to IP hydrolysis in the guinea-pig and the rabbit uterus
(Scheimann et al., 1991; Suzuki, 1991). ATP has been observed to stimulate DAG
formation in the rabbit uterus, indicative of PLC activation (Suzuki, 1991), and
stimulation of adenosine receptors leads to rapid accumulation of inositol phosphates
in the guinea-pig uterus (Scheimann et al., 1991). Thus, it is also possible that
adenosine, ATP and ATP analogues stimulate PGF2ot output from the guinea-pig
uterus by the actions ofPLC, diaglyceride lipase and monoglyceride lipase.
Diacylglycerol (DAG) can also activate protein kinase C (PKC), a second messenger
system that has been implicated in stimulation of PGHS expression (DeWitt, 1991).
PKC stimulates a kinase cascade leading to mitogen-activated protein kinase
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(MAPK) activation (Qiu & Leslie, 1994). MAPK activates transcription factors
(Karin & Hunter, 1995), and in particular NF-kB which leads to the induction of
expression of many immediate early genes (Baeuerle, 1991). NF-kB has been
observed to increase PGHS-2 synthesis in lipopolysaccharide (LPS)-stimulated
macrophages (Flwang et al., 1997). Previous studies have shown the presence of
PGHS-2 in the guinea-pig endometrium by Western blotting (Naderali & Poyser,
1994). It was demonstrated that PGHS-2 is the main functional form of PGHS in the
guinea-pig endometrium and myometrium (Naderali & Poyser, 1996a). Thus, the
increase in PG synthesis by the guinea-pig endometrium observed after 24 h of
culture may be due to adenosine, ATP and ATP analogues increasing the synthesis of
PGHS-2 by processes involving the activation ofPKC, MAPK and NF-kB.
MAPK also activates cPLA2 (Lin et al., 1993) which, in turn, results in increased PG
synthesis. Inositol 1,4,5-triphosphate (IP3) is a specific breakdown product of PLC-
mediated phosphatidyl-4,5-biphosphate (PIP2) hydrolysis and is a unique second
messenger that releases calcium from the endoplasmic reticulum of several cell
types, including the sarcoplasmic reticulum of smooth muscle cells (Schrey et al.,
1988). Scheimann et al. (1991) suggest that IP3 is capable of releasing calcium from
the guinea-pig uterine intracellular stores. Increased calcium concentration can
activate PLA2 enzymes, which stimulate arachidonic acid mobilisation and increased
PG synthesis. Therefore, adenosine, ATP and ATP analogues may initiate
arachidonic acid release via IP3-induced IP3 calcium release, with the calcium
activating cPLA2. Overall, there are a number of possible mechanisms for
arachidonic acid release and stimulation of PG synthesis in the guinea-pig uterus by
ATP, ATP analogues and adenosine.
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In order to further elucidate the mechanisms of actions of ATP, ATP analogues and
adenosine on PG production by the non-pregnant guinea-pig uterus, it is necessary to
examine the effect of the A and P2 antagonists, 8-sulphophenyltheophylline and
suramin, on PG production by cultured endometrium and myometrium. This will
determine whether these compounds have any significant effect on PG outputs from
the guinea-pig uterus on their own. The use of a PLA2 antagonist would be useful to
determine whether ATP and adenosine-induced increases in PGF2a output from the
superfused guinea-pig uterus are caused by activation of PLA2. Further studies are
required to elucidate which pathways are actually involved in PG synthesis by the
guinea-pig uterus in response to adenosine and ATP.
It is well documented that PGF2ct is the luteolytic hormone in many species and that
PGF2a output from the guinea-pig uterus increases from day 11 of the oestrous cycle
(see Poyser, 1995). Measurement of the PGF2a metabolite, 5a, 7a-dihydroxy-l 1-
ketotetranor-prostanoic acid, in guinea-pig urine showed that PGF2a production by
the guinea-pig uterus is suppressed during pregnancy during the time luteolysis takes
place if the animal is not pregnant (Granstrom & Kindahl, 1976). However the
concentration of PGF2a metabolite in the guinea-pig urine rapidly increases at
approximately day 25 of gestation, and remains high as pregnancy proceeds.
Removal of the pregnant uterus during pregnancy results in a rapid fall in the urinary
concentration of PGF2ci metabolite (Granstrom & Kindahl, 1976). Therefore, the
pregnant guinea-pig uterus or its contents must be the source of the PGF2a produced
during pregnancy. PGF2ct output from the guinea-pig placenta increased 8-fold
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between days 22 and 29 of pregnancy after 2 h of culture, and remained higher on
day 29 when compared to day 22 throughout the 24 h culture period (see Section
3B. 1.1). PGF2a output from the guinea-pig sub-placenta was also high after 2 h of
culture and was 2-fold higher on day 29 than on day 22 (see Section 3B.1.1).
Previous experiments by Norman & Poyser (1998b) showed that PGF2(X output from
the guinea-pig placenta increases 15-fold between days 22 and 36 of pregnancy.
Norman & Poyser (1998b) speculated that this increase in PGF2ot output may account
for the increase in PGF2a metabolite observed in guinea-pig urine from day 25 of
pregnancy. It has previously been observed that the placenta is a major site of PG
biosynthesis during pregnancy (Keirse, 1979). This study has shown that PGFM
output from the guinea-pig placenta was very high. This high output of PGFM could
mean that the basal PGF2a outputs from day 22 and day 29 guinea-pig placentae have
been underestimated and that perhaps the metabolite levels should have been
measured throughout. When the outputs of PGF2a from day 22 and day 29 are
considered together with the PGFM outputs from day 22 and day 29 placenta, it does
appear that there may be a decrease in metabolism within the first 2 h of culture.
After 2 h of culture, metabolism does appear to increase with increased PGF2(X
production by the day 29 guinea-pig placenta. The metabolism of PGF2a may be an
important mechanism for maintaining pregnancy and may act as a barrier to prevent
primary active PGs getting to the myometrium and causing unwanted contraction of
the mid-pregnant uterus. It has been suggested that the guinea-pig placenta has a
decreased capacity for PG metabolism in late gestation (Moussard et al., 1986).
However, day 29 is considered as mid-pregnancy. The high metabolite levels
observed in guinea-pig urine by Granstrom & Kindahl (1976) suggest that metabolite
levels may increase with PGF2(X production by the guinea-pig placenta. However,
further investigation is required to determine whether metabolism does actually
decrease as pregnancy proceeds.
PGF2a output from both the placenta and sub-placenta was significantly greater than
the outputs of PGE2 and 6-keto-PGFla from the guinea-pig placenta and sub-
placenta. The PG synthesising capacity of guinea-pig placental homogenates
increased between days 22 and 29 of pregnancy, which suggests that the increase in
placental PG output between these two days is due to increased PGHS synthesis.
Schellenberg & Kirby (1997) propose that PGHS is the rate-limiting step for PG
production by the guinea-pig placenta, and previous studies have provided evidence
which suggests that PGHS activity in the placenta gradually increases during
pregnancy (Moussard et al., 1986; Rice et al., 1988, 1989). Up-regulation of PGHS
expression is a common effect ofmany agents that stimulate PG synthesis, including
growth factors, hormones, interleukins and phorbol esters (see DeWitt, 1991).
It has been suggested that PGHS activity plays a key role in the maintenance of
pregnancy in humans (Kelly, 1994). Two PGHS enzymes have been identified,
cloned and sequenced (DeWitt & Smith, 1988; Merlie et al., 1988; Kujubu et al.,
1991; O'Banion et al., 1992). Previous workers have observed PGHS-2 to be the
predominant enzyme involved in PG synthesis by the ovine and the human placenta
(Wimsatt et al., 1993; Freed et al., 1995; Rice et al., 1995; Macchia et al., 1997).
Non-steroidal anti-inflammatory drugs (NSAIDS) inhibit the cyclooxygenase activity
of PGHS enzymes. The effects of indomethacin (a non-selective inhibitor of PGHS)
and NS-398 (a selective inhibitor of PGHS-2) were studied to determine which
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PGHS enzyme was responsible for the increase in PG output from the guinea-pig
placenta and sub-placenta between days 22 and 29 of pregnancy. Indomethacin and
NS-398 were equipotent at inhibiting PGF2a output from the day 22 and day 29
guinea-pig placenta and sub-placenta. This functional study showed that PGHS-2 is
the predominant enzyme responsible for PGF2a synthesis by day 22 and 29 guinea-
pig placenta and sub-placenta. PGHS-2 is not normally present in cells. So PGHS-2
expression may be induced in the placenta as pregnancy proceeds. It appears that
there is a large increase in PGHS-2 expression in guinea-pig placenta between days
22 and 29 of pregnancy. Indomethacin was more effective in inhibiting PGE2 and 6-
keto-PGFla outputs from the guinea-pig placenta and sub-placenta than NS-398. This
suggests that both isoforms of the PGHS enzyme (PGHS-1 and PGHS-2) are
involved in PGE2 and 6-keto-PGFla synthesis by day 22 and day 29 guinea-pig
placenta and sub-placenta. PGHS-1 and PGHS-2 are often co-expressed in the same
cell, and it has been proposed that PGHS-2 may co-localise with PGHS-1 to augment
the function of PGHS-1 or substitute for it if PGHS-1 is lacking (Smith et al., 1996).
PGHS-2 is also associated with cell differentiation and replication (Otto & Smith,
1995), which could be an advantage for the developing fetus and placenta. The
signal transduction mechanism responsible for stimulation of PGHS expression and
increased PG synthesis by the guinea-pig placenta and sub-placenta as pregnancy
proceeds requires further investigation. The availability of specific PGHS-1
inhibitors would help to determine the degree of importance of either PGHS-1 or
PGHS-2 with respect to prostaglandin production by the guinea-pig placenta and sub-
placenta as pregnancy proceeds.
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PGHS is destroyed during PG biosynthesis, therefore fresh enzyme must be provided
if biosynthesis is to be maintained (Lands, 1979). The process of protein synthesis is
necessary for the continued production of PGHS, the enzyme responsible for the
conversion of arachidonic acid to PGs. Protein synthesis inhibitors (cycloheximide,
puromycin and actinomycin D) had an inhibitory effect on the outputs of PGF2a,
PGE2 and 6-keto-PGFla from day 29 guinea-pig placenta and sub-placenta after 24 h
of culture (see Section 3B.2.1). Therefore, PG production by day 29 guinea-pig
placenta and sub-placenta may be dependent on the fresh synthesis of proteins.
Protein synthesis inhibitors have previously been observed to inhibit the output of
PGs, particularly PGF2a, from guinea-pig endometrium on days 7 and 15 of the
oestrous cycle (Riley & Poyser, 1989). In addition the protein synthesis inhibitors
prevented the synthesis of PGHS in the guinea-pig endometrium during culture
(Riley & Poyser, 1989). These results suggest that protein synthesis is necessaiy for
the production ofPGHS enzymes and that protein synthesis may be a requirement for
the production of PGs by day 29 guinea-pig placenta and sub-placenta. The protein
synthesis inhibitors used, particularly cycloheximide, were also observed to stimulate
PG output from the guinea-pig placenta and sub-placenta, especially PGF2a output
(see Section 3B.2.1). This stimulatory effect was most pronounced when higher
concentrations of the protein synthesis inhibitors were used. Riley & Poyser (1989)
have previously observed that protein synthesis inhibitors stimulate PG production
by the superfused guinea-pig uterus, particularly cycloheximide. Naderali & Poyser
(1996b) have also observed that cycloheximide was not as effective in inhibiting PG
output from cultured guinea-pig endometrium as actinomycin D and puromycin
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because it has a short-term stimulatory effect. It has also been shown that expression
of PGHS mRNA can be superinduced by cycloheximide (DeWitt et al., 1990; Maier
et al., 1990). This stimulation of PGHS may account for the observed increase in
PGF2a output from the placenta and sub-placenta after 24 h of culture in the presence
of cycloheximide. The stimulatory effects of cycloheximide, puromycin and
actinomycin D may account for the lack of inhibition observed, particularly
regarding PGE2 output from the guinea-pig placenta. Overall, this study has shown
that protein synthesis is necessary for the continued production of PGs.
Phospholipase (PL) A2 enzymes are usually responsible for arachidonic acid release
from membrane phospholipids, and some of these PLA2 enzymes are dependent on
calcium for their activation. It is well documented that arachidonic acid release for
PG synthesis is triggered in cells by many calcium mobilising agonists (Clark et al.,
1995). Therefore the calcium requirement for PG production by day 29 guinea-pig
placenta and sub-placenta was investigated. Culturing day 29 guinea-pig placenta for
24 h in the presence of calcium-depleted culture medium had no significant effect on
PGF2a and PGE2 outputs. Therefore, PGF2a and PGE2 production by day 29 guinea-
pig placenta does not appear to be dependent on extracellular calcium. 6-Keto-PGFla
output from the guinea-pig placenta was significantly reduced throughout culture in
the presence of calcium-depleted medium. This suggests that 6-keto-PGFla
production by the day 29 guinea-pig placenta is dependent on extracellular calcium.
PGF2oi, PGE2 and 6-keto-PGFla outputs from the guinea-pig sub-placenta were
significantly reduced in the presence of calcium-depleted culture medium,
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suggesting that extracellular calcium is a requirement for their synthesis by the sub-
placenta. However, the extracellular calcium required for 6-keto-PGFla production
by the placenta and PGF2a, PGE2 and 6-keto-PGFla production by the sub-placenta
may only be needed to replenish intracellular calcium stores.
To determine whether intracellular calcium was required for PG production by day
29 guinea-pig placenta and sub-placenta, the effects of TMB-8, an intracellular
calcium antagonist, was investigated. PGF2a, PGE2 and 6-keto-PGFia production by
the guinea-pig placenta and sub-placenta appear to be dependent on intracellular
calcium since TMB-8 inhibited PGF2c(, PGE2 and 6-keto-PGFlcx outputs from the
placenta and the sub-placenta, particularly after 24 h of culture. TMB-8 was
observed to have opposing actions on PGF2a production by the placenta, inhibiting
PGF2a output at a low concentration and stimulating PGF2ct output at a higher
concentration (see Section 3B.3.2). The opposing actions of TMB-8 shown here have
been seen previously by Poyser (1985b), who observed that TMB-8 stimulated PG
output from the superfused guinea-pig uterus. Nevertheless, the findings in the
present study support that PG production by day 29 guinea-pig placenta and sub-
placenta requires extracellular and/or intracellular calcium, probably for the
activation of PLA2 and the consequent mobilisation of arachidonic acid from
membrane phospholipids. This free arachidonic acid may then be available for PG
synthesis. There are several different types of PLA2, some of which are dependent on
calcium for their activation and some ofwhich are not. The presence of this diverse
family of PLA2 enzymes provides multiple differentially regulated pathways for the
important process of fatty acid turnover (Leslie, 1997). To date only four types of
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PLA2 enzyme have been identified in the human placenta; cPLA2, type II sPLA2, type
IV sPLA2 and type V sPLA2 (Seilhamer et al., 1989; Bennett et al., 1993; Chen el al.,
1994; Buhl et al., 1995; Freed et al., 1997; Rice et al., 1998). Type II sPLA2 appears
to be the dominant type in the human placenta (Freed et al., 1997). Which PLA2
enzymes are present in the guinea-pig placenta and sub-placenta requires further
investigation.
Calmodulin is a calcium-binding protein and functions in a variety of cells (Cheung,
1980). In some tissues PLA2 can be a calmodulin-dependent enzyme (Wong &
Cheung, 1979; Maskowitz et al., 1983). Calmodulin antagonists, TFP and W-7, had
no significant inhibitory effect on PGF2a and PGE2 outputs from the guinea-pig
placenta or the sub-placenta (see Section 3B.3.2). Therefore, it is unlikely that PGF2a
and PGE2 production by the guinea-pig placenta requires calmodulin. TFP and W-7
significantly reduced 6-keto-PGF!a output from the placenta in culture. They have no
effect on 6-keto-PGFla output from the sub-placenta. Therefore, 6-keto-PGFla
production by the guinea-pig placenta, but not the sub-placenta, appears to require
calmodulin for its synthesis. The calmodulin antagonists used (TFP and W-7) had
stimulatory effects, as well as some inhibitory effects, on PG production by the
guinea-pig placenta and sub-placenta. TFP and W-7 had similar stimulatory effects
on PG output from the superfused guinea-pig uterus and cultured guinea-pig
endometrium (Poyser, 1985a; Riley & Poyser, 1987b). The mechanisms involved in
this stimulatory action of TFP and W-7 remain unclear.
This thesis has shown that calcium is a requirement for PG production by the guinea-
pig placenta and sub-placenta, whether it is of extracellular and/or intracellular
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origin. Calcium influx may be via voltage-dependent calcium channels. PGF2a, PGE2
and 6-keto-PGFla outputs from the placenta and the sub-placenta appear to be
dependent on calcium entry via voltage-dependent calcium channels as the voltage-
dependent calcium channel blockers, nifedipine and verapamil, reduced PGF2a,
PGE2 and 6-keto-PGFI(X outputs from the placenta and sub-placenta after 24 h of
culture. Nifedipine had a marked effect. These results suggest that calcium of
extracellular origin may enter cells of the guinea-pig placenta and sub-placenta via
voltage-dependent calcium channels. Verapamil has previously been observed to
reduce calcium uptake by the ovine placenta by > 70% (Jones et al., 1997). Once
inside the cell, the calcium may stimulate PLA2 to release arachidonic acid from
membrane phospholipids in the placenta or replenish intracellular calcium stores.
However, nifedipine and verapamil may be acting intracellularly, as removal of
extracellular calcium from tissue culture medium (TCM) had no effect on PGE2 and
6-keto-PGFla outputs from the guinea-pig placenta. Riley & Poyser (1987b) suggest
that calcium channel blockers may be inhibiting PG output from the guinea-pig
uterus by intracellular actions. This could explain why nifedipine and verapamil had
an inhibitory effect on PG output from the guinea-pig placenta and sub-placenta.
Verapamil, at high concentrations, had a stimulatory effect on PG output from the
guinea-pig placenta and sub-placenta after 24 h of culture. Riley & Poyser (1987b)
have previously observed similar opposing actions of verapamil on PG output from
the guinea-pig endometrium.
It is well documented that phorbol esters stimulate the activation of protein kinase C
(PKC). It has been reported that phorbol esters also stimulate PGHS-2 mRNA
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expression in cultured human amnion cells (Zakar et al., 1996). Mitogen-activated
protein kinase (MAPK) may also be involved in PLA2 activation, particularly
cytosolic PLA2, and this may or may not require PKC for its activation (Lin et al.,
1992; Qiu et al., 1993; de Carvahlo et al., 1996). The activation of PKC does not
appear to be a requirement for PGF2ct, PGE2 or 6-keto-PGFla synthesis by the guinea-
pig placenta or sub-placenta. The PKC activator, TPA, had no stimulatory effect on
PG output from the guinea-pig placenta or sub-placenta after 24 h of culture (see
Section 3B.3.4). If cytosolic PLA2 is involved in PG production by guinea-pig
placenta and sub-placenta, it appears to be PKC-independent. However, this does not
exclude a role for MAPK, which does not always require PKC for its activation.
It has been proposed (Kang et al., 1991) that gonadotropin releasing hormone
(GnRH) may have a key role to play in the maintenance of pregnancy. Kang et al.
(1991) observed that treatment of the human placenta with GnRH significantly
reduced PGF and PGE outputs from the human placenta, particularly by the lower,
more physiological levels of GnRH. Previous studies by the same group
demonstrated that GnRH could stimulate as well as inhibit PG output from the
human placenta (Siler-Khodr et al., 1986a, b). In another study PGF2a output from
the human placenta was observed to increase in the presence of GnRH (Hanig et al.,
1982). GnRH had no significant effect on PGF2a output from day 29 guinea-pig
placenta after 2 and 8 h of culture. However, after 24 h of culture, PGF2c( output was
inhibited by the lower concentrations of GnRH used. The effect of GnRH on PGF2a
output from the guinea-pig sub-placenta was more pronounced than its effect on the
guinea-pig placenta. GnRH was observed to decrease PGF2a output after 2 h of
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culture, while stimulating PGF2ct output from the sub-placenta after 8 h and,
particularly, after 24 h of culture. The stimulation of PGF2(X output from the sub-
placenta in the presence of GnRH may be due to an increase in PGHS synthesis
(Thorburn, 1991).
PGE2 output from the placenta and the sub-placenta was largely unaffected by the
presence of GnRH. GnRH had some inhibitory effect on PGE2 output from the
placenta and some stimulatory effect on PGE2 output from the sub-placenta.
Therefore, GnRH had the same effects on PGE2 output as on PGF2ct output from the
placenta and the sub-placenta but to a lesser extent. GnRH significantly inhibited 6-
keto-PGFl0( output from the guinea-pig placenta after 2 h of culture, but had no
inhibitory effects after this time. Stimulation of 6-keto-PGFia output from the
placenta was observed after 24 h of culture in the presence of 10 nM GnRH. 6-Keto-
PGFia output from the guinea-pig sub-placenta was mostly unaffected by the GnRH
treatments used.
Bland & Donovan (1969) postulated that placental hormones may be responsible for
luteal function. It has also been suggested that in the guinea-pig these placental
hormones may be related to human chorionic gonadotrophin (Humphreys et al.,
1982). Davies et al. (1961) concluded that the guinea-pig sub-placenta was the
source of a gonadotrophin responsible for the maintainence of pregnancy. GnRH,
produced by the placenta, may be stimulating this gonadotrophin in the guinea-pig.
Humphreys et al. (1982) observed the presence of gonadotrophin in the guinea-pig
placenta and sub-placenta from day 10 of pregnancy, which reached a maximum
after 3 weeks of gestation. This gonadotrophin could help reduce the luteolytic
227
effects of PGF2a. Siler-Khodr et al. (1983, 1986a) observed an increase in PG output
from the human placenta in the presence ofGnRH and North et al. (1991) concluded
that GnRH may mediate its effect via hCG. Specific binding sites (receptors) for
GnRH have been demonstrated in the human placenta (Currie et al., 1989) and
bioactive GnRH and GnRH mRNA have also been observed (Gibbons et al., 1975;
Kelly et al., 1991). Whether specific binding sites for GnRH are present in the
guinea-pig placenta and sub-placenta requires further investigation.
There are a number of possibilities for future work in this field. With hindsight, the
effects of the P2 purinoceptor antagonist, suramin, and the adenosine (A) receptor
antagonist, 8-sulphophenyltheophylline, on PG outputs from the guinea-pig uterus
could have been further investigated. Different concentrations of drug could have
been used. In culture experiments with ATP, adenosine, suramin and 8-
sulphophenyltheophylline, the effects of suramin and 8-sulphophenyltheophylline
alone on PG outputs from the guinea-pig endometrium and myometrium would have
proved useful. The use of more specific antagonist would also have been beneficial
in determining which receptor subtypes were involved. Unfortunately, specific
receptor antagonists were not available.
A specific PGHS-1 antagonist would have been useful to determine the involvement
of PGHS-1 and PGHS-2 in PG production by the guinea-pig placenta and sub-
placenta. Several PLA2 enzymes have been identified in the human placenta (Freed
et al., 1997; Rice et al., 1994; Buhl et al., 1995). It would also have been useful to
determine which PLA2 enzymes are involved in PG production by the guinea-pig
placenta and sub-placenta. There are PLA2 antagonists and activators available but
these are not specific. Northern and Western blotting techniques may have been
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useful to demonstrate the presence of specific PGHS and PLA2 activity.
The results presented in this thesis have demonstrated that the mechanisms involved
in PG production by the mid-pregnant guinea-pig placenta and sub-placenta are
complex. These include the synthesis and availability of PLA2, PGHS and calcium
(extracellular and intracellular). Different cells within the guinea-pig placenta may
produce different PGs, and may have differentially regulated pathways for their
production. There may also be expression of different phospholipase enzymes in the
different cell types. Although PLA2 type II appears to be the predominat
phospholipase enzyme in the human placenta, several phospholipae enzymes have
been observed in the placenta and may have a role to play in PG production. This
may also be the case in the guinea-pig placenta and sub-placenta. Once released,
arachidonic acid may form distinct pools which may only be available to specific
PGHS enzymes (PGHS-1 or PGHS-2) for the production of specific PGs. This work
has also shown that the guinea-pig placenta is a major source of PGs during
pregnancy and that PG production by the guinea-pig placenta and sub-placenta may
have an important role to play during gestation. The fact that PG output from the
guinea-pig placenta, particularly PGF2a, increased as pregnancy proceeded suggests
that PGs of placental origin may be required during pregnancy. Previous workers
have suggested several functions for increased PG synthesis and output during
pregnancy including regulation of uterine contractions, ripening of the cervix,
regulation of the patency of the ductus arteriosus, luteolysis, fetal maturation and
regulation of utero-placental haemodynamics (Moussard ei al., 1986; Hoedemaker et
al., 1991; Rice et al., 1995). This study has looked at PG output from mid-pregnant
guinea-pig placenta and sub-placenta. Therefore, it is unlikely that increased PGF2ot
output from the guinea-pig placenta is involved in uterine contractions or ripening of
the cervix. It remains to be established whether PGs produced by the day 29 guinea-
pig placenta and sub-placenta are involved in the other processes mentioned.
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